CURRICULUM VITAE NAME: Martin Roy First TITLE: Professor of Medicine Department of Internal Medicine Division of Nephrology & Hypertension University of Cincinnati Medical Center Cincinnati, Ohio 45267 DATE OF BIRTH: 17 June 1943 MARITAL STATUS: Married - 2 children CITIZENSHIP: United States of America GRADUATE EDUCATION: University of Witwatersrand, M.B., B.Ch., 1966 POSTGRADUATE EDUCATION: House Surgeon, Johannesburg General Hospital Johannesburg, South Africa, January – June, 1967 House Physician, Johannesburg General Hospital Johannesburg, South Africa, July - December, 1967 Medical Officer, South African Defense Force Pretoria, South Africa, January - December, 1968 Registrar, Johannesburg General Hospital and Department of Medicine, University of Witwatersrand, Johannesburg, South Africa, January 1969 - December 1971 ACADEMIC APPOINTMENTS: Renal Research Fellow, Michael Reese Hospital Chicago, Illinois, May 1972 - April 1973 Renal Fellow, University of Cincinnati Medical Center Cincinnati, Ohio, May 1973 - February 1974 Assistant Professor of Medicine, Division of Nephrology Department of Internal Medicine, University of Cincinnati Medical Center, March 1974 - August 1978 Associate Professor of Medicine, Division of Nephrology Department of Internal Medicine, University of Cincinnati Medical Center, September 1978 - August 1985

2

Professor of Medicine, Division of Nephrology, Department of Internal Medicine, University of Cincinnati Medical Center, September 1985 - Present Attending Physician Cincinnati Veterans Administration Hospital, 1977 - Director, Section of Transplantation, University of Cincinnati Medical Center, Division of Nephrology, 1987 - Present PROFESSIONAL SOCIETIES: South Africa Renal Society American Federation for Clinical Research American Society of Nephrology The Transplantation Society American Society of Transplant Physicians Central Society for Clinical Research American Council on Transplantation Pan American Society of Dialysis and Transplantation European Dialysis and Transplant Association LICENSURE: South African Medical and Dental Council, January 1967 General Medical Council of the United Kingdom, January 1972 Illinois License (Flex Examination) December 1973 Ohio License, March 1974 POSTGRADUATE Education Council for Foreign Medical Graduates EXAMINATIONS: September 1966 Fellow of College Physicians of South Africa F.P.C. (S.A.) October 1970 American Board of Internal Medicine, June 1976 American Boards of Nephrology, October 1976 University of Cincinnati Medical Center COMMITTEE APPOINTMENTS: Internal Medicine Search Committee for Chairman of Department of Internal Medicine 1975-1977 Internal Medicine Residents Selection Committee 1976-1990 Internal Medicine Audit Committee 1977-1978 Faculty Representataive of Department of Medicine on Research and Education Fund Board of Trustees 1978-1980 University of Cincinnati Medical Center Committee on Human Research, 1979-1981 University of Cincinnati Medical Center Committee on Quality Assurance, 1980-1981 University of Cincinnati Medical Center Ad Hoc Nominating Committee for the Appointments and Promotions Committee, 1982

3

University of Cincinnati Medical Center, Department of Internal Medicine Promotions and Tenure Committee, 1982-1991

Ethics Committee Study Group, 1984-1985 Executive Committee of the Medical Center Fund of Cincinnati, 1987-1991 University of Cincinnati Medical Center, Department of Internal Medicine Chairman, Promotions and Tenure Committee, 1989-1991 University of Cincinnati Medical Center Associates (UCMA) Board of Trustees, 1994-1995 Faculty Achievement Award winner for significant contributions to the University of Cincinnati, 1994 Executive Committee of the Medical Staff of the University Hospital, 2000 -present Regional Health Planning Association of the Central Ohio River Valley (CORVA) Kidney Disease Coordinating Committee 1974-1976 Ohio Valley Organ Procurement Program (OVOPP) 1975-1978 Kidney Foundation of Greater Cincinnati - Medical Advisory Board, 1977-1987 - Research Advisory Committee, 1977-1979 - Vice-Chairman of Medical Advisory Board, 1981-1983 - Chairman, Direct Patient Services Committee, 1981-1983 - Executive Committee, 1981 -1994 - Chairman, Medical Advisory Board, 1983-1987 Ohio Valley Renal Disease, Network 17 - Cincinnati General Hospital Representative to the Coordinating Council, 1979-1988 - Director, Bylaws and Procedures Committee, 1980-1981 - Organ Retrieval and Transplant Committee, 1980 - - Executive Committee, 1981-1988 - Planning Subcommittee, 1982-1988 - Medical Review Board, 1982-1988 Kentucky Colonel - (Appointed by Governor Brown 1982 for outstanding contribution to the community) Executive Committee, Ohio Valley Life Center, 1996- National Representative of Kidney Foundation of Greater Cincinnati to the National Kidney Foundation Medical Advisory Board 1978 Alternate Representative, University of Cincinnati Medical Center, Southeastern Organ Procurement Foundation (SEOPF) 1980-1985 Membership Committee of American Society of Transplant

4

Physicians, 1983-1988 Board of Directors, Region 2, United Network For Organ Sharing (UNOS), 1986 - Chairman, Membership Committee of American Society of Transplant Physicians, 1985-1987 Councillor, American Society of Transplant Physicians, 1986 -1992 Member, for Training and Certification of Transplant Physicians, American Society of Transplant Physicians, 1986 -1992 President, American Society of Transplant Physicians, 1990-1991 Advisory Committee, American Society of Transplant Physicians, 1991 -1997 Awards Committee, American Society of Transplant Physicians, 1991-1993 Chairman, Ad Hoc Donations Committee United Network for Organ Sharing (UNOS), 1993-1995 National Kidney and Urologic Diseases Advisory Board, Task Force on Transplantation, 1994-1995 Chairman, Ortho Biotech Transplant Institute, 1995 -1997 Scientific Studies Committee, United Network for Organ Sharing (UNOS), 1996 - 1998 Program and Publications Committee, American Society of Transplant Physicians 1996 -1999 Co-chairman , Organ Donation Committee, American Society of Transplant Physicians, 1996 -1998 Ad Hoc Committee on Steroid Withdrawal in Solid Organ Transplantation, American Society of Transplant Physicians, 1998-1999 Patient Care and Education Committee, American Society of Transplantation, 2000-2002

Ad Hoc Task Force on AST Election Procedure, American Society of Transplantation, 2001-2002

Clinical Trials Committee, The Council of American Kidney Societies, 1996 - 1997 Scientific Advisory Board, National Kidney Foundation, 1998-2000 Chairman, Organ Donation Committee, American Society of Transplant Physicians 1998-2000 Data and Safety Monitoring Board, Cooperative Clinical Trials in Transplantation, National Institutes of Health, 1998 -

5

Councillor, International Transplantation Society, 1998- Food and Drug Administration, Center for Drug Evaluation and Research, Advisor and Consultant Staff, 1999 – Patient Education Committee, American Society of Transplantation, 2000-

6

EDITORIAL BOARDS: - Literature Scan: Transplantation, 1991 - - Associate Editor, American Journal of Kidney Disease, 1992 - - Kidney, 1992 - - Section Editor, Transplantation, The Principles and Practice of Nephrology. Jacobson HR, Striker GE, Klahr S (Eds.), 2nd edition, Mobsy-Year Book, Inc., St. Louis, 1996 - Editorial Board, Transplantation Proceedings, 1996 - - Editorial Board, Transplantation, 1996 - - Journal of the American Society of Nephrology, 1996 - - Assistant Editor, American Society of Transplant Physicians Newsletter, 1996 - - Clinical Transplantation, 1997 -

- Graft, 1998 – - Associate Editor, Graft. 2000-

- American Journal of Tansplantation, 2000- REVIEWER: - American Journal of Kidney Disease - Transplantation - Clinical Transplantation - Journal of the American Medical Association - Journal of American Society of Nephrology - American Journal of Medicine - Journal of Nephrology - New England Journal of Medicine - Kidney International - Clinical Drug Investigation - Transplantation Proceedings - Graft MISCELLANEOUS: National Institute of Allergy and Infectious Diseases (NIAID) special review

7

committee on Transplantation Immunology, 1992 Chairperson, Clinical Transplantation Abstract Selection Committee American Society of Nephrology, 1993 Department of Health and Human Services, Food and Drug Administration, Office of Orphan Products Development Grant Program, Ad hoc reviewer, 1995

8

BIBLIOGRAPHY

MARTIN ROY FIRST, M.D. ______________________________________________________________________________

1. First MR. Skull fractures in suid fossils from Makapansgat. Leech 34: 143. 1964 (Publication of Witwatersrand Medical School). 2. First MR, Jacobson R, Goldin AR, Seftel HC. Acute methyl alcohol poisoning. S Afr Med J 44:503-505, 1970 3. Kew MC, First MR. A trial of Ro 4-2137 in the treatment of hypertension. Curr Ther Res 14:343-348, 1972 4. First MR. Familial systemic lupus erythematosus. S Afr Med J 47:147, 1973 5. First MR. Sodium handling by the kidney in health and disease. S Afr Med J 47:839-843, 1973 6.. Ooi BS, Orlina AR, Masaitis L, First MR, Pollak VE, Ooi YM. Lymphocytotoxins in aging. Transplantation

18:190-192, 1974 7. Ooi BS, First MR, Pesce AJ, Pollak VE, Bernstein IL, Jao W. IgE levels in interstitial nephritis. Lancet 1:1254-

1256, 1974 8. Pollak VE, First MR, Pesce AJ. Value of the sieving coefficient in the interpretation of renal protein clearances.

Nephron 13:82-89, 1974 9. Clyne DH, Brendstrup L, First MR, Pesce AJ, Finkel PN, Pollak VE, Pirani CL. Renal effects of intraperitoneal

Kappa chain injection: induction of crystals in renal tubular cells. Lab Invest 31:131-142, 1974 10. Ooi BS, Jao W, First MR, Mancilla R, Pollak VE. Acute interstitial nephritis. Am J Med 59:614-629, 1975 11. Alexander JW, Smith EJ, McAdams AJ, Fidler JP, First MR, Muthiah V, Alexander NS, Korelitz J. Comparison

of goat ATLG and ASLG in human renal transplants. J Surg Res 19:287-295, 1975 12. Munda R, Alexander JW, Fidler JP, First MR. Use of dacron vascular graft in arterial stenosis following renal

allograft transplantation. Am Surg 42:604-607, 1976 13. First MR. Effects of chronic lead exposure on the kidney. Seminar on lead exposure and toxic effects, National

Institute of Occupation Safety and Health, 8-11, Cincinnati, Ohio, 1976 14. Linnemann CC, First MR, Alvira MM, Alexander JW, Schiff GM. Herpes hominis type 2 meningoencephalitis

following renal transplantation. Am J Med 61:703-708, 1976 15. First MR, Sloan DE, Pesce AJ, Pollak VE. Albumin excretion by the kidney: the effects of volume expansion. J

Lab Clin Med 89:25-29, 1977 16. Munda R, First MR, Alexander JW, Fidler JP, Gartside P. Pulmonary infections following renal transplantation.

Proc Clin Dial Transpl Forum 6:1-7, 1976 17. Sethi K, First MR, Pesce AJ, Fidler JP, Pollak VE. Proteinuria following renal transplantation. Nephron 18:49-

59, 1977

9

18. Ooi YM, Ooi BS, Vallota EH, First MR, Pollak VE. Circulating immune complexes after renal transplantation:

Correlation of increased 125I-Clq binding activity with acute rejection characterized by fibrin deposition in the kidney. J Clin Invest 60:611-619, 1977

19. Munda R, Alexander JW, Miller S, First MR, Fidler JP. Renal allograft artery stenosis. Am J Surg 134:400-403,

1977 20. First MR, Linnemann CC, Munda R, McConnell CM, Ramundo N, Alexander JW, Nathan P. Transmitted

streptococcal infection and hyperacute rejection: Possible cross-reaction of streptococcal antigens and antibodies with mammalian tissues. Transplantation 24:400-404, 1977

21. First MR, Patel VP, Pesce AJ, Bramlage RJ, Pollak VE. Albumin excretion by the kidney: The effects of osmotic

diuresis. Nephron 20:171-175, 1978 22. Munda R, Alexander JW, Fidler JP, First MR, Gartside P. Pulmonary infections in renal transplant recipients.

Ann Surg 197:126-133, 1978 23. First MR, Ooi BS, Jao W, Pollak VE. Pre-eclampsia and the nephrotic syndrome. Kidney Int 13:166-177, 1978 24. Linnemann CC, Dunn CR, First MR, Alvira M, Schiff GM. Late onset of fatal cytomegalovirus infection after

transplantation. Arch Int Med 138:1247-1250, 1978 25. Fidler JP, Dajani F, First MR, Munda R, Alexander JW. The value of urine cytology in renal transplantation.

Transplantation 26:133-134, 1978 26. Stinnett JD, Alexander JW, Ogle CK, McClellan MA, Brady D, First MR. Immune function of kidney transplant

patients in relation to infection. Transplant Proc 10:639-645, 1978 27. First MR, Bramlage RJ, Pesce AJ, Pollak VE. Albumin excretion by the kidney: The effects of furosemide

diuresis. Proc Soc Exp Biol Med 158:550-553, 1978 28. Munda R, Alexander JW, First MR, Fidler JP. Hypothermic pulsatile perfusion and transplantation of pediatric

cadaveric kidneys into adults. Am Surg 44:451-454, 1978 29. Linnemann CC, Kaufman CA, First MR, Schiff GM, Phair JP. Immune response to cytomegalovirus infection

after renal transplantation. Infection and Immunity 22:176-180, 1978 30. Nathan P, Plessinger RT, First MR. The correlation of kidney transplant survival with lymphocyte mediated

cytotoxicity on B cell targets. Proc Clin Dial Transpl Forum 8:62o-67, 1979 31. Linnemann CC, First MR. Risk of pneumococcal infections in renal transplant patients. JAMA 241:2619-2621,

1979 32. Hong CD, Kapoor BS, First MR, Pollak VE, Alexander JW. Fractional excretion of sodium after renal

transplantation. Kidney Int 16:167-178, 1979 33. Majeski JA, Alexander JW, First MR, Munda R, Fidler JP. Transplantation of a horseshoe kidney. JAMA

242:1066, 1979 34. Spreng WM, Nathan PE, First MR. BW-4/BW-6 matching and renal allograft survival in hemozygous

recipients. Proc Clin Dial Transpl Forum 9:93-94, 1979 35. Munda R, Alexander JW, First MR, Knowles HC, Weiss MA. Synchronous transplantation of a kidney and

duct obliterated segmental pancreas. Report of a case. Transplant Proc 12:98-102, 1980

10

36. First MR, Munda R, Kant KS, Fidler JP, Alexander JW. Steroid withdrawal following HLA -identical related donor transplantation. Transplant Proc 13:319-322, 1981

37. Munda R, Alexander JW, First MR, Laver MC, Majeski JA. Autotransplanta- tion and ex-vivo surgery for renovascular disease. Arch Surg 116:772-777, 1981 38. First MR, Glueck CJ. Plasma lipids and coronary heart disease in renal failure. Int J Artif Organs 4: 120-122,

1981 39. Barcelli U, Crissman J, First MR, Pollak VE. Rapidly progressing arterio-occlusive syndrome (Kohlmeier-

Degos' disease?) in a patient on chronic hemodialysis. Arch Int Med 141:1331-1335, 1981 40. Linnemann CC, First MR, Schiffman G. Response to pneumococcal vaccine in renal transplant and

hemodialysis patients. Arch Int Med 141:1637-1640, 1981 41. Majeski JA, Alexander JW, First MR, Munda R, Fidler JP. Microbial contamination of transplanted cadaver

kidneys. Ann Surg 117:221-224, 1982 42. Roy MT, First MR, Myre SA, Cacini W. Effect of co-trimoxazole and sulfamethoxazole on serum creatinine in

normal subjects. Therap Drug Monitoring 4:77-79, 1982 43. Dosekun AK, First MR, Chandran PKG, Kant KS, Glas-Greenwalt P, Weiss MA, Alexander JW, Pollak VE.

Successful treatment by defibrination with ancrod in a patient with hyperacute renal allograft failure and a deficiency of plasma prostacyclin stimulating factor. Clin Nephrol 18:101-105, 1982

44. Kuller J, First MR, D'Achiardi R, Munda R. Pneumocystis carinii pneumonia in renal transplant recipients. Am

J Nephrol 2:312-315, 1982 45. Chandran PKG, First MR, Weiss MA, Hess EV, Alexander JW, Pazmino P. Wegener's granulomatosis:

Prolonged patient survival after pneumonectomy and renal transplantation. Am J Nephrol 2:325-329, 1982 46. Chandran PKG, First MR, Wegener's granulometosis, clinical - pathological correlations and long-term course (letter). Am J Kidney Dis. 1:255, 1982. 47. Munda R, First MR, Alexander JW, Linnemann CC, Fidler JP, Kittur D. Polytetrafluoroethylene graft survival

in hemodialysis. JAMA 249:219-222, 1983 48. Levine MG, Miodovnik M, Siddiqu TA, First MR, Knowles HC. A successful pregnancy in a juvenile diabetic

with a renal transplant complicated by preeclampsia. Transplantation 35:498-499, 1983 49. First MR, Munda R. Secondary vascular access for hemodialysis. Int J Artif Organs 6:107-108, 1983 50. First MR, Glueck CJ. Black-white differences in high density lipoproteins, apolipoproteins, and triglycerides:

Relationship to coronary heart disease in non-uremic populations and in uremic subjects receiving hemodialysis. Int J Artif Organs 6:233-234, 1983

51. Munda R, First MR, Suttman MP, Alexander JW. Simultaneous kidney and pancreas procurement. Transplant

Proc 16:248-250, 1984 52. Alexander JW, First MR, Majeski JA, Munda R, Fidler JP, Morris MJ, Suttman MP. The late adverse effect of

splenectomy on patient survival following cadaveric renal transplantation. Transplantation 37:467-470, 1984 53. Munda R, First MR, Webb C, Alexander JW. Clinical experience with segmental pancreatic allografts.

Transplant Proc 16:692-694, 1984

11

54. First MR, Ettenger M, Robson M, Pollak VE, Ooi BS, Goldberg M. Acute deterioration in renal function in patients with pre-existing renal dis ease. Arch Int Med 144:2233-2238, 1984

55. First MR, Mendoza N, Maryniak RK, Weiss MA. Membranous glomerulopathy following kidney

transplantation: Association with renal vein thrombosis in 2 of 9 cases. Transplantation 38:603-607, 1984 56. First MR, Vaidya PN, Maryniak RK, Weiss MA, Munda R, Fidler JP, Penn I, Alexander JW. Proteinuria

following transplantation: Correlation with histopathology and outcome. Transplantation 38:607-614, 1984 57. Garcia-Garcia G, Deddens JA, D'Achiardi-Rey R, First MR, Samuels SJ, Kant KS, Pollak VE. Results of

treatment in patients with end-stage renal disease: A multivariate analysis of risk factors and survival in 341 successive patients. Am J Kidney Dis 5:10-18, 1985

58. Meakin CJ, Hopson CN, First MR. Avascular (Aseptic) necrosis of bone following renal transplantation. Int J

Artif Organs 8:19-20, 1985 59. First MR, Linnemann CC, Munda R, Alexander JW. Beneficial effects of pneumococcal polysaccharide

vaccine in splenectomized renal transplant recipients. Transplant Proc 17:147-150, 1985 60. Munda R, First MR, Joffe SN, Alexander JW. Experience with pancreatic allografts in renal transplant

recipients. Transplant Proc 17:353-357, 1985 61. Maryniak RK, Weiss MA, First MR. Transplant glomerulopathy--Evolution of morphologically distinct

changes. Kidney Int 27:799-806, 1985 62. Hayes DK, Majeski JA, Alexander JW, Rajagopalan PR, Fitts G, First MR, Munda R, Fidler JP. Renal

transplantation in Alport's syndrome. Am Surg 51:414-417, 1985 63. Goldstein G, Schindler J, Tsai H, Cosimi AB, Russell PS, Cho SI, Burdick JF, Williams GM, Stuart FP, Shields

CF, Alexander JW, First MR, Gailiunas P, Helderman JH, Wathen RL, Lordon RE, Normal D, Barry J, Sampson D, Levin BS, Monaco A. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313:337-342, 1985

64. Balakrishnan K, Whitacre L, First MR, Munda R, McEnery PT, Alexander JW. Donor-specific transfusions:

Sensitization patterns. Transplant Proc 17:2354-2356, 1985 65. Schroeder TJ, Wadhwa NK, Pesce AJ, First MR. An acute overdose of cyclosporine. Transplantation 41:406-

409, 1986 66. First MR, Alexander JW, Wadhwa N, Penn I, Munda R, Fidler JP, Weiskittel P. The use of low doses of

cyclosporine, azathioprine, and prednisone in renal transplantation. Transplant Proc 18:132-135, 1986 67. Penn I, First MR. Development and incidence of cancer following cyclosporine therapy. Transplant Proc

18:210-213, 1986 68. Linnemann CJ, First MR, Schiffman G. Revaccination of renal transplant and hemodialysis recipients with

pneumococcal vaccine. Arch Int Med 146:1554-1556, 1986 69. Munda R, Tom WT, First MR, Gartside P, Alexander JW. Pancreatic allograft exocrine urinary tract diversion:

Pathophysiology. Transplantation 43:95-99, 1987 70. Wadhwa NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on

the absorption of cyclosporine. Transplant Proc 19:1730-1733, 1987 71. Tom WT, Munda R, First MR, Alexander JW. Physiologic consequences of pancreatic allograft exocrine

drainage into the urinary tract. Transplant Proc 19:2339-2342, 1987

12

72. Munda R, Weiss MA, First MR, Alexander JW. Sychronous pancreatic and renal allografts with urinary tract

drainage of the pancreas. Transplant Proc 19:2343-2344, 1987 73. Wadhwa NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on

the absorption of cyclosporine. Transplantation 43:211-213, 1987 74. Wadhwa NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, Munda R, First MR. Interaction between

erythromycin and cyclosporine in a kidney and pancreas allograft recipient. Therap Drug Monitoring 9:123-125, 1987

75. Myre SA, McCann J, First MR, Cluxton RJ. Effect of trimethoprim on serum creatinine in healthy and chronic

renal failure volunteers. Therap Drug Monitoring 9:161-165, 1987 76. Schroeder TJ, Melvin DB, Clardy CW, Wadhwa NK, Myre SA, Reising JM, Wolf RK, Collins JA, Pesce AJ,

First MR. The use of cyclosporine and ketoconazole without nephrotoxicity in two cardiac transplant recipients. J Heart Transplant 6:84-89, 1987

77. Tom WT, Munda R, First MR, Alexander JW. Autodigestion of the glans penis and urethra by activated

transplant pancreatic exocrine enzymes. Surgery 102:99-101, 1987 78. Munda R, First MR, Weiss MA, Alexander JW. Pancreas transplantation at the University of Cincinnati.

Transplant Proc 19:17-23, 1987 79. Wadhwa NK, Schroeder TJ, Pesce AJ, Myre SA, Clardy CW, First MR. Cyclosporine drug interactions.

Therap Drug Monitoring 9:399-406, 1987 80. Waymack JP, Penn I, First MR, Alexander JW. Portal vein gas and sepsis after administration of OKT3 (letter).

Lancet 1:984, 1987. 81. Weir MR, Henry M, Blackmore M, Smith J, First MR, Irwin B, Shen S, Genemans G, Alexander JW, Corry RJ,

Nghiem DD, Ferguson R, Kittur D, Shield CF III, Sommer B, Williams FM. Incidence and morbidity of cytomegalovirus disease associated with a seronegative recipient receiving seropositive donor specific transfusion and living related donor transplantation: A multi-center evaluation. Transplantation 45:111-116, 1988

82. Schroeder TJ, Pesce AJ, Hassan FM, Wermeling JR, Warner A, Schlueter KT, First MR. Comparison of

Abbott TDX fluorescence polarization immunoassay (FPIA), Sandoz radioimmunoassay (RU), and high performance liquid chromatography (HPLC) methods for assay of serum cyclosporine. Transplant Proc 20(Suppl 2):345-347, 1988

83. Munda R, Schroeder TJ, Pedersen S, Clardy CW, Wadhwa NK, Myre SA, Pesce AJ, First MR. Cyclosporine

pharmacokinetics in pancreas transplant recipients. Transplant Proc 20(Suppl 2):487-490, 1988 84. Myre SA, Schroeder TJ, Melvin DB, Clardy CW, Pesce AJ, Wadhwa NK, Collins JA, Wolf RK, Brown LL,

Stephens GW, First MR. Use of cyclosporine by constant-rate intravenous infusion immediately following heart transplantation. Transplant Proc 20(Suppl 3):316-322, 1988

85. Shah B, First MR, Mendoza NC, Clyne DH, Alexander JW, Weiss MA. Alport's syndrome: Risk of

glomerulonephritis induced by anti-glomerular-basement-membrane antibody after renal transplantation. Nephron 50:34-38, 1988

86. First MR, Schroeder TJ. Monoclonal antibodies in organ transplantation. Clin Transplant 2:162, 1988

13

87. First MR, Schroeder TJ, Melvin DB, Munda R, Fidler JP, Balistreri WF, Hurtubise PE, Alexander JW, Penn I, Ryckman FD. OKT3 therapy in kidney, liver, heart and pancreas transplantation. Clin Transplant 2:185-189, 1988

88. Clardy CW, Schroeder TJ, Wadhwa NK, Pesce AJ, First MR, Myre SA, McEnery PT, Balistreri WF, Harris RE,

Melvin DB. The clinical variability of cyclosporine pharmacokinetics in adult and pediatric renal, cardiac, hepatic and bone marrow transplants. Clin Chem 34:2012-2015, 1988

89. Shah B, First MR, Munda R, Penn I, Fidler JP, Alexander JW. Current experience with renal transplantation in

older patients. Am J Kidney Dis 12:516-523, 1988 90. First MR, Schroeder TJ, Hurtubise PE, Mansour ME, Penn I, Munda R, Balistreri WF, Alexander JW, Melvin

DB, Fidler JP, Ryckman FC, Brunson ME. Successful retreatment of allograft rejection with OKT3. Transplantation 47:88-91, 1989

91. Schroeder TJ, Brunson ME, Pesce AJ, Hindenlang LL, Mauser PA, Ruckrigl DL, Weibel ML, Wadih G, First

MR. A comparison of the clinical utility of the RIA, HPLC, and TDX cyclosporine assays in outpatient renal transplant recipients. Transplantation 47:262-266, 1989

92. Schroeder TJ, Myre SA, Melvin DB, Stephens GW, Collins JA, Van Der Bel Kahn, J, Wolf RK, Brown LL,

Pesce AJ, First MR. The efficacy and safety of constant rate intravenous cyclosporine infusion immediately following cardiac transplantation. J Heart Transplant 8:5-10, 1989

93. First MR, Smith RD, Weiss MA, Schroeder TJ, Kant KS, Munda R, Stephens GW, Penn I, Alexander JW.

Cyclosporine-associated glomerular and arteriolar thrombosis following renal transplantation. Transplant Proc 21:1567-1570, 1989

94. Hariharan S, First MR, Munda R, Penn I, Schroeder TJ, Fidler J, Weiskittel P, Alexander JW. Prednisone

withdrawal in HLA -identical living related donor transplant recipients. Transplant Proc 21:1617-1619, 1989 95. First MR, Schroeder T, Penn I, Munda R, Balistreri W, Alexander JW, Melvin D, Ryckman F, Brunson M.

Immune monitoring during retreatment with OKT3. Transplant Proc 21:1753-1754, 1989 96. Munda R, Hutchins M, First MR, Carey M, Schroeder T, Alexander JW. Infection in OKT3 treated patients

receiving additional antirejection therapy. Transplant Proc 21:1763-1765, 1989 97. Balakrishnan K, Munda R, First MR, Alexander JW. Outcome of kidney transplants across B cell positive

crossmatches. Transplant Proc 21:1836, 1989 98. Schroeder T, Gremse D, Mansour M, Theurling A, Brunson M, Ryckman F, Suchy F, Penn I, Alexander W,

Pesce AJ, First MR, Balistreri WF. Lidocaine metabolism as an index of liver function in hepatic transplant donors and recipients. Transplant Proc 21:2299-2301, 1989

99. Myre S, Melvin D, Pesce A, Schroeder T, Collins J, Stephens G, Kahn A, First MR. Comparison of the safety

and efficacy of oral vs constant-rate intravenous infusion cyclosporine immediately following orthotopic heart transplantation. Transplant Proc 21:2484-2486, 1989

100. Munda R, First MR, Kranias G, Alexander JW. Effects of pancreatic transplantation on diabetic complications.

Transplant Proc 21:2865-2866, 1989 101. Schroeder TJ, Pesce AJ, Hindelang LL, Mauser PA, Ruckrigl DL, Weibel ML, Wadih G, First MR. An

evaluation of the cyclosporine and metabolites whole blood TDX assay. Therap. Drug Monit 11:480-482, 1989

102. Schroeder TJ, First MR, Hurtubise PE, Marmer DJ, Martin DM, Monsour ME, Melvin DB. Immunological

monitoring with orthoclone OKT3 therapy. J Heart Transplant 8:371-380, 1989

14

103. Schroeder TS, First MR, Mansour ME, Alexander JW, Penn I. Prophylactic use of OKT3 in immunological

high risk renal transplant recipients. Am J Kidney Dis 14 (Suppl 2):14-18, 1989 104. First MR, Schroeder TJ, Weiskittel P, Myre SA, Alexander JW, Pesce AJ. Concomitant administration of

cyclosporin and ketoconazole in renal transplant recipients. Lancet 2:1198-1201, 1989 105. First MR, Schroeder TJ, Carey MA, Chavinson DS. Effect of race on transplant outcome and response to

OKT3 monoclonal antibody therapy. Transplant Proc 21:3849-3952, 1989 106. Schroeder TJ, First MR, Mansour ME, Hurtubise PE, Hariharan S, Ryckman FC, Munda R, Melvin DB, Penn I,

Ballistreri WF, Alexander JW. Antimurine antibody formation following OKT3 therapy. Transplantation 49:48-51, 1990

107. Schroeder TJ, Munda R, Pederson SH, Hurtubise SH, Alexander JW, First MR. Failure of orthoclone OKT3

retreatment in a pancreas transplant recipient with antimurine antibody. J Clin Lab Anal 4: 99-101, 1990 108. Shah BV, Hong CD, First MR. Effect of cyclosporine on fractional excretion of sodium (FENa) in renal

transplant patients. Clin Transplant 4: 102-107, 1990 109. Pesce AJ, Schroeder TJ, First MR. An evaluation of cyclosporine monitoring by nonselective fluorescence

polarization immunoassay. Transplant Proc 22: 1171-1174, 1990 110. Sridhar N, Schroeder TJ, Pesce AJ, First MR. Clinical correlations of cyclosporine HPLC and FDIA levels in

renal transplant recipients. Transplant Proc 22:1257-1279, 1990 111. First MR, Schroeder TJ. Beware possible interactions between cyclosporine and antimicrobial agents. J Crit

Illness 5:891-892, 1990 112. Kashtan CE, Butowski RJ, Kleppel MR, First MR, Michael AF. Posttransplant anti-glomerular basement

membrane nephritis in related males with Alport syndrome. J Lab Clin Med 116:508-515, 1990 113. Tchervenkov JI, Munda R, Weiss M, First MR, Alexander JW. Adult respiratory distress syndrome following

chronic rejection of a pancreatic allogrant - a case report. Transplantation 50:883-884, 1990 114. Schroeder TJ, Weiss MA, Smith RD, Stephens GW, Carey M, First, MR. The use of OKT3 in the treatment of

acute vascular rejection. Transplant Proc 23:1043-1045, 1991 115. Fisher RA, Tchervenkov JI, Schroeder TJ, Alexander JW, Munda R, Penn I, Carey M, First MR. Efficacy of

induction therapy in cadaveric renal transplantation comparing rabbit antithymocyte serum and Minnesota antilymphoblast globulin. Transplant Proc 23:1253-1255, 1991

116. Schroeder TJ, Weiss MA, Smith RD, Stephens GW, First MR. The efficacy of OKT3 in vascular rejection.

Transplantation 51:312-315, 1991 117. First MR, Schroeder TJ, Alexander JW, Stephens GW, Weiskittel P, Myre SA, Pesce AJ. Cyclosporine dose

reduction by ketoconazole administration in renal transplant recipients. Transplantation 51:365-370, 1991 118. First MR, Schroeder TJ. Solid-organ transplantation in the pediatric population. Clin Transplant 5:132-136,

1991 119. Schroeder TJ, Ryckman FC, Hurtubise PE, Pedersen SH, Batistreri WF, First MR. Immunological monitoring

during and after OKT3 therapy in children. Clin Transplant 5:191-196, 1991

15

120. Sridhar NR, Tchervenkov JJ, Weiss MA, Hijazi YM, First MR. Disseminated histoplasmosis in a renal transplant patient: A cause of renal failure several years following transplantation. Am J Kidney Dis 17:719-721, 1991

121. First MR. The dilemma of organ donation and distribution. J Transplant Coordination 1:60-64, 1991 122. Schroeder TJ, Pesce AJ, Vine WH, First MR. Cyclosporine monitoring: An update. Am Assoc Clin Chem 13: 7-16, 1991 123. First MR. Donation and transplantation: Where will we be in 2010? Surgeon General's Workshop on

Increasing Organ Donation Washington, D.C., July 8-10, 1991. U.S. Department of Health and Human Services, Public Health Service, pp 15-25

124. First MR. The organ donation problem. Literature Scan: Transplantation 7:1-2, 1991 125. Myre SA, Schroeder TJ, Grund VR, Wandstrat TL, Nicely PG, Pesce AJ, First MR. Critical ketoconazole

dosage range for cyclosporine clearance inhibition in the dog. Pharmacology 43: 233-241, 1991 126. First MR. New immunosuppressive drugs. Am J Kidney Dis 19: 3-9, 1992 127. First MR. Transplantation in the nineties. Presidential address, American Society of Transplant Physicians.

Transplantation 53: 1-11, 1992 128. Schroeder TJ, Helling T, McKenna RM, Rush D, Jeffrey JR, Brewer B, Martin LA, Traylor D, Fisher RA, First

MR, Muth KL. A multicenter study to evaluate a novel assay for quantitation of a soluble interleukin 2 receptor in renal transplant recipients. Transplantation 53:34-40, 1992.

129. First MR, Schroeder TJ, Hariharan S, Alexander JW, Weiskittel P. The effect of indomethacin on the febrile

response following OKT3 therapy. Transplantation 53: 91-94, 1992 130. Gorman KJ, First, MR. An economics grand rounds presentation: The economics of renal transplantation.

Transplant Surgical Resource Series 5:1-26, 1992 131. First MR. Future prospects of transplantation. What will happen in the next 20 years? Biomedical Market

Newsletter 2:13-16, 1992 132. Alexander JW, Babcock GF, First, MR, Davies CB, Madden RL, Munda R, Penn I, Fidler JP, Cofer BR,

Stephens G, Schroeder TJ, Hariharan S, Cardi M, Manzler A, Cohen L, Mendoza N, Clyne D, Giese F. The induction of immunologic hyporesponsiveness by preoperative donor-specific transfusions and cyclosporine in human cadaveric transplants. Transplantation 53:423-427, 1992

133. Sridhar N, Schroeder TJ, Hariharan S, Pesce AJ, First MR. Influence of concomitant medication on

cyclosporine dosage and blood concentrations in renal allograft recipients. Clin Transplantation 6:134-138, 1992

134. Shield CF, Kahana L, Pirsch J, Vergne-Marini P, First MR, Schroeder TJ, Cohen D, Norman DJ, Monaco A, Martinez A, Dinarello CA, Dehlinger J, Wu SCH, Van Horn A. Use of indomethacin to minimize

the adverse reactions associated with orthoclone OKT3 treatment of kidney allograft rejection. Transplantation 54:164-166, 1992

135. Davies CB, Alexander JW, Cofer BR, First MR, Schroeder TJ. Efficacy of a single pretransplant donor-

specific transfusion and cyclosporin A administered 24 to 48 hours before one-haplotype- mismatched living related donor kidney transplant. Ann Surg 215:618-626, 1992 136. First MR. New immunosuppressive agents. Literature Scan: Transplantation 8:1-3, 1992

16

137. Hariharan S, Schroeder TJ, Carey MA, First MR. Renal transplantation in patients with systemic lupus erythematosus. Clin Transplantation 6:345-349, 1992

138. Sridhar NR, Munda R, Balakrishnan K, First MR. Evaluation of flowcytometric crossmatching in renal

allograft recipients. Nephron 62:262-266, 1992 139. Sridhar NR, Blanton M, Whitacre L, Balakrishnan K, First MR. Flow cytometric evaluation of cytotoxic

peripheral blood lymphocytes in acute renal allograft rejection. J Am Soc Nephrol 3:1220-1226, 1992 140. Schroeder TJ, First MR, Pouletty C, Hariharan S, Pouletty P. Rapid detection of anti-OKT3 antibodies with

the transtat assay. Transplantation 55: 297-299, 1993 141. Alexander JW, Davies CB, First MR, Cofer BR, Munda R, Madden RL, Hariharan S. Single pretransplant

donor - specific transfusion in cadaver and living related donor renal transplantation. Transplant Proc 25:485-487, 1993

142. First MR, Schroeder TJ, Michael A, Hariharan S, Weiskittel P, Alexander JW. Safety and efficacy of long-term cyclosporine-ketoconazole administration and preliminary results of a randomized trial. Transplant Proc 25:591-594, 1993 143. Madden RL, Munda R, Hariharan S, Alexander JW, First MR. Outcome of cadaver kidneys using nonideal

donors. Transplant Proc 25:1568-1569, 1993. 144. Mahoney MC, Racadio JM, Merhar GL, First MR. Safety and efficacy of kidney transplant biopsy: Tru-cut

needle vs sonographically guided biopty gun. Am J Roentgen 160:325-326, 1993 145. First MR, Schroeder TJ, Hariharan S. OKT3-induced cytokine-release syndrome: Renal effects (cytokine

nephropathy). Transplant Proc 25 (suppl. 1): 25-26, 1993 146. First MR, Schroeder TJ, Hariharan S, Weiskittel P. Reduction of the initial febrile response to OKT3 with

indomethacin. Transplant Proc 25 (suppl. l):52-54, 1993 147. Schroeder TJ, Hariharan S, First MR: Antibody response to OKT3 and methods for monitoring. Transplant

Proc 25 (suppl. l):77-80, 1993 148. Alexander JW, First MR, Davies CB, Campbell P, Babcock GF. Donor - Specific transfusion - induced

tolerance in animals and man: A therapeutic strategy. Transplant Sci 3:72-75, 1993 149. First MR, Schroeder TJ, Michael A, Hariharan S, Weiskittel P, Alexander JW. Cyclosporine-ketoconazole

interaction: Long-term follow-up and preliminary results of a randomized trial. Transplantation 55:1000-1004, 1993

150. Schroeder TJ, Sridhar N, Pesce AJ, Alexander JW, First MR. Clinical correlations of cyclosporine-specifc and

- nonspecific assays in stable renal transplants, acute rejection, and cyclosporine nephrotoxicity. Ther Drug Monit 15:190-194, 1993

151. Hariharan S, Schroeder TJ, First MR. Effect of race on renal transplant outcome. Clin Transplant 7:235-239,

1993 152. Sternberg RI, Baughman RP, First MR. Erythromycin-induced hearing loss in immunosuppressed transplant

patients. Clin Transplant 7:269-272, 1993 153. Madden RL, Schroeder TJ, Schleuter KT, Davies CB, Myre SA, Hariharan S, Alexander JW, First MR.

Ketoconazole fails to increase cyclosporine G blood levels in Lewis rats. Pharmacol Comm 3:275-281, 1993

17

154. Rossi SJ, Schroeder TJ, Hariharan S, First MR. Prevention and management of adverse effects associated with immunosuppressive therapy. Drug Safety 9:104,131, 1993

155. First MR. Long-term complications after transplantation. Am J Kidney Dis 22:477-486, 1993 156. Hariharan S, Schroeder TJ, Weiskittel P, Alexander JW, First MR. Prednisone withdrawal in HLA identical

and one haplotype - matched live-related donor and cadaver renal transplant recipients. Kidney Int 44 (suppl 43):30-35, 1993

157. Sternberg RI, Baughman RP, Dohn MN, First MR. Utility of bronchoalveolar lavage in assessing pneumonia

in immunosuppressive renal transplant recipients. Am J Med 95:358-364, 1993 158. Barrett WL, First MR, Aron BS, Penn I. Clinical course of malignancies in renal transplant recipients. Cancer

72:2186-2189, 1993 159. Myre SA, Schroeder TJ, Pesce AJ, Mechlinski W, First MR. Influence of cyclosprine A or ketoconozole

blood levels and oral clearance in the dog. Pharmacol Comm 4:49-53, 1993 160. Anderson P, Schroeder TJ, Hariharan S, First MR. Incidence of posttransplant lymphoproliferative disease in

OKT3-treated renal transplant recipients. Clin Transplant 7:582-585, 1993 161. First MR. Renal allograft survival after 1 and 10 years: comparison between precyclosporin and cyclosporin

data. Nephrol Dial Transplant 9:90-97, 1993 162. Schroeder TJ, First MR. Monoclonal antibodies in organ transplantation. Am J Kidney Dis 23:138-147, 1994 163. Hricik DE, Kupin WL, First MR. Steroid-free immunosuppression after renal transplantation. J Am Soc

Nephrol 4:S10-16, 1994 164. First MR, Neylan JF, Rocher LL, Tejani A. Hypertension after renal transplantation. J Am Soc Nephrol 4:S30-

S36, 1994 165. Gruber SA, Stephanian E, Dunn DL, First MR. A complicated case of skin cancer in a renal allograft recipient.

Transplant Sci 4:17-19, 1994 166. Schroeder TJ, First MR. Cytomegalovirus infection and the role of ganciclovir prophylaxis in transplant

recipients. J Nephrol 7:77-88, 1994 167. Madden RL, Schroeder TJ, Alexander JW, First MR. Single dose OKT3: Adverse effects, pharmacokinetics,

and anti-OKT3 antibody response. Transplant Sci 4:112-114, 1994 168. Schroeder TJ, Michael AT, First MR, Hariharan S, Bhat G, Hanto DW, Ryckman FC, Balistreri WF. Variations

in serum OKT3 concentration based upon age, sex, transplanted organ, treatment regimen, and anti-OKT3 antibody status. Ther Drug Monit 16:361-367, 1994

169. Masroor S, Schroeder TJ, Michler RE, Alexander JW, First MR. Monoclonal antibodies in organ

transplantation: An overview. Transplant Immunol 2:176-189, 1994 170. First MR. Ten years of cyclosporin A. Literature Scan: Transplantation 10:1-3, 1994 171. Schroeder TJ, Hariharan S, First MR. Relationship between cyclosporine bioavailability and clinical outcome

in renal transplant patients. Transplant Proc 26:2787-2790, 1994. 172. Muirhead N, Cattran DC, Zaltzman J, Jindal K, First MR, Boucher A, Keown PA, Munch LC, Wong C. Safety

and efficacy of recombinant human erythropoietin in correcting anemia of patients with chronic renal allograft dysfunction. J Am Soc Nephrol 5:1216-1222, 1994

18

173. Schroeder TJ, Hariharan S, First MR. Variations in bioavailability of cyclosporine and relationship to clinical

outcome in renal transplant subpopulations. Transplant Proc 27: 837-839, 1995 174. First MR, Combs CA, Weiskittel P, Miodovnik M. Lack of effect of pregnancy on renal allograft survival or

function. Transplantation 59: 472-476, 1995 175. Sketris I, Yatscaff R, Keown P, Canafax DM, First MR, Holt DW, Schroeder TJ, Wright M. Optimizing the use

of cyclosporine in renal transplantation. Clin Biochem 28:195-211, 1995 176. First MR. Living-related donor transplants should be performed with caution in patients with focal segmental

glomerulosclerosis. Pediatr Nephrol 9:S40-42, 1995 177. Skannal DG, Dungy-Poythress LJ, Miodovnik M, First MR. Pregnancy in a combined liver and kidney

transplant recipient with type I primary hyperoxaluria. Obstet Gynec 86:641-643, 1995 178. Schroeder TJ, First MR, Gaber AO. Monitoring and management of immunosuppression in pediatric

transplant patients. Clin Immunother 4:425-444, 1995 179. Hariharan S, Munda R, Demmy AM, Schroeder TJ, Alexander JW, First MR. Conversion from cyclosprine to

tacrolimus after pancreas transplantation. Transplant Proc 27:2981-2982, 1995 180. Peddi VR, Hariharan S, Munda R, Schroeder TJ, First MR. Impact of ganciclovir prophylaxis on

cytomegalovirus infecion in cadaveric kidney vs combined kidney and pancreas transplantation. Transplant Proc 27:3076-3077, 1995

181. El-Ghoroury M, Hariharan S, Munda R, Demmy AM, Schroeder TJ, Alexander JW, First MR. Comparison

between methylprednisolone and OKT3 treatment for the first acute rejection episode in combined kidney and pancreas transplant recipients. Transplant Proc 27:3133-3134, 1995

182. Peddi VR, Hariharan S, Schroeder TJ, First MR. Role of granulocyte colony stimulating factor (G-CSF) in

reversing neutropenia in renal allograft recipients. Clin Transplant 10:20-23, 1996 183. Rossi S, Schroeder TJ, Muth K, Hanto D, Munda R, Hariharan S, First MR, Ryckman F, Balistreri W. Serial

monitoring of soluble interleukin-2 receptor as a rapid marker of cytomegalovirus infection and response to therapy. Clin Transplant 10:45-50, 1996

184. First MR, Schroeder TJ, Monaco AP, Simpson MA, Curtis J, Armenti VT. Cyclosporine bioavailability dosing

implication and impact on clinical outcomes in select transplantation subpopulations. Clin Transplant 10:55-59, 1996

185. Viero RM, First MR, Cavallo T. Detection of Epstein-Barr virus message in renal allografts. Transplantation

61:321-323, 1966 186. Peddi VR, Hariharan S, First MR. Disseminated histoplasmosis in renal allograft recipients. Clin Transplant

10:160-165, 1996 187. Hariharan S, Alexander JW, Schroeder TJ, First MR. Outcome of cadaveric renal transplantation by induction

treatment in the cyclospsorine era. Clin Transplant 10:186-190, 1996 188. Hariharan S, Munda R, Cavallo T, Demmy AM, Schroeder TJ, Alexander JW. Rescue therapy with tacrolimus

after combined kidney/pancreas transplantation in patients with severe cyclosporine nephrotoxicity. Transplantation 61:1161-1165, 1996

189. First MR, Schroeder TJ. The relationship between cyclosporin bioavailability, clinical outcome and resource

utilization in renal transplant recipients. Perspectives 1:8-10, 1996

19

190. Schroeder TJ, Shah M, Hariharan S, First MR. Increased resources are required in patients with low

cyclosporine bioavailability. Transplant Proc 28:2151-2155, 1996 191. Skannal DG, Miodovnik M, Dungy-Poythress LJ, First MR. Successful pregnancy after combined renal-

pancreas transplantation: A case report and literature review. Am J Perinatol 13:383-387, 1996 192. Pescovitz MD, Brayman K, Brenner D, Brinker K, Burke J, Canafax D, Chan L, First MR, Greenstein S, Gruber

S, Lewis R, Metzger R, Mulgoankar S, Neylan J, Perez R, Peterson J, Shapiro R, Vanderwerf B, Wright C. Conversion from Sandimmune to Neoral in stable renal transplant

patients. Transplant Proc 28:2196-2198, 1996 193. Cavallo T, First MR. "Recurrence" of cyclosporine nephrotoxicity in a heart transplant recipient. Am J

Kidney Dis 28:466-468, 1996 194. Hariharan S, Smith RD, Viero R, First MR. Diabetic nephropathy after renal transplantation. Transplantation

62:632-635, 1996 195. Marterre WF, Hariharan S, First MR, Alexander JW. Gastric bypass in morbidly obese kidney transplant

recipients. Clin Transplant 10:414-419, 1996 196. Peters TG, Kittur DS, McGaw LJ, First MR, Nelson EW. Organ donors and non donors. An American

dilemma. Arch Int Med 156:2419-2424, 1996 197. First MR. Living unrelated renal donors. Literature Scan: Transplantation 12:1-2, 1996 198. Hariharan S, Alexander JW, Schroeder TJ, First MR. Impact of first acute rejection episode and severity of

rejection on cadaveric renal allograft survival. Clin Transplant 10:538-541, 1996 199. First MR. An update on new immunosuppressive drugs undergoing preclinical and clinical trials: Potential

applications in organ transplantation. Am J Kidney Dis 29:303-317, 1997 200. First MR. Controversies in organ donation: Minority donation and living unrelated renal donors. Transplant Proc 29: 67-69, 1997 201. First MR. Cadaveric organ procurement - An overview of two aspects: Donor hospital networks, and

minority donation. Transplant Proc 29: 70-72, 1997 202. Peddi VR, Dean DE, Hariharan S, Cavallo T, Schroeder TJ, First MR. Proteinuria following renal

transplantation: Correlation with histopathology. Transplant Proc 28: 101-103, 1997 203. Gaber LW, Moore LW, Gaber AO, First MR, Guttmann RD, Pouletty P, Schroeder TJ. A multicenter report on

the utilization of the Banff grading in acute renal rejection. Transplant Proc 29: 184-185, 1997 204. Miller J, Pirsch JD, Deierhoi M, Vincenti F, Filo RS, Adams M, Bennett WM, Bowen PA, Burdick J, First MR,

Inokuchi S, Jensik SC, Kahana L, Laskow D, Light JA, Mendez R, Neylan JF, Shield CF, Stuart FP, Vergne-Marini P. FK 506 in kidney transplantation: Results of the U.S.A. randomized comparative phase III study. Transplant Proc 29: 304-305, 1997.

205. El-Ghoroury M, Hariharan S, Peddi VR, Munda R, Schroeder TJ, Demmy AM, Alexander JW, First MR.

Efficacy and safety of tacrolimus versus cyclosporine in kidney and pancreas transplant recipients. Transplant Proc 29: 649-651, 1997

206. Hariharan S, Peddi VR, Munda R, Demmy AM, Schroeder TJ, Alexander JW, First MR. Long-term renal and

pancreas function with tacrolimus rescue therapy following kidney/pancreas transplantation. Transplant Proc 29: 652-653, 1997

20

207. Stratta RJ, First MR, Egidi F, Corry RJ, Johnson CP, Marsh CL, Burke GW, Gruessner RWG, Sutherland DER,

Kaufman D, Bartlett ST, Sollinger HW, Boudreany JP, Benedetti E. Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: A multicenter report. Transplant Proc 29: 654-655, 1997

208. Schroeder TJ, Levy R, Pouletty P, First MR. A generic cyclosporine develoment program. Transplant Proc

29: 1235-1238, 1997 209. First MR. Xenotransplantation: Social, ethical, religious, and political issues. Kidney Int 51 (suppl 58): 46-47,

1997 210. Peddi VR, Hariharan S, Schroeder TJ, First MR. Impact of ganciclovir prophylaxis on cytomegalovirus

infection n recipients of cadaveric renal allografts. Nephron 76:49-55, 1997 211. Peddi VR, First MR. Primary care of patients with renal transplants. Med Clin North Am 81:767-784, 1997 212. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS, Adams MB, Bennett WM, Bowen PA, Burdick J,

Rascusen L, First MR, Inokuchi S, Jensik SC, Kahana L, Laskou D, Light JA, Mendez R, Neylan JF, Shield CF, Stuart FP, Vergne-Marini P, Solez K, Facklam D, Kershner R. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 63:977-983, 1997

213. First MR. Expanding the donor pool. Semin Nephrol 17:373-380, 1997 214. Valente JF, Hariharan S, Peddi VR, Schroeder TJ, Ogle CK, Alexander JW, First MR. Causes of renal allograft loss in black vs. white transplant recipients in the cyclosporine era. Clin Transplant 11:231-236, 1997 215. Gruessner RWG, Gruessner A, Drangstveit MB, Sutherland DER, Egidi F, Corry R, Starzl T, Burke G, Stratta R,

Marsh C, Perkins J, Munda R, First MR, Johnson C, Benedetti E, Kaufman D, Brayman K, Fabrega M, Martin M, Boudreaux P, Frey D, Stock P, Melzer J. Tacrolimus in pancreas transplantation: A multicenter analysis. Clin Transplant 11:299-312, 1997

216. Rahusen F, Munda R, Hariharan S, First MR, Demmy A. Combined kidney-pancreas and parathyroid

transplantation: A case report. Clin Transplant 11:341-343, 1997 217. Daoud AJ, Schroeder TJ, Kano J, Horn HR, Berger-Moran H, First MR. The US compassionate experience

with thymoglobulin for the treatment of resistant acute rejection. Transplant Proc 29 (Suppl 7A):18-20, 1997 218. Kamath S, Dean D, Peddi VR, Schroeder TJ, Alexander JW, Cavallo T, First MR. Efficacy of OKT3 as primary

therapy for histologically confirmed acute renal allograft rejection. Transplantation 64:1428-1432, 1997 219. Whiting JF, Golconda M, Smith R, O’Brien S, First MR, Alexander JW. Clinical and economic outcomes of

expanded criteria donors in renal transplantation. Transplant Proc 29:3258, 1997 220. First MR. The donor supply. Transplant Proc 29:3299-3000, 1997 221. Whiting JF, Golconda M, Smith R, O’Brien S, First MR, Alexander JW. Economic costs of expanded criteria

donors in renal transplantation. Transplantation 65:204-207, 1998 222. Golconda MS, Whiting JF, Smith R, Hayes R, Alexander JW, First MR. Long-term outcome of kidney

transplantation from expanded criteria donors: A single center experience. Transplant Proc 29:3379-3381, 1997

21

223. Gaber LW, Moore LW, Gaber AD, First MR, Guttmann RD, Pouletty P, Schroeder TJ, Soulillou J-P. Utillity of standardized histological classification in the management of acute rejection. Transplantation 64:376-380, 1998

224. Neylan JF, Adams MB, Bennett WB, Bowen AB, Mulloy L, Burdick J, Filo RS, First MR, Inokuchi S, Jensik

SC, Kahana L, Laskow D, Deierhoi M, Light JA, Mendez R, Miller J, Pirsch JD, Shield CF, Stuart FP, Vergne-Marini P, Vincenti F, Solez K, Racusen L, Mekki Q, Facklam D. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 65:515-523, 1998.

225. First MR. Clinical applications of immunosuppressive agents in renal transplantation. Surg Clin North Am

78:61-76, 1998 226. Peddi VR, Kamath S, Schroeder TJ, Munda R, First MR. Efficacy of OKT3 as primary therapy for

histologically confirmed acute renal allograft rejection in simultaneous kidney and pancreas transplant recipients. Transplant Proc 30:285-287, 1998

227. Peddi VR, Demmy AM, Munda R, Alexander JW, First MR. Tacrolimus eliminates actue rejection as a major

complication following combined kidney and pancreas transplantation. Transplant Proc 30:509-511, 1998 228. First MR, Peddi VR. Complications occurring after transplantation. Literature Scan 14:1-3, 1998 229. First MR. Who should fund chronic rejection trials? Graft 1 (suppl 2):107-109, 1998 230. Hariharan S, Peddi VR, Savin VJ, Johnson CP, First MR, Roza AM, Adams MB. Recurrent and de novo renal

diseases after renal transplantation: A report from the renal allograft recurrent disease registry. Am J Kidney Dis 31:928-931, 1998

231. First MR, Gaber AO, Guffmann RD, Moore LW, Schroeder TJ, Soulillon JP. Efficacy endpoints conference on

acute rejection in renal transplantation: Introduction. Am J Kidney Dis 31 (suppl 1):1-2, 1998 232. Al-Awwa IA, Hariharan S, First MR. Importance of allograft biopsy in renal transplant recipients: Correlation

between clinical and histologic diagnosis. Am J Kidney Dis 31 (suppl 1): 15-18, 1998 233. Schroeder TJ, Moore LW, Alsina A, Cantarovich D, Chapman J, Charpentier B, Cohen D, First MR, Gaber O,

Glotz D, Guttmann R, Halloran P, Hunsicker L, Koene R, Legendre C, Leichtman A, Margreiter R, Matas A, Ponticelli C, Remuzzi G, Woodle S. Efficacy endpoints conference on acute rejection in kidney transplantation: Summary report of the database. Am J Kidney Dis 31 (suppl1):31-39, 1998

234. Guttmann RD, Soulillon JP, Moore LW, First MR, Gaber AO, Pouletty P, Schroeder TJ. Proposed consensus

for definitions and endpoints for clinical trials of acute renal transplant rejection. Am J Kidney Dis 31 (suppl 1):40-46, 1998

235. Jensik SC, Adams MB, Bennett WM, Bowen PA, Malloy L, Burdick J, Filo RS, First MR, et al. Tacrolimus (FK

506) in kidney transplantation: Three-year survival results of the US multicenter, randomized, comparative trial. Transplant Proc 30:1216-1218, 1998

236. Kamath S, Dean D, Peddi VR, Schroeder TJ, Alexander JW, Cavallo T, First MR. Primary therapy with OKT3

for biopsy-proven acute renal allograft rejection. Transplant Proc 30:1178-1180, 1998 237. Peddi VR, Munda R, Demmy AM, Alexander JW, First MR. Long-term kidney and pancreas function with

tacrolimus immunosuppression following simultaneous kidney and pancreas transplantation. Transplant Proc 30:1541-1543, 1998

238. First MR. New solutions to overcome the organ donor shortage. Graft 1:117-118, 1998

22

239. Peddi VR, Whiting J, Weiskittel PD, Alexander JW, First MR. Characteristics of long-term renal transplant survivors. Am J Kidney Dis 32:101-106, 1998

240. Gaber AO, First MR, Tesi RJ, Gaston RS, Mendez R, Mulloy LL, Light JA, Gaber LW, Squiers E, Taylor RJ,

Neylan JF, Steiner RW, Knechtle S, Norman DJ, Shihab F, Basadonna G, Brennan DC, Hodge EE, Kahan BD, Kahana L, Steinberg S, Woodle ES, Chan L, Ham JM, Stratta RJ, Wahlstrom E, Lamborn KR, Horn HR, Moran HB, Pouletty P, Schroeder TJ.

Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus ATGAM in the treatment of acute graft rejection episodes after renal transplantation.

Transplantation 66:29-37, 1998 241. Kaplan AJ, Valente JF, First MR, Demmy AM, Munda R. Early operative intervention for urologic

complications of kidney-pancreas transplantation. World J Surg 22:890-894, 1998 242. Shah MB, Martin JE, Schroeder TJ, First MR. Evaluation of the safety and tolerability of Neoral and

Sandimmune: A Meta-analysis. Transplant Proc 30:1697-1700, 1998 243. First MR, Weiskittel P, Burton M, Shah M, Dreyer D, Fleck C, Bey R, Peddi R, Canafax D, Schroeder TJ.

Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method. Transplant Proc 30:1701-1705, 1998

244. Pescovitz MD, First MR. Improved cyclosporine pharmacokinetics in maintenance renal transplant

recipients converted to cyclosporine for microemulsion. Transplant Int 11 (Suppl 1):594-597, 1998 245. First MR, Peddi VR. Malignancies complicating organ transplantation. Transplant Proc 30:2768-2770, 1998 246. Peddi VR, Kamath S, Munda R, Demmy AM, Alexander JW, First MR. Use of tacrolimus eliminates acute

rejection as a major complication following simultaneous kidney and pancreas transplantation. Clin Transplant 12:401-405, 1998

247. Peddi VR, First MR. Screening of patients with pre-transplant malignancies. Curr Opin Organ Transplant

3:78-81, 1998 248. First MR. The state of present and future immunosuppressive therapy in renal transplantation. Contemp Dial Nephrol 19:24-28, 1998 249. First MR, Alloway R, Schroeder TJ. Development of Sang-35: A cyclosporine formulation bioequivalent to

Neoral. Clin Transplant 12:518-524, 1998 250. First MR, Weiskittel P, Shah M, Peddi VR, Canafax D, Schroeder TJ. Conversion of stable renal transplant

recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation using a dose-adjusted method. Transplant Proc 30:3955-3957, 1998

251. Shah MB, Martin JE, Schroeder TJ, First MR. A meta-analysis to assess the safety and tolerability of two

formulations of cyclosporine: Sandimmune and Neoral. Transplant Proc 30:4048l-4053, 1998 252. Fleck PR, Schroeder TJ, Dauod AJ, Peddi VR, First MR. Tacrolimus use in kidney-pancreas recipients is

associated with less acute renal dysfunction than cyclosporine. Transplant Proc 30:4070-4072, 1998 253. Daoud AJ, Schroeder TJ, Shah M, Hariharan S, Peddi VR, Weiskittel P, First MR. A comparison of the safety

and efficacy of mycophenolate mofetil, prednisone and cyclosporine, and tacrolimus. Transplant Proc 30:4079-4081, 1998

254. Baker GM, Martin JE, Jang R, Schroeder TJ, Armistead JA, Myre S, First MR. Pharmacoeconomic analysis of

mycophenolate mofetil versus azathioprine in primary renal transplantation. Transplant Proc 30:4082-4084, 1998

23

255. First MR. Immunosuppressive therapy strategies in the immunological high-risk renal transplant recipients.

Organs Tissues 2:83-87, 1998 256. Woodle ES, First MR, Gaber AO, Gaston RS, Mendez R, Mulloy LL, Kano JM, Schroeder TJ. Twelve month

outcome of the double blind, randomized multicenter rejection trial of thymoglobulin vs Atgam in renal transplants. Graft 2 (suppl 1):24-27, 1999

257. Shah MB, Martin JE, Schroeder TJ, First MR. Va lidity of open labeled versus blinded trials: A meta-analysis

comparing Neoral and Sandimmune. Transplant Proc 31:217-219, 1999

258. Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, Ouseph R, Peddi VR, Pelz C, Roza AM, Vincenti F, Ge orge V. Recurrent and de novo glomerular diseases after renal transplantation: A report from The Renal Allograft Disease Registry. Transplant Proc 31:223-224, 1999

259. First MR. Immunologically high-risk recipient strategies. Transplant Proc 31:243-246, 1999 260. Golconda MS, Valente JF, Bejarano P, Gilinsky N, First MR. Mycophenolate mofetil - induced colonic

ulceration in renal transplant recipient. Transplant Proc 31:272-273, 1999 261. Khosla UM, Martin JE, Baker GM, Schroeder TJ, First MR. One-year, single-center cost analysis of

mycophenolate mofetil versus azathioprine following cadaveric renal transplantation. Transplant Proc 31:274-275, 1999

262. First MR, Weiskittel P, Burton ML, Shah MB, Dreyer D, Peddi VR, Canafax DM, Schroeder TJ. Nine-month

follow-up of SangCyA (Sang-35) in kidney transplant patients after conversion from Sandimmune. Transplant Proc 31:324-325, 1999

263. Gaston R, Alloway RR, Gaber AO, Rossi SJ, Schroeder TJ, Irish WD, Canafax DM, First MR. Pharmacokinetic

and safety evaluation of SangCyA vs Neoral or Sandimmune in stable renal transplant recipients. Transplant Proc 31:326-327, 1999

264. Peddi VR, Munda R, Demmy AM, First MR. Long-term outcome in simultaneous kidney and pancreas

recipients with functioning allografts at 1-year post transplantation. Transplant Proc 31:608-609, 1999 265. Peddi VR, Schroeder TJ, Weiskittel P, First MR. Graft outcome in patients with biopsy-proven chronic renal

allograft rejection. Transplant Proc 31:1308-1309, 1999 266. Whiting JF, Zavala EY, Alexander JW, First MR. The cost-effectiveness of transplantation with expanded

donor kidneys. Transplant Proc 31:1320-1321, 1999 267. Shah MB, Schroeder TJ, First MR. Guidelines for immunosuppression management and monitoring after

transplantation in children. Transplant Rev 13:83-97, 1999 268. Martin JE, Daoud AJ, Schroeder TJ, First MR. The clinical and economic potential of cyclosporin drug

interactions. Pharmacoeconomics 15:317-337, 1999 269. First MR. Post-transplant management in the 21st century: New challenges in clinical care. Graft 2 (suppl 2):

24, 1999 270. First MR. Clinical definition of graft rejection: Are the pathologic criteria adequate to identify the clinical

problem? Graft 2 (suppl 2):28-30, 1999

24

271. Lowance D, Newmayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee K, Griffith P, Kletzmayr J, Besse T, Lalaoui H, Salmela K, Besthoux F, Kreis H, Lebranchu Y, Hauser I, Castagneto M, Fauchabl P, Hickey D, Noreiga A, Leski M, Altmann P, Lee H, Rodgers R, Conti D, DeVault G, Holman J, Drummer S, Van Buren D, Dunn D, First R, Gaber AO, Alloway R, Vosatka K, Silibovsky R, Zuckerman J, VanSickler J, Colthart J, Popp F, Wind J, Grant D. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 340:1462-1470, 1999

272. Shah MD, Martin JE, Schroeder TJ, First MR. The evaluation of the safety and tolerability of two

formulations of cyclosporine: Neoral and Sandimmune. Transplantation 67:1411-1417, 1999 273. Schroeder TJ, First MR, Alloway RR, Pan S-H, Gaber AO, Lopez RR, Fisher RA, Irish WD, Canafax DM,

Pouletty P. Review of cyclosporine pharmacokinetic trials in healthy volunteers and kidney and liver transplant recipients: Sang CyA versus Neoral and Sandimmune. Transplant Rev 13:128-134, 1999

274. Brennan DC, Barbetto R, Burke J, Brayman K, Greenstein S, Chang T, Boinker K, Chan L, Conti D, First MR,

Lewis R, Matas A, Metzger R, Mulgoankal S, Neylan J, Perez R, Pescovitz M, Tischer C, Vanderweof B, Wright C. Safety of Neoral conversion in maintenance renal transplant patients: A one-year, double-blind study. Kidney Int 56:685-691, 1999

275. Peddi VR, First MR. Early post-transplant care of renal transplant recipients. Semin Dial 12:320-328, 1999 276. Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, Ouseph R, Peddi VR, Pelz CJ, Roza

AM, Vincent F, George V. Recurrent and de novo glomerular disease after renal transplantation. Transplantation 68:635-641, 1999

277. Dean DE, Kamath S, Peddi VR, Schroeder TJ, First MR, Cavallo T. A blinded retrospective analysis of renal

allograft pathology using the Banff Schema. Implications for clinical management. Transplantation 68:642-645, 1999

278. First MR, Peddi VR. Recurrent disease after renal transplantation. Literature Scan: Transplantation 15:4-5,

1999 279. Alexander JW, Light JA, Donaldson LA, Delmonico FL, Drethelm AG, Wilkinson A, Rosenthal JT,

Thistlethwaite JR, Hunsicker LG, Matas AJ, First MR, Reinsmoen NL, Rose SM. Evaluation of pre and post-transplant donor-specific transfusion/cyclosporine A in non-HLA identical living donor kidney transplant recipients. Transplantation 68:1117-1124, 1999

280. Canafax DM, Irish WD, Moran HB, Squiers E, Levy R, Puoletty P, First MR, Christians U. An individual

approach to compare the intrasubject variability of two cyclosporin formulations, SangCya and Neroal. Pharmacology 59:78-88, 1999

281. First MR, Gaber AO, Olyaei A. Drug substitution in transplantation. Am J Kidney Dis 34:1-2, 1999 (letter). 282. Penn I, First MR. Merkel’s cell carcinoma in organ recipients: Report of 41 cases. Transplantation 68:1717-

1721, 1999 283. First MR, Alloway RR, Fisher RA, Pan S-H, Lopez R, Renlund D, Schnitzler M, Gaber AO. Generic drug

substitution in transplantation: Examples from the epic of cyclosporine development. Dial Transplant 29:260-267, 2000

284. Christians U, First MR, Benet LZ. Recommendations for bioequivalence testing of cyclosporine generics

revisited. Therapy Drug Monit 22:330-345, 2000 285. Brown MR, Noffsinger A, First MR, Penn I, Husseinzadeh N. HPV subtype analysis in lower genital tract

neoplasms of female renal transplant recipients. Gynecol Oncol 79:220-224, 2000

25

286. First MR. What is the role of recently-approved immunosuppressive agents? An update. Contemp Dial Nephrol 21:30-32, 2000

287. First MR. Hepatitis C virus infection in the renal transplant recipient. Nephrol Dial Transplant 15 (suppl

8):60-64, 2000 288. Whiting JF, Woodward R, Zavala EY, Cohen DS, Martin JE, Singer GG, Lowell JA, First MR, Brennan DC,

Schnitzler MA. Economic cost of expanded criteria donors in cadaveric renal transplantation: Analysis of Medicare payments. Transplantation 70:755-760, 2000

289. Whiting J, Evans R, First MR, Keown P, Martin J, Pinson PW, Schnitzler M, Schroeder T, Whiting J, Zavala

E. Standards for economic and quality of life studies in transplantation. Transplantation 70:1115-1121, 2000 290. Roy-Chaudhury P, Alexander JW, First MR, Peddi VR, Munda R, Cavallo T. Immediate allograft dysfunction

due to atheroembolic disease. Am J Kidney Dis 2:423-426, 2001 291. First MR, The organ shortage and allocation issues. Transplant Proc 31:806-810, 2001 292. Phillips AL, Walker EL, Martin JE, First MR, Hanto DW, Whiting JF. Quality of life as a predictor of

morbidity, mortality, and resource utililzation after transplantation. Transplant Proc 33:1886, 2001 293. Boyd SR, Martin JE, First MR, Whiting, JF. Health utililty scores following renal transplantation. Transplant

Proc 33:1900, 2001 294. Martin JE, Shireman TI, First MR, Whiting JF. Quality of life following solid organ transplantation in

Medicaid beneficiaries. Transplant Proc 33:1909, 2001 295. First MR. Post-transplant diabetes mellitus. Literature Scan: Transplantation 17:4-5, 2001 296. First MR. Tailoring immunosuppressive therapy based on donor and recipient risk factors. Transplant Proc

33:2207-2211, 2001 297. Kelly BS, Alexander JW, Dreyer D, Greenberg NA, Ericson A, Whiting JF, Ogleck, Babcock GF, First MR.

Oral arginine improves blood pressure in renal transplant patients. J Parent Ent Nutr 25:194-202, 2001 298. Peddi VR, First MR. Recent advances in immunosuppressive therapy for reanl transplantation. Semin Dial

14:218-222, 2001 299. First MR. Interactive Grand Rounds Case 1: Persistent acute rejection after kidney transplantation.

Transplantation 71:1697-1698, 2001 300. First MR. Interactive Grand Rounds Case 2: Post-transplant diabetes mellitus in renal transplantation.

Transplantation 71:1872-1873, 2001 301. First MR. Interactive Grand Rounds Case 3: Cardiovascular disease in renal transplantation. Transplantation

72:556-557, 2001 302. First MR. Interactive Grand Rounds Case 4: Post-transplant lymphoproliferative disease in renal

transplantation. Transplantation 72:754-755, 2001 303. First MR. Interactive Grand Rounds Case 5: Recurrent disease in transplantation. Transplantation 72:979,

2001 304. First MR. Interactive Grand Rounds Case 6: Benefits and risks of OKT3 treatment in renal transplantation.

Transplantation 72:1177-1178, 2001

26

305. First MR. Strategies to minimize immunological and nonimmunological risk factors in the renal transplant population. Transplantation 72 (suppl): S20-S24, 2001

306. Buell JF, Trofe J, Hanaway MJ, Lo A, Rosengard B, Rilo H, Alloway R, Beebe T, First MR, Woodle ES.

Transmission of donor cancer into cardiothoracic recipients. Surgery 130:660-668, 2001

27

BOOKS AND CHAPTERS 1. Pesce AJ, First MR. Proteinuria - An Integrated Review. Marcel Dekker, Inc., New York and Basel, 1979 2. First MR, Pollak VE. Renal insufficiency in the diabetic patient with heart disease. In, Clinical Cardiology and

Diabetes. Scott RC (Ed.), Vol. III, Part 2, Futura Publishing Co., Inc., Mount Kisco, New York, 1981, pp 63-92 3 First MR. Chronic Renal Failure. Pathophysiology, Clinical Manifestations, and Management. Medical

Examination Publishing Co., Inc., Flushing, New York, 1982 4 First MR. Renal function. In, Clinical Chemistry. Kaplan LA, Pesce AJ (Eds.), C. V. Mosby & Co., St. Louis,

Missouri, 1984, pp 403-419 5. First MR. Post-traumatic acute renal failure. In, Common Problems in Trauma and Critical Care. Hurst JM (Ed.),

Year Book Medical Publishers, Inc., Chicago, 1987, pp 407-412 6. First MR. The use of laboratory tests in renal disease, acid-base and electrolyte disorders. In, Methods in

Clinical Chemistry. Pesce AJ, Kaplan LA (Eds.), C. V. Mosby & Co., St. Louis, Missouri, 1987, pp 2-4 7. First MR. Blood tranfusion and immunosuppression. In, Southeastern Organ Procurement Tissue Typing

Manual. Macqueen JM (Ed.), Chapter 8, 1987, pp 8:1 - 8:6 8. Alexander JW, First MR, Munda R, Fidler JP, Penn I, Weiskittel P, Collins J, Waymack JP. The transfusion

effect. In, Chronic Renal Failure and Transplantation. Haberal MA (Ed.), Turkish Transplantation and Burn Foundation, Ankara, Turkey, 1987, pp 185-193

9. First MR, Pollak VE. Pregnancy and renal disease. In, Diseases of the Kidney. Schrier RW, Gottschalk CW

(Eds.), 4th Edition, Vol. III, Chapter 83, Little Brown & Co., Boston, 1988, pp 2533-2559 10. First MR. The evaluation and medical management of the immunosuppressed host who requires operative

intervention. In, Surgery in the Immunocompromised Host, Problems in General Surgery. Pollak R, Nyhus LM (Eds.), Vol. 6, Number 3, J. P. Lippincott & Co., Philadelphia, 1989, pp 388-394

11. First MR, Renal function. In, Clinical Chemistry: Theory, analysis and correlation. Second edition. Kaplan LA,

Pesce AJ (Eds.), C.V. Mosby Company, St. Louis, Missouri, 1989, pp 346-358 12. Schroeder TJ, Myre SA, Pesce AJ, First MR. Practical aspects of cyclosporine use and monitoring at the

University of Cincinnati Medical Center. In, Advances in Therapeutic Drug Monitoring. Tanaka K, Pippenger CE, Mimaki T, Walson PD, Ohgitani S (Eds.), Enterprise, Tokyo, 1990,

pp 262-270 13. First MR. Pre-transplant evaluation and preparation of donors and recipients. In, The Principles and Practice

of Nephrology. Jacobson HR, Striker GE, Klahr S (Eds.), B. C. Decker, Inc., Philadelphia, 1991, pp 820-825 14. First MR. Annual review of transplantation. In, Clinical Transplants 1990. PI Terasaki (Ed.) UCLA Tissue

Typing Laboratory, Los Angeles, 1991, pp 357-373 15. Schroeder TJ, First MR, Penn I. Multi-organ transplant experience with OKT3 and strategies for use at the

University of Cincinnati Medical Center. In, Organ Transplantation 1990. Abouna GM, Kumar MSA, White AG (Eds.), Kluwer Academic Publishers, Dordrecht, Netherlands, 1991, pp 91-100

16. Alexander JW, First MR, Hariharan S, Penn I, Schroeder TS, Ryckman F, Munda R, Bhat G, Bolce R. Recent contributions to transplantation at University of Cincinnati. In, Clinical Transplants, 1991. PI Terasaki,

JM Cecka (Eds.) UCLA Tissue Typing Laboratory, Los Angeles, 1992, pp 159-178

28

17. First MR, Pollak VE. Pregnancy and renal disease. In, Diseases of the Kidney. Schrier RW, Gottschalk CW

(Eds.), 5th Edition, Vol. III, Chapter 83, Little Brown & Co., Boston, 1993, pp 2287-2310 18. Hariharan S, Schroeder TJ, First MR. Cytomegalovirus infection after renal transplantation. In, Asian

Nephrology - Proceedings of the Fifth Asian Pacific Congress of Nephrology. Chugh KS (Ed.), Oxford University press, Delhi, 1994, Chapter 77, pp 689-694

19. Hariharan S, Schroeder TJ, First, MR. Cyclosporine A drug interactions. In, Asian Nephrology - Proceedings of

the Fifth Asian Pacific Congress of Nephrology. Chugh KS, (Ed.), Oxford University Press, Delhi, 1994, Chapter 85, pp 748-754.

20. First MR. Pretransplant evaluation and preparation of donors and recipients. In, The Principles and Practice of

Nephrology. Jacobson HR, Striker GE, Klahr S (Eds.), 2nd edition, Mosby-Year Book, Inc., St. Louis, 1995, pp 805-810

21. Johenning AR, First MR. Is chronic renal disease a contraindication to pregnancy? In, International Yearbook of

Nephrology Dialysis Transplantation. Andreucci VE, Fine LG (Eds.), Oxford University Press, Oxford, 1995, pp 35-44

22. First MR, Schroeder TJ. The relationship between cyclosporin bioavailability, clinical outcome and resource

utilization in renal transplant recipients. In, Rational use of Neoral. R. Johnson (Ed.), The Royal Society of Medicine Press Limited, London, 1996, pp 5-13.

23. First MR. Clinical diagnosis of renal allograft rejection. In, Solid Organ Transplant Rejection: Mechanisims,

Pathology, and Diagnosis. Solez K, Racusen LC, Billingham ME (Eds.), Marcel Dekker, Inc., New York, 1996, pp 431-443

24. First MR. Renal Function. In, Clinical Chemistry: Theory, analysis and correlation. Third edition. Kaplan LA,

Pesce AJ (Eds.), C.V. Mosby Company, Chicago, Illinois, 1996, pp 484-504 25. Schroeder TJ, Rossi SJ, Schleuter KT, First MR. Laboratory evaluation of the transplant recipient and donor. In,

Clinical Chemistry: Theory, analysis and correlation. Third edition. Kaplan LA, Pesce AJ (Eds.), C.V. Mosby Company, Chicago, Ilinois, 1996, pp 1004-1116

26. First MR. The role of polyclonal and monoclonal antibodies in organ transplantation. In, Current

Immunosuppression: An Update. NS Hakim (Ed.), The Royal Society of Medicine Press Limited, London, 1997, pp 7-14

27. First MR. Immunosuppression and treatment of rejection. In, Therapy of Renal Diseases and Related Disorders.

Third edition. Suki WN, Massry SG (Eds.), Kluwer Academic Publishers, Boston, 1997, pp 1107-1137 28. First MR. The evaluation and preparation of donors and recipients for renal transplantation. In, Therapy in

Nephrology and Hypertension. A companion to Brenner and Rector's The Kidney. Brady HR, Wilcox CS (Eds.), W. B. Saunders Company, Philadelphia, PA, 1998, pp 603-607.

29. Peddi VR, First MR. Medical complications of kidney transplantation. In, Dialysis and Transplantation. A

companion to Brenner and Rector’s The Kidney. Owen BF, Pereira BJG, Sayegh MH (Eds.), W. B. Saunders Company, Philadelphia, PA, 2000, pp 595-612.

30. Roy-Chaudhury P, Whiting JF, Miller MA, Reaves A, Denman D, Munda R, Heffelfinger SC. Neointimal

hyperplasia and hemodialysis access dysfunction: A pathogenetic role for cytokines, matrix proteins, and specific cell types. In, Vascular Access for Hemodialysis. Henry ML (Ed.), W. L. Gore and Associates, Inc., Precept Press, 2000, pp 45-53.

29

31. Peddi VR, First MR. Antilymphocyte antibodies. In, Textbook of Nephrology, Massry SG, Glassock RJ (Eds.), 4th edition, Lippincott Williams and Wilkins, 2001, pp 1640-1646

32. Peddi VR, First MR. Diagnosis and treatment of renal dysfunction episodes. In, Primer on Transplantation.

Norman DJ, Turka LA (Eds.), 2nd edition, American Society of Transplantation, 2001, pp 459-466

30

ABSTRACTS M. ROY FIRST

*1. DIPYRIDAMOLE (PERSANTIN) AND WARFARIN IN THE TREATMENT OF GLOMERULONEPHRITIS

First MR, Goldberg B, and Abrahams C S Afr Med J 46: 848-849, 1972 2. THE EFFECT OF HUMAN LIGHT (KAPPA) CHAINS OF FUNCTION AND MORPHOLOGY OF THE RAT

KIDNEY Clyne DH, Brendstrup L, First MR, Pesce AJ, Levy ME, and Pollak VE Proceedings of the annual meeting of the American Society for Clinical Investigation, Atlantic City, New Jersey, 1973. Abstract 68, J Clin Invest 52: 19a, 1973 *3. INTERSTITIAL NEPHRITIS: CLINICAL AND PATHOLOGIC OBSERVATIONS AND POSSIBLE

PATHOGENESIS Ooi BS, Jao W, First MR, and Pollak VE Clin Res 21: 895a, 1973 4. INJECTION OF HUMAN KAPPA CHAIN IN THE RAT: INDUCTION OF TUBULAR PROTEINURIA AND

INTRACELLULAR CRYSTALS Clyne DH, Brendstrup L, First MR, Pirani CL, Pesce AJ, and Pollak VE Proceedings of 6th annual meeting of the American Society of Nephrology Washington, D, C., p. 23, 1973 5. PROTEINURIA FOLLOWING RENAL TRANSPLANTATION Sethi KK, Pesce AJ, First MR, Hsu MA, Alexander JW, and Pollak VE Proceedings of 7th annual meeting of the American Society of Nephrology Washington, D.C., p. 81, 1974 *6. FULMINANT PNEUMOCOCCAL SEPSIS IN SPLENECTOMIZED RENAL ALLOGRAFT RECIPIENTS McEnery PT, Flanagan J, First MR, and Laver MD Proceedings of 8th annual meeting of the American Society of Nephrology Washington, D.C., 1975 Kidney International 8: 499, 1975 7. ALBUMIN EXCRETION BY THE KIDNEY: EFFECTS OF OSMOTIC DIURESIS Patel VB, First MR, Pesce AJ, and Pollak VE Clin Res 24: 408a, 1976 8. PULMONARY INFECTIONS IN RENAL TRANSPLANT PATIENTS Munda R, Alexander JW, Fidler JP, First MR, and Gartside P Association for Academic Surgeons, 1976 9. RENAL ALLOGRAFT ARTERIAL STENOSIS Munda R, Alexander JW, Fidler JP, First MR, and Miller S Association of International Transplant Surgeons, 1976 *10. HYPOTHERMIC PULSATILE PERFUSION AND TRANSPLANTATION OF PEDIATRIC CADAVERIC KIDNEYS INTO ADULTS Munda R, Miller JC, Alexander JW, First MR, and Fidler JP International Transplantation Society, New York, 1976 *11. PULMONARY INFECTIONS IN RENAL TRANSPLANT RECIPIENTS Munda R, Alexander JW, Fidler JP, and First MR Clinical Dialysis and Transplant Forum, Washington, D.C., p. 13, 1976 12. EFFECT OF VOLUME EXPANSION AND OSMOTIC DIURESIS ON RENAL ALBUMIN EXCRETION

31

First MR, Patel VB, Sloan DE, Pesce AJ, and Pollak VE Clin Res 24: 553a, 1976 13. MANAGEMENT OF AZATHIOPRINE DOSAGE DURING ACUTE TUBULAR NECROSIS FOLLOWING

CADAVERIC RENAL TRANSPLANTATION Laver MC, First MR, and Alexander JW Proceedings of the 9th annual meeting of the American Society of Nephrology, Washington, D.C., p.

122, 1976 *14, PRE-ECLAMPSIA WITH THE NEPHROTIC SYNDROME First MR, Ooi BS, Jao W, and Pollak VE Proceedings of the 9th annual meeting of the American Society of Nephrology, Washington, D.C.,

p.12, 1976 15. DEMONSTRATION OF CIRCULATING IMMUNE COMPLEXES IN RELATION TO REJECTION EPISODES

AFTER RENAL TRANSPLANTATION Ooi YM, Ooi BS, Vallota EH, First MR, and Pollak VE Proceedings of the 9th annual meeting of the American Society of Nephrology, Washington, D.C., p.

122, 1976 *16. ERYTHROCYTE SPERMINE DEFICIENCY AND THE ANEMIA OF CHRONIC RENAL FAILURE Denton DD, First MR, Glazer HS, Smith FG, Edwards BK, and Hogg JW American Society of Hematology, Boston, 1976 17. SURVEY OF FAMILY ATTITUDES TOWARDS ANATOMICAL DONATION FOLLOWING DEATH AND

ORGAN RECOVERY Schott DL, Hartman MP, First MR, and Alexander JW American Society of Transplant Surgeons, Chicago, 1977 *18. THE VALUE OF URINE CYTOLOGY IN RENAL TRANSPLANTATION Fidler JP, Dajani FA, First MR, and Alexander JW American Society of Transplant Surgeons, Chicago, 1977 *19. CORRECTION OF ERYTHROID POLYAMINE METABOLISM BY RENAL TRANSPLANTATION Denton DD, First MR, Glazer HA, Smith FG, and Edwards BK American College of Physicians Regional Meeting, September, 1977 *20. BENEFICIAL EFFECT OF PRIOR SPLENECTOMY ON GRAFT SURVIVAL IN CADAVERIC RENAL

TRANSPLANTATION Laver MC, Pollak VE, First MR, Clyne DH, and Alexander JW Proceeding of the 10th annual meeting of the American Society of Nephrology, Washington, D. C., 1977, p. 81 *21. TWELVE YEAR SURVIVAL IN A PATIENT WITH WEGENER'S GRANULOMATOSIS: TREATMENT WITH

PNEUMONECTOMY AND RENAL TRANSPLANTATION Hess EV, First MR, and Johnson RL Proceedings of the Pan-American Congress of Pheumatic Diseases Bogota, Columbia, 1978 *22. DYNAMIC CHANGES IN FRACTIONAL EXCRETION OF FILTERED SODIUM (FENa) AFTER RENAL

TRANSPLANTATION Hong CD, Kapoor BS, First MR, and Pollak VE VII International Congress of Nephrology Montreal, Quebec, Canada, June, 1978

32

*23. INJECTION OF ALTERED HUMAN ALBUMIN (pI 9.6) IN THE RAT: INDUCTION OF INCREASED GLOMERULAR PERMEABILITY AND ACUTE RENAL FAILURE

Pesce AJ, Miller WC, Clyne DH, First MR, Bramlage R, Purtell JN, and Pollak VE VII International Congress of Nephrology Montreal, Quebec, Canada, June, 1978 *24. VOLUME EXPANSION, OSMOTIC DIURESIS AND FUROSEMIDE DIURESIS ON RENAL ALBUMIN

EXCRETION First MR, Patel VB, Sloan DE, Pesce Aj, and Pollak VE VII International Congress of Nephrology Montreal, Quebec, Canada, June, 1978 * 25. NON-SPECIFIC DEFENSE AGAINST INFECTION DURING THE EARLY POST-TRANSPLANT PERIOD Alexander JW, Stinnett JD, Ogle CK, Bright MW, and First MR Proceedings of New Frontiers in Transplantation, Rome, Italy, 1978 *26. THE CORRELATION OF KIDNEY TRANSPLANT SURVIVAL WITH LYMPHOCYTE MEDIATED

CYTOTOXICITY (LMC) ON B CELL TARGETS Nathan P, Plessinger RT, and First MR National Kidney Foundation Clinical Dialysis and Transplant Forum, 1978 *27. EXPERIENCE WITH EXPANDED POLYTETRAFLEUROETHYLENE (PTFE) AS A SECONDARY PROCEDURE

FOR ANGIO-ACCESS IN HEMODIALYSIS PATIENTS Munda R, First MR, Alexander JW, and Linnemann CC National Kidney Foundation Clinical Dialysis and Transplant Forum, 1979 28. PNEUMOCYSTIS CARINII PNEUMONIA (PCP) FOLLOWING RENAL TRANSPLANTATION First MR, Hamoui T, Munda R, Alexander JW, and Fidler JP National Kidney Foundation Clinical Dialysis and Transplant Forum, 1978 *29. MEASUREMENT OF URINE UREA NITROGEN (UUN) AND CREATININE (UCr) ON THE IL 919 BY KINETIC

METHODS Suddendorf LR, Kaplan LA, First MR, and Stien FA American Association for Clinical Chemistry Meeting, Chicago, May, 1979 30. AN APPROACH TO SURVIVAL ANALYSIS IN PATIENTS WITH CHRONIC RENAL FAILURE (ESRD) Garcia G, First MR, Samuels S., Kant KS, Hong CD, Ooi BS, and Pollak VE Proceedings of the 12th Annual Meeting of the American Society of Nephrology, Boston, 1979, p. 160 *31. HLA-BW4 AND BW6 MATCHING AND RENAL ALLOGRAFT SURVIVAL Spreng WM, Nathan P, and First MR National Kidney Foundation Clinical Dialysis and Transplant Forum, Boston, 1979 *32. STEROID WITHDRAWAL FOLLOWING HLA -IDENTICAL RELATED DONOR TRANSPLANTATION First MR, Munda R, Fidler JP, and Alexander JW 8th International Congress of the Transplant Society, Boston, 1980 *33. PROSPECTIVE LYMPHOCYTE MEDIATED CYTOTOXICITY ON B-CELL TARGETS AND THE SELECTION

OF HUMAN KIDNEY ALLOTRANSPLANT RECIPIENTS Nathan P, Plessinger RT, Alexander JW, and First MR American Physiological Society Annual Meeting, Toronto, 1980 *34 MICROBIAL CONTAMINATION OF TRANSPLANTED CADAVER KIDNEYS Majeski JA, Alexander JW, First MR, Munda R, Fidler JP, and Craycraft TK

33

lst Annual Meeting of the Surgical Infection Society, Chicago, 1981 *35. URINARY RETENTION CAUSED BY NON-ANATOMICAL URETHRAL OBSTRUCTION FOLLOWING RENAL

TRANSPLANTATION Sugarman SR, Munda R, Alexander JW, and First MR American Society of Transplant Surgeons, Chicago, 1981 *36. THE SPECIFIC MIXED LYMPHOCYTE CULTURE (MLC)-LYMPHOCYTE MEDIATED CYTOTOXICITY (LMC)

TEST TO MATCH RELATED DONORS AND RECIPIENTS FOR KIDNEY ALLOTRANSPLANTS Nathan P, Plessinger RT, Alexander JW, and First MR Federation of the American Society for Experimental Biology, Atlanta, 1981 *37. PULMONARY INFECTIONS FOLLOWING RENAL TRANSPLANTATION First MR, Munda R, Alexander JW, Linnemann CC, Jr., Fidler JP, and Majeski JA VIIIth International Congress of Nephrology, Athens, Greece, 1981

*38. COMPLICATIONS OF POLYTETRAFHOROETHYLENE (PTFE) GRAFTS FOR

CHRONIC HEMODIALYSIS Munda R, First MR, and Alexander JW European Society for Surgical Research, Pavia, Italy, 1982

*39 BENEFICIAL EFFECT OF PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN RENAL TRANSPLANT

RECIPIENTS First MR, Linnemann CC, Munda R, and Alexander JW 9th International Congress of the Transplant Society Brighton, England, 1982 *40. DNCB TESTING PREDICTS EFFECT OF SPLENECTOMY ON RENAL

TRANSPLANT OUTCOME Alexander JW, First MR, Majeski JA, Munda R, Fidler JP, and Morris, MJ 5th Tripartite Meeting of the Society of University Surgeons Salzburg, Austria, 1982 *41. PRE-TRANSPLANT DONOR SPECIFIC TRANSFUSIONS, SENSITIZATION AND OUTCOME IN RENAL

TRANSPLANTS First MR, Balakrishnan K, Alexander JW, Munda R, and Whitacre LR American Assoc. of Blood Banks, 35th Annual Meeting Anaheim, California, 1982, In, Transfusion, 1982, p. 403 *42. SIMULTANEOUS KIDNEY AND PANCREAS PROCUREMENT: THE CINCINNATI EXPERIENCE Munda R, Suttman MP, First MR, and Alexander JW International Congress on Organ Procurement, Maastricht, Netherlands, 1983 43. PULMONARY INFECTIONS IN RENAL TRANSPLANT RECIPIENTS ANALYSIS OF RESULTS BY PERIODS. Munda R, First MR, Alexander JW, Linnemann CC, Fidler JP, and Morris MJ 3rd Annual Meeting of the Surgical Infectious Society Fort Lauderdale, Florida, 1983 44. PULMONARY INFECTIONS IN RENAL TRANSPLANT RECIPIENTS Munda R, First MR, Alexander JW, Linnemann CC, Fidler JP, and

34

Morris MJ American Society of Transplant Surgeons, Chicago, Illinois, 1983 *45. ACUTE RENAL FAILURE DELAYS FIRST REJECTION EPISODE FOLLOWING CADAVERIC RENAL TRANSPLANTATION Imler G, Alexander JW, First MR, and Munda R American Society of Transplant Surgeons, Chicago, Illinois, 1983 *46. BENEFICIAL EFFECT OF PNEUMOCCAL POLYSACCHARIDE VACCINE IN RENAL TRANSPLANT RECIPIENTS First MR, Linnemann CC, Munda R, and Alexander JW American Society of Transplant Physicians, Chicago, Illinois, 1983 47. PRE-TRANSPLANT DONOR SPECIFIC TRANSFUSIONS, SENSITIZATION OUTCOME IN RENAL TRANSPLANTS First MR, Balakrishnan K, Alexander JW, Munda R, and Whitacre LR American Society of Transplant Physicians, Chicago, Illinois, 1983 *48. CLINICAL EXPERIENCE WITH SEGMENTAL PANCREATIC ALLOGRAFTS Munda R, First MR, Webb C, and Alexander JW International Symposium on Organ Transplantation in Diabetics, Hague, The Netherlands, 1983 *49. PRE-TRANSPLANT DONOR SPECIFIC TRANSFUSIONS AND SENSITIZATION First MR, Balakrishnan K, Alexander JW, Munda R, and Whitacre LR V International Congress of Immunology, Japan, 1983 *50. PROTEINURIA FOLLOWING TRANSPLANTATION: CORRELATION WITH HISTOPATHOLOGY AND OUTCOME First MR, Vaidya P, Maryniak RC, Weiss MA, Munda R, Fidler JP, Penn I, and Alexander JW American Society of Transplant Physicians, Chicago, Illinois, 1984 *51. MEMBRANOUS GLOMERULOPATHY FOLLOWING KIDNEY TRANSPLANTATION. ASSOCIATION WITH RENAL VEIN THROMBOSIS IN TWO OF SEVEN CASES First MR, Mendoza N, Maryniak RC, and Weiss MA American Society of Transplant Physicians, Chicagio, Illinois, 1984 *52. TRANSPLANT GLOMERULOPATHY - EVOLUTION OF MORPHOLOGICALLY DISTINCT CHANGES Maryniak RC, Weiskittel P, First MR, and Weiss MA Ninth International Congress of Nephrology, Los Angeles, California, 1984 *53. PULMONARY INFECTIONS IN RENAL TRANSPLANT RECIPIENTS Munda R, First MR, and Alexander JW 3rd International Symposium on Infections in the Immunocompromised Host, Toronto, Canada, 1984

35

*54. BENEFICIAL EFFECT OF PNEUMOCOCAL POLYSACCHARIDE VACCINE IN RENAL TRANSPLANT RECIPIENTS First MR, Linnemann CL, Munda R, and Alexander JW 10th International Congress of the Transplant Society, Minneapolis, Minnesota, 1984 *55. EXPERIENCE WITH PANCREATIC ALLOGRAFTS IN RENAL TRANSPLANT RECIPIENTS Munda R, Alexander JW, First MR, LeRoith D, Joffe SN, and Frohman LA 10th International Congress of the Transplant Society Minneapolis, Minnesota, 1984 *56. DONOR SPECIFIC PRETRANSPLANT BLOOD TRANSFUSIONS - SENSITIZATION PATTERNS Balakrishnan K, Whitacre L, First MR, Alexander JW, and Munda R International Symposium on Relevant Immunological Factors in Clinical Kidney Transplantation, Heidelberg, June, 1985 57. PHARMACOKINETICS AND DRUG INTERACTIONS OF CYCLOSPORINE AND ERYTHROMYCIN Wadhwa N, Schroeder T, O'Flaherty E, Pesce A, and First MR Clin. Res. 34: 638A, 1986 *58. LOW DOSE TRIPLE IMMUNOSUPPRESSIVE THERAPY IN RENAL TRANSPLANTATION First MR, Alexander JW, Wadhwa NK, Penn I, Munda R, and Fidler JP 5th Annual Meeting of American Society of Transplant Physicians, Chicago, May, 1986 *59. THE EFFECT OF ORAL METOCLOPRAMIDE ON THE ABSORPTION OF ORAL CYCLOSPORINE Wadhwa NK, Schroeder T, O'Flaherty, Pesce E, Myre S, and First MR 5th Annual Meeting of American Society of Transplant Physicians, Chicago, May, 1986 *60. PANCREATIC ALLOGRAFT EXOCRINE URINARY TRACT DIVERSION; PATHOPHYSIOLOGY Munda R, Tom WW, First MR, and Alexander JW American Society of Transplant Surgeons, Chicago, May, 1986 *61. HLA ANTIGENS IN DIABETIC END STAGE RENAL DISEASE Balakrishnan K, Wadhwa N, First MR, Munda R, Whitacre L, and Alexander JW 6th International Congress of Immunology, Toronto, July, 1986 *62. CYCLOSPORINE COMPARISONS INVOLVING CHANGES IN MATRIXES AND METHODS Schroeder TJ, Pesce AJ, Wadhwa NK, and First MR 38th National Meeting of the American Association for Clinical Chemistry, Chicago, 1986 *63. PHYSIOLOGIC CONSEQUENCES OF PANCREATIC ALLOGRAFT EXOCRINE DRAINAGE INTO THE URINARY TRACT Tom WW, Munda R, First MR, and Alexander JW 11th International Congress of the Transplantation Society Helsinki, August, 1986 *64. SYNCHRONOUS PANCREATIC AND RENAL ALLOGRAFTS WITH URINARY TRACT DRAINAGE OF THE PANCREAS

36

Munda R, First MR, Weiss MA, and Alexander JW 11th International Congress of the Transplantation Society Helsinki, August, 1986 *65. THE EFFECT OF ORAL METOCLOPRAMIDE ON THE ABSORPTION OF CYCLOSPORINE Wadhwa NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, and First MR 11th International Congress of the Transplantation Society, Helsinki, August, 1986 *66. PRELIMINARY CYCLOSPORINE PHARMACOKINETIC COMPARISONS IN ADULT AND ADOLESCENT RENAL TRANSPLANTS AND ADULT CARDIAC TRANSPLANTS Schroeder T, Clardy C, Wadhwa N, McEnery P Pesce A, Melvin D, and First MR ClinChem-86, New York, Novewmber, 1986 *67. CURRENT EXPERIENCE WITH RENAL TRANSPLANTATION IN ELDERLY PATIENTS Shah B, First MR, Alexander JW, Penn I, Munda R, and Fidler J 16th Annual Scientific Meeting, National Kidney Foundation, Inc., Washington, D.C., December, 1986 *68. PANCREAS TRANSPLANTATION AT THE UNIVERSITY OF CINCINNATI Munda R, First MR, Weiss MA, and Alexander JW Second International Workshop in Clinical Pancreatic Transplantation, Munich, December, 1986 69. A NEW METHOD FOR PHARMACOKINETIC MODELING OF CYCLOSPORINE Clardy C, Schroeder T, Wadhwa N, McEnery P, Pesce A, Melvin D, and First MR 19th Annual Meeting of the American Society of Nephrology, Washington, December, 1986 *70. THE USE OF CYCLOSPORINE AND KETOCONAZOLE WITHOUT NEPHROTOXICITY IN TWO HEART TRANSPLANT RECIPIENTS Schroeder TJ, Melvin DB, Clardy CW, Myre SA, Reising JM, Wolf RK, Collins JA, Pesce AJ, and First MR 7th Annual Scientific Session, The International Society for Heart Transplantation, New Orleans, March, 1987 * 71. TRANSPLANTATION IN PATIENTS WITH HIGH PANEL REACTIVE ANTIBODIES Balakrishnan K, Whitacre L, Tressler T, First MR, Alexander JW, Munda R, and McEnery P American Society of Transplant Surgeons, Chicago, 1987 * 72. LOW DOSE CYCLOSPORINE IN RENAL TRANSPLANTATION; 3 YEARS EXPERIENCE Wadhwa NK, First MR, Alexander JW, Balakrishnan K, Munda R, Penn I, and Fidler JP American Society of Transplant Physicians, Chicago, May, 1987 *73. CURRENT EXPERIENCE WITH RENAL TRANSPLANTATION IN PATIENTS 50 YEARS AND ABOVE

37

Shah BV, First MR, Munda R, Penn I, Fidler JP, and Alexander JW American Society of Transplant Physicians, Chicago, May, 1987 *74. CLINICAL EFFICACY AND SIDE EFFECTS OF OTHOCLONE OKT3 IN RENAL PANCREATIC, HEPATIC AND CARDIAC TRANSPLANTATION Schroeder TJ, Weiskittel P, Bailey D, Melvin DB, Munda R, Clardy CW, Balisteri WF, Penn I, Fidler JP, Alexander JW, and First MR American Society of Transplant Physicians, Chicago, May, 1987 *75. THE CLINICAL VARIABILITY OF CYCLOSPORINE PHARMACOKINETICS IN ADULT AND PEDIATRIC

RENAL, CARDIAC, HEPATIC, AND BONE MARROW TRANSPLANTS Clardy CW, Schroeder TJ, Wadhwa NK, Pesce AJ, First MR, Myre SA, McEnery PT, Balisteri WF, Harris RE, and Melvin DB American Society of Transplant Physicians, Chicago, 1987 *76. INCIDENCE AND MORBIDITY OF CYTOMEGALOVIRUS DISEASE ASSOCIATED WITH A SERONEGATIVE RECIPIENT RECEIVING SEROPOSITIVE DONOR SPECIFIC TRANSFUSION AND LIVING RELATED DONOR TRANSPLANTATION: A MULTI-CENTER EVALUATION Weir MR, Henry ML, Blackmore M, Smith J, First MR, Irwin B, and Shen, S American Society of Transplant Physicians, Chicago, May, 1987 *77. CLINICAL VARIABILITY OF CYCLOSPORINE PHARMACOKINETICS Clardy CW, Schroeder TJ, Wadhwa NK, Pesce AJ, First MR, Myre SA, McEnery PT, Balisteri WF, Harris RE, and Melvin DB 39th Annual Meeting of the American Association for Clinical Chemistry, San Francisco, July, 1987 *78. CHANGES IN CYLCLOSPORINE METABOLISM WITH CO-ADMINISTRATION OF KETOCONAZOLE Schroeder TJ, Melvin DB, Clardy CW, Wadhwa NK, Myre SA, Reising JM, Wolf RK, Collins JA, Pesce AJ, and First MR 39th Annual Meeting of the American Association for Clinical Chemistry San Francisco, July, 1987 79. HLA ANTIGENS AND DONOR SPECIFIC BLOOD TRANSFUSION IN DIABETIC RENAL ALLOGRAFT RECIPIENTS Wadhwa NK, Balakrishnan K, First MR, Whitecre L, and Alexander JW 10th International Congress of Nephrology, London, July, 1987 80. LOW DOSE CYCLOSPORINE IN CACAVERIC RENAL TRANSPLANTATION: 3 YEARS EXPERIENCE Wadhwa NK, First MR, Alexander JW, Balakrishnan K, Munda R, Penn I, and Fidler JP Second International Congress on Cyclosporine Washington, D.C., November, 1987 *81. USE OF CYCLOSPORINE BY CONSTANT-RATE INTRAVENOUS INFUSION IMMEDIATELY FOLLOWING HEART TRANSPLANTATION Myre S, Schroeder T, Clardy C, First MR, Pesce A, Wadhwa N, and Melvin D Second International Congress on Cyclosporine Washington, D.C., November, 1987 *82. CYCLOSPORINE PHARMACOKINETICS IN PANCREAS TRANSPLANT RECIPIENTS

38

Munda R, Schroeder TJ, Pedersen S, Clardy CW, Washwa NK, Myre SA, Pesce AJ, and First MR Second International Congress on Cyclosporine Washington, D.C., November, 1987 *83. EVALUATION OF ABBOTT TDX FLUROESCENCE POLARIZATION IMMUNOASSAY AND SANDOZ RADIOIMMUNOASSAY METHODS FOR THE ASSAY OF SERUM CYCLOSPORINE Schroeder TJ, Pesce AJ, Hasson FM, Wermeling JR, and First MR Second International Congress on Cyclosporine Washington, D.C. November, 1987 *84. LYMPHOCYTE SUBSET ANALYSIS IN TRANSPLANT RECIPIENTS TREATED

WITH EITHER RABBIT ANTITHYMOCYTE SERUM OF ORTHOCLONE OKT3 Schroeder TJ, Hurtubise PE, Marmer DJ, Melvin DB, Collins JA, Alexander JW, and First MR 2nd Annual Meeting on Clinical Application of Cytometry Charleston, S.C., October, 1987 *85. USE OF ORTHOCLONE OKT3 IN HEPATIC ALLOGRAFT TRANSPLANT RECIPIENTS Schroeder TJ, Balistreri WF, Pedersen SH, Ryckman FC, Suchy FJ, Noseworthy J, Blitzer B, Foote M, Penn I, Alexander JW, and First MR Am. Assoc. for the Study of Liver Disease, Chicago, October, 1987 86. SURVIVAL PATTERNS IN LUPUS NEPHRITIS WITH END-STAGE RENAL DISEASE Wadhwa NK, Kant KS, Clyne DH, First MR, and Pollak VE 20th Annual Meeting of American Society of Nephrology Washington, D.C., December, 1987 87. EFFECT OF CYCLOSPORINE ON FRACTIONAL EXCRETION OF SODIUM IN RENAL TRANSPLANT

PATIENTS Shah BV, Hong CD, and First MR 20th Annual Meeting of American Society of Nephrology Washington, D.C., December, 1987

*88. OUTCOME OF KIDNEY TRANSPLANTS ACROSS B CELL POSITIVE CROSSMATCHES Balakrishnan K, Munda R, First MR, and Alexander JW Biology of Transfusion Induced Immunosuppression Snowbird, Utah, January, 1988 *89. CYCLOSPORINE PHARMACOKINETICS IN PANCREAS TRANSPLANT RECIPIENTS Pesce Aj, and First MR

First International Congress on Pancreatic and Islet Transplantation Stockholm, Sweden, March, 1988 *90. LONG TERM EFFECTS OF SUCCESSFUL PANCREAS ALLOGRAFT TRANSPLANTATION Munda R, First MR, Pedersen S, Kranias G, and Alexander JW First International Congress on Pancreatic and Islet Transplantation Stockholm, Sweden, March, 1988 *91. THE EFFICACY, TOXICITY AND PREDICTABILITY OF CONSTANT-RATE INTRAVENOUS CYCLOSPORINE

INFUSION IMMEDIATELY FOLLOWING CARDIAC TRANSPLANTATION Pesce AJ, and First MR

8th Annual Meeting of the International Society for Heart Transplantation, Los Angeles, California, April, 1988

39

*92. USE OF ORTHOCLONE OKT3 IN PEDIATRIC LIVER ALLOGRAFT TRANSPLANT RECIPIENTS Schroeder TJ, Balistreri WF, Ryckman FC, Suchy FJ, Pedersen SH, Foote M, and First MR

The American Pediatric Society/The Society for Pediatric Research Washington, D.C., June, 1988 *93. CYCLOSPORINE-ASSOCIATED GLOMERULAR AND ARTERIOLAR THROMBOSIS FOLLOWING RENAL

TRANSPLANTATION First MR, Smith RD, Weiss MA, Schroeder TJ, Kant KS, Munda R, Stephens GW, Penn I, and Alexander JW American Society of Transplant Physicians, Chicago, June, 1988 *94. THE TDx FLUROESCENT POLARIZATION IMMUNOASSAY (PPIA) PROVIDES RAPID CYCLOSPORINE

LEVELS Schroeder T, Brunson M, Pesce A, Hindenlang L, Mauser P, Ruckrigl D, Weibel M, Wadih G, and First MR

American Society of Transplant Physicians, Chicago, June, 1988 *95. PREDNISONE WITHDRAWAL IN HLA -IDENTICAL LIVING RELATED DONOR TRANSPLANT RECIPIENTS Hariharan S, First MR, Munda R, Penn I, Schroeder TJ, Fidler JP, Weiskittel P, and Alexander JW American Society of Transplant Physicians, Chicago, June, 1988 *96. SUCCESSFUL RETREATMENT OF REJECTION WITH ORTHOCLONE OKT3 First MR, Schroeder TJ, Penn I, Munda R, Balistreri WF, Alexander JW, Melvin DB, Fidler Jp, Ryckman FC, and Brunson ME American Society of Transplant Surgeons, Chicago, June, 1988 *97. EVALUATION OF THE TDXR FLUORESCENT POLARIZATION IMMUNOASSAY (PPIA) FOR THE

MONITORING OF CYCLOSPORINE IN SERUM Schroeder TJ, Pesce A, Mauser P, Weibel M, Hindenlang L, and First MR American Association of Clinical Chemists, New Orleans, July, 1988 *98. EVALUATION OF TDXR FLUORESCENCE POLARIZATION IMMUNOASSAY (FPIA) FOR THE MONITORING

OF CYCLOSPORINE IN WHOLE BLOOD Schroeder TJ, Pesce AJ, Hindenlang L, Ruckrigl D, Mauser P, Wadih G, Weibel M, and First MR

American Association of Clinical Chemists, New Orleans, July, 1988 *99. TDx FLUORESCENT POLARIZATION IMMUNOASSAY (FPIA) PROVIDES RAPID CYCLOSPORINE LEVELS Pesce AJ, Schroeder T, Brunson M, Hindenlach L, Mauser P, Ruckrigl D, Weibel M, Wadih G, and First MR

12th International Congress of the Transplantation Society, Sydney, Australia, August, 1988 *100. CYCLOSPORINE-ASSOCIATED GLOMERULAR AND ARTERIOLAR THROMBOSIS FOLLOWING RENAL

TRANSPLANTATION Smith R, First MR, Weiss M, Kant KS, Munda R, Stephens G, Penn I, and Alexander JW 12th International Congress of the Transplantation Society, Sydney, Australia, August, 1988 *101. SUCCESSFUL RETREATMENT OF REJECTION WITH ORTHOCLONE OKT3 First MR, Schroeder T, Penn I, Munda R, Balistreri W, Alexander JW, Melvin D, Ryckman F, and Brunson M

40

12th International Congress of the Transplantation Society, Sydney, Australia, August, 1988 *102. PREDNISONE WITHDRAWAL IN HLA -IDENTICAL LIVING RELATED DONOR TRANSPLANT RECIPIENTS Hariharan S, First MR, Munda R, Penn I, Fidler J, and Weiskittel P 12th International Congress of the Transplantation Society, Sydney, Australia, August, 1988 *103. COMPARISON OF THE SAFETY AND EFFICACY OF ORAL VS CONSTANT-RATE INTRAVENOUS

INFUSION CYCLOSPORINE IMMEDIATELY FOLLOWING ORTHOTOPIC HEART TRANSPLANTATION Myre S, Melvin D, Pesce A. Schroeder T, Collins J, Stephens G, Kahn A, and First MR 12th International Congress of the Transplantation Society, Sydney, Australia, August, 1988 *104. LONG TERM EFFECTS OF SUCCESSFUL PANCREAS ALLOGRAFT TRANSPLANTATION Munda R, First MR, Pedersen S, Kranias G, and Alexander JW 12th International Congress of the Transplantation Society, Sydney, Australia, August, 1988 *105. INFECTION IN OKT3 TREATED PATIENTS HAVING MULTIPLE REJECTION EPISODES Munda R, Hutchins M, First MR, Carey M, Schroeder T, and Alexander JW 12th International Congress of the Transplantation Society, Sydney, Australia, August, 1988 *106. OUTCOME OF KIDNEY TRANSPLANTS ACROSS B CELL POSITIVE CROSSMATCHES Balakrishnan K, Munda R, First MR, and Alexander JW 12th International Congress of the Transplantation Society, Sydney, Australia, August, 1988 *107. ASSESSING DONOR AND RECIPIENT LIVER FUNCTION; A RAPID AND REPRODUCIBLE TECHNIQUE

UTILIZING LIDOCAIN METABOLISM Schroeder T, Gremse D, Mansour M, Balistreri W, Theurling A, Brunson M, Ryckman F, Suchy F, Penn I,

Alexander W, Pesce A, and First MR 12th International Congress of the Transplantation Society, *108. PRETRANSPLANT INTERLEUKIN-2 RECEPTOR LEVELS IN LIVING RELATED DONOR KIDNEY RECIPIENTS

RECEIVING DONOR SPECIFIC BLOOD TRANSFUSIONS Harden EA, Schroeder TJ, Munda R, Brunson ME, Hurtubise PE, Pesce AJ, Balakrishnan K, Alexander

JW, and First MR American Federation for Clinical Research, Chicago, Illinois, Nov., 1988 *109. IMMUNOLOGIC MONITORING DURING RETREATMENT WITH OKT3 First MR, Schroeder TJ, Hurtubise PE, and Monsour ME. American Society of Nephrology, San Antonio, Texas, Dec., 1988 *110. PRE-TRANSPLANT INTERLEUKIN-2 RECEPTOR LEVELS IN LIVING RELATED DONOR KIDNEY RECIPIENTS

RECEIVING DONOR SPECIFIC BLOOD TRANSFUSIONS Harden EA, Schroeder TJ, Munda R, Brunson ME, Hurtubise PE, Pesce AJ, Balakrishnan K, Alexander

JW, and First MR American Society of Nephrology, San Antonio, Texas, Dec., 1988 *111. PROPHYLACTIC USE OF OKT3 IN IMMUNOLOGICAL HIGH RISK CADAVER TRANSPLANT RECIPIENTS First MR, Schroeder TJ, Mansour ME, Alexander JW, and Penn I American Society of Transplant Physicians, Chicago, Illinois, May, 1989

41

*112. ANTIMURINE ANTIBODY FORMATION FOLLOWING OKT3 THERAPY Schroeder TJ, First MR, Mansour ME, Hurtubise PE, Hariharan S, Ryckman FC, Munda R, and Melvin

DB American Society of Transplant Physicians, Chicago, Illinois, May, 1989 *113. KETOCONAZOLE PREDICTABLY REDUCES CYCLOSPORINE DOSING REQUIREMENTS WITHOUT

TOXICITY IN THE DOG MODEL Myre SA, Schroeder TJ, Grund VR, Wandstrat TL, Abbott LJ, Pesce AJ, and First MR *114. THE USE OF MONOCLONAL ANTIBODY OKT3 IN SOLID ORGAN TRANSPLANTATION First MR, and Schroder TJ American Association of Colleges of Pharmacy and Association of Faculties of Pharmacy of Canada,

Portland, Orego, July, 1989 *115. CYCLOSPORINE KINETICS WITH CONCOMITANT KETOCONAZOLE THERAPY Schroeder TJ, Weiskittel P, Pesce AJ, Myre, SA, Alexander JW, and First MR American Association of Clinical Chemists, Atlanta, Georgia, July, 1989 *116. POST-TRANSPLANT ANTI-GBM NEPHRITIS (GN) IN RELATED ALPORT MALES: TARGET ANTIGEN Kashtan R, Butkowski R, Kleppel M, First MR, Weislander, Jr., and Michael A American Society of Nephrology, 22nd annual meeting Washington, D.C., December, 1989 *117. THE ABBOTT TDX FLORESCENT POLARIZATION IMMUNOASSAY (FPIA) PROVIDES A RAPID AND

ACCURATE MEASUREMENT OF CYCLOSPORINE AND METABOLITIES Schroeder TJ, Pesce AJ, and First MR Expert Workshop: Optimal use of cyclosporine and therapeutic drug monitoring, Hawk's Cay,

Florida, January, 1990 *118. CYCLOSPORINE PHARMACOKINETICS WITH CONCOMITANT KETOCONAZOLE THERAPY (CP-525) Schroeder TJ, Weiskittel P, Pesce AJ, Myre A, Alexander JW, and First MR

Clinical and Diagnostic Immunology Division , American Association for Clinical Chemistry, Newsletter, 4:13-14, 1990 *119. CLINICAL CORRELATIONS OF CYCLOSPORINE HPLC AND FPIA LEVELS IN RENAL TRANSPLANT

RECIPIENTS Sridhar N, Schroeder TJ, Pesce AJ, and First MR Expert Workshop: Optimal use of cyclosporine and therapeutic drug monitoring, Hawk's Cay, Florida, January, 1990 *120. CLINICAL CORRELATIONS OF CYCLOSPORINE SPECIFIC AND NON-SPECIFIC ASSAYS IN STABLE RENAL

TRANSPLANTS, ACUTE REJECTION, AND NEPHROTOXICITY Schroeder TJ, Sridhar N, Pesce AJ, Alexander JW, and First MR American Society of Transplant Physicians, 9th annual meeting Chicago, Illinois, May, 1990 *121. CYCLOSPORINE DOSE REDUCTION BY KETOCONAZOLE ADMINISTRATION IN RENAL TRANSPLANT

RECIPIENTS First MR, Schroeder TJ, Weiskittel P, Stephens GW, Myre SA, Alexander JW, and Pesce AJ American Society of Transplant Physicians, 9th annual meeting Chicago, Illinois, May, 1990

42

*122. THE EFFICACY OF OKT3 IN ACTIVE VASCULAR REJECTION Schroeder TJ, Weiss MA, Smith RD, Stephens GW, and First MR American Society of Transplant Physicians, 9th annual meeting Chicago, Illinois, May, 1990 *123. USE OF KIDNEYS FOR TRANSPLANTATION FROM HIGH RISK DONORS Alexander JW, Sc D, First MR, Craycraft BS, Munda R, Penn I, Fidler JP, Tchervenkov JI, and Fisher RA American Society of Transplant Physicians, 9th annual meeting Chicago, Illinois , May, 1990 *124. CYCLOSPORINE DOSE REDUCTION BY KETOCONAZOLE ADMINISTRATION IN RENAL TRANSPLANT

RECIPIENTS First MR, Schroeder TJ, Weiskittel P, Stephens GW, Myre SA, and Pesce AJ International Congress of Nephrology, Tokyo, Japan, July, 1990 *125. MEASUREMENT OF ADENOSINE DEAMINASE BINDING PROTEIN (ABP) AS A MONITOR OF RENAL

FUNCTION Schroeder TJ, Pesce AJ, Nauman PM, and First MR International Congress of Nephrology, Tokyo, Japan, July, 1990 *126. BETA-2-MICROGLOBULIN LEVELS IN PATIENTS WITH RENAL DISEASE EVALUATED BY THE ABBOTT

IMX Pesce AJ, Schroeder TJ, Chavinson D, Horowitz ME, and First MR International Congress of Nephrology, Tokyo, Japan, July, 1990 *127. THE EFFICACY OF OKT3 IN ACUTE VASCULAR REJECTION Schroeder TJ, Weiss MA, Smity RD, Stephens GW, and First MR 13th International Congress of the Transplantation Society San Francisco, California, August, 1990 *128. EFFICACY OF INDUCTION THERAPY IN CADAVERIC RENAL TRANSPLANTATION COMPARING RATS

AND MALG Fisher RA, Tchervenkov JI, Schroeder TJ, Alexander JW, Sc D, and First MR 13th International Congress of the Transplantation Society San Francisco, California, August, 1990 *129. CYCLOSPORINE (CsA) PRETRANSPLANTATION REDUCES REJECTION EPISODES AND IMPROVES

ALLOGRAFT FUNCTION IN LIVING RELATED 1-HAPLOTYPE MISMATCHED RENAL (HMLR) TRANSPLANT PATIENTS

Tchervenkov J, Brunson M, Alexander W, Schroeder T, First MR, Munda R, and Fisher R American Society of Neprhology, 23rd annual meeting Washington, D.C., December, 1990 *130. MEASUREMENT OF ADENOSINE DEAMINASE BINDING PROTEIN AS A MONITOR OF RENAL FUNCTION Schroeder T, Nauman P, Pesce A, and First MR American Society of Nephrology, 23rd annual meeting Washington, D.C., December, 1990 *131. RAPID SOLUBLE INTERLEUKIN-2 RECEPTOR ANALYSIS IN RENAL TRANSPLANT RECIPIENTS SERA BY

MICROPARTICLE ENZYME IMMUNOASSAY Muth KL, Schroeder TJ, Martin LA, Hindenlang L, Traylor D, Pesce AJ, and First MR American Society of Nephrology, 23rd annual meeting Washington, D.C., December, 1990

43

*132. MALIGNANCIES FOLLOWING RENAL TRANSPLANTATION: INCIDENCE AND CLINICAL COURSE Barrett W, First MR, Penn I, and Aron B The Ohio State Radiological Society, 51st annual meeting Columbus, Ohio, May, 1991 *133. RETROSPECTIVE STUDY OF THE ECONOMICS OF RENAL TRANSPLANT WITH OKT*3 VS. MALG OR

CONVENTIONAL INDUCTION THERAPY Gorman KJ, First MR, and Fein AJ American Society of Transplant Physicians, 10th annual meeting Chicago, Illinois, May, 1991 *134. THE ECONOMICS OF TRANSPLANTATION: ATTITUDES AND KNOWLEDGE OF THE RENAL

TRANSPLANT COMMUNITY Gorman KJ, First MR, and Fein AJ

American Society of Transplant Physicians, 10th annual meeting Chicago, Illinois, May, 1991 *135. CYCLOSPORINE (CYA) DOSING AND BLOOD LEVELS IN RENAL TRANSPLANT RECIPIENTS RECEIVING

OTHER THERAPEUTIC AGENTS Sridhar N, Schroeder SJ, Hariharan S, Pesce AJ, and First MR American Society of Transplant Physicians, 10th annual meeting Chicago, Illinois, May, 1991 *136. THE USE OF INDOMETHACIN TO DECREASE THE EARLY ADVERSE EFFECTS OF OKT3 First MR, Schroeder TJ, Hariharan S, Alexander JW, and Weiskittel P American Society of Transplant Physicians, 10th annual meeting Chicago, Illinois, May, 1991 *137. A MULTI-CENTER STUDY TO EVALUATE A NOVEL ASSAY FOR QUANTITATION OF SOLUBLE

INTERLEUKIN-2 RECEPTOR (SlL-2R) IN RENAL TRANSPLANT RECIPIENTS Schroeder T, Helling T, McKenna R, Rush D, Jeffrey J, Brewer B, Martin L, Traylor D, Fisher R, and First

MR American Society of Transplant Physicians, 10th annual meeting Chicago, Illinois, May, 1991 *138. RENAL TRANSPLANTATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS Hariharan S, Schroeder TJ, Carey MA, and First MR American Society of Transplant Physicians, 10th annual meeting Chicago, Illinois, May, 1991 *139. IMMUNOLOGIC HYPORESPONSIVENESS IS INDUCED BY DONOR SPECIFIC TRANSFUSIONS (DST) AND

CYCLOSPORINE (CsA) IN HUMAN CADAVERIC TRANSPLANTS Alexander JW, Babcock GF, Madden RL, Munda R, Penn I, Fidler JP, First MR, Stephens G, Schroeder T, Cardi M, Manzler A, Cohen L, Mendoza N, Clyne D, and Geise F American Society of Transplant Surgeons, Chicago, Illinois, July, 1991 *140. EVALUATION OF THE NEW CYCLOSPORINE MONOCLONAL ANTIBODY FLUORESCENT POLARIZATION

IMMUNOASSAY IN CARDIAC AND RENAL TRANSPLANTS Schroeder T, Vine W, Ruckrigl D, Pesce A, Bhat G, and First MR American Association of Clinical Chemists, Washington, D.C., July, 1991

44

*141. FLOCYTOMETRIC CROSSMATCHING IN RENAL TRANSPLANTATION: EXPERIENCE WITH QUADRUPLE IMMUNOSUPPRESSION Sridhar N, Munda R, Balakrishnan K, and First MR American Society for Histocompatibility and Immunogenics, 17th annual meeting, Washington, D.C., October, 1991 *142. FLOWCYTOMETRIC EVALUATION OF CYTOTOXIC PERIPHERAL BLOOD LYMPHOCYTES IN ACUTE RENAL GRAFT REJECTION Sridhar N, Blanton M. Whitacre L, Balakrishnan K, and First MR American Society of Nephrology, 24th annual meeting Baltimore, MD, November, 1991 *143. EXPERIENCE WITH PREDNISONE REDUCTION AND WITHDRAWAL IN LIVE AND CADAVER RENAL

TRANSPLANT RECIPIENTS Hariharan S, Schroeder T, and First MR American Society of Nephrology, 24th annual meeting Baltimore, MD, November, 1991 *144. RAPID DETECTION OF ANTI-OKT3 ANTIBODIES Schroeder TJ, First MR, Hariharan S, Pouletty C, and Pouletty P American Society of Nephrology, 24th annual meeting Baltimore, MD, November, 1991 *145. EFFICACY OF A SINGLE DONOR SPECIFIC TRANSFUSION AND CYCLOSPORINE A ADMINISTERED ONE

DAY PRIOR TO ONE-HAPLOTYPE MISMATCHED LIVING RELATED DONOR KIDNEY TRANSPLANTATION

Davies CB, Alexander JW, Cofer BR, First MR, Schroeder TJ Southern Surgical Association, 130th annual meeting Hot Springs, VA, December, 1991 *146. INCIDENCE OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLPD) IN OKT3 - TREATED

RENAL TRANSPLANT RECIPIENTS Anderson PJ, Schroeder TJ, Hariharan S, First MR American Society of Transplant Physicians, 11th annual meeting Chicago, Illinois, May 1992 *147. CYCLOSPORINE A (CYA) DOSING AND BLOOD LEVELS IN RENAL TRANSPLANT RECIPIENTS RECEIVING

DILTIAZEM (SLOW RELEASE) 180 MG AND 240 MG DAILY Hariharan S, Schroeder TJ, Michael AT, First MR American Society of Transplant Physicians, 11th annual meeting Chicago, Illinois, May 1992 *148. OKT3 MONOCLONAL ANTIBODY THERAPY AS A FIRST LINE AGENT IN ACUTE RENAL ALLOGRAFT

REJECTION Schroeder TJ, First MR, Michael AT, Hariharan S American Society of Transplant Physicians, 11th annual meeting Chicago, Illinois, May 1992 *149. CYCLOSPORINE-KETOCONAZOLE INTERACTION: LONGTERM FOLLOW-UP, AND PRELIMINARY

RESULTS OF A RANDOMIZED TRIAL First MR, Schroeder TJ, Michael AT, Hariharan S, Weiskittel PD, Alexander JW American Society of Transplant Physicians, 11th annual meeting Chicago, Illinois, May 1992 *150. EFFECT OF RACE ON RENAL TRANSPLANT OUTCOME

45

Hariharan S, Schroeder TJ, First MR American Society of Transplant Physicians, 11th annual meeting Chicago, Illinois, May 1992 *151. SAFETY AND EFFICACY OF KIDNEY TRANSPLANT BIOPSY: TRU-CUT NEEDLE VS SNONOGRAPHICALLY

GUIDED BIOPTY GUN Mahoney MC, Racadio JM, Merhar GL, First MR American Roentgen Ray Society, annual meeting Orlando, Florida, May 1992 *152. CYCLOSPORINE-KETOCONAZOLE INTERACTION: LONGTERM FOLLOW-UP, AND PRELIMINARY

RESULTS OF A RANDOMIZED TRIAL First MR, Schroeder TJ, Michael AT, Hariharan S, Weiskittel PD, Alexander JW 14th International Congress of the Transplantation Society Paris, France, August, 1992 *153. OUTCOME OF CADAVER KIDNEYS USING NON-IDEAL DONORS Madden R, Munda R, Hariharan S, Alexander JW, First, MR. 14th International Congress of the Transplantation Society Paris, France, August, 1992 *154. THE USE OF A SINGLE PRETRANSPLANT DONOR SPECIFIC TRANSFUSION (DST) IN CADAVER AND

LIVING-RELATED DONOR (LRD) RENAL TRANSPLANTS Alexander JW, Davies CB, First MR, Cofer BR, Munda R, Madden RL, Hariharan S, Schroeder TJ 14th International Congress of the Transplantation Society Paris, France, August, 1992 *155. VARIATIONS IN SERUM OKT3 CONCENTRATIONS BASED UPON AGE, SEX, TRANSPLANT TYPE,

TREATMENT TYPE AND ANTI-OKT3 ANTIBODY STATUS Schroeder TJ, Michael A, First MR, Hariharan S, Bhat G, Hanto D, Ryckman F American Society of Nephrology, 25th annual meeting, Baltimore, MD November, 1992 *156. CYCLOSPORINE DOSAGE CHANGES WITH GANCICLOVIR THERAPY IN RENAL TRANSPLANT PATIENTS Schlueter KT, Hariharan S, Schroder TJ, First MR American Society of Nephrology, 25th annual meeting Baltimore, MD, November, 1992

*157. PATIENT OUTCOME AFTER FAILED RENAL TRANSPLANTATION: ANALYSIS OF RISK FACTORS Hariharan S, Schroeder TJ, First MR American Society of Nephrology, 25th annual meeting Baltimore, MD, November, 1992 *158. THE EFFECT OF DILTIAZEM ON CYCLOSPORIN A (CYA) BIOAVAILABILITY IN PATIENTS TREATED

WITH CYA AND KETOCONAZOLE Hariharan S, Schroeder TJ, First MR American Society of Nephrology, 25th annual meeting Baltimore, MD, November, 1992 *159. PHARMACOKINETICS OF 256U87, AN ACYCLOVIR PRODRUG IN RENAL TRANSPLANT PATIENTS First MR, Blum MR, Brennan R, Connors J, Dummer S, Lee I, Schroeder TJ Smily L, Van Buren D, Warwick J, Weller S American Society of Clinical Pharmacology and Therapeutics Honolulu, Hawaii, March 1993

46

*160. RANDOMIZED CONTROLLED STUDY OF COADMINISTRATION OF CYCLOSPORINE AND KETOCONAZOLE IN RENAL TRANSPLANT RECIPIENTS

First MR, Schroeder TJ, Michael A, Hariharan S, Weiskittel P, Alexander JW American Society of Clinical Pharmacology and Therapeutics Honolulu, Hawaii, March 1993 *161. CYCLOSPORINE DOSING AND BLOOD LEVELS IN RENAL TRANSPLANTS RECEIVING PROCARDIA XL Rossi SJ, Hariharan S, Schroeder TJ, First, MR American Society of Clinical Pharmacology and Therapeutics Honolulu, Hawaii, March 1993 *162. INFLUENCE OF CYCLOSPORINE (CsA) ON KETOCONAZOLE (KC) RELATIVE ORAL BIOAVAILABILITY

AND CLEARANCE IN THE DOG Myre SA, Schroeder TJ, Pesce AJ, Mechlinski W, First MR American Society of Clinical Pharmacology and Therapeutics Honolulu, Hawaii, March 1993 *163. PREDNISONE WITHDRAWAL IN HLA IDENTICAL AND ONE HAPLOTYPE MATCHED LIVE RELATED

DONOR AND CADAVER RENAL TRANSPLANT RECIPIENTS Hariharan S, Schroeder TJ, Weiskittel P, Alexander JW, First MR

American Society of Transplant Physicians, 12th annual meeting Houston, Texas, May 1993 *164 DIABETIC NEPHROPATHY AFTER RENAL TRANSPLANTATION: CLINICAL AND PATHOLOGIC

FEATURES Hariharan S, Smith RD, First MR American Society of Transplant Physicians, 12th annual meeting Houston, Texas, May 1993 *165. SOLUBLE INTERLEUKIN-2 RECEPTOR (sIL-2R) MONITORING IS A MARKER OF CYTOMEGALOVIRUS

(CMV) PATHOGENESIS AND RESPONSE TO ANTIVIRAL THERAPY Rossi S, Schroeder TJ, Muth K, Hanto D, Munda R, Hariharan S, First, MR

American Society of Transplant Physicians, 12th annual meeting Houston, Texas, May 1993 *166. CYCLOSPORINE-KETOCONAZOLE INTERACTION: LONG-TERM FOLLOW- UP AND PRELIMINARY

RESULTS OF A RANDOMIZED TRIAL First MR, Schroeder TJ, Michael A, Hariharan S, Weiskittel P, Alexander JW XIIth International Congress of Nephrology, Jerusalem, Israel, June 1993 *167. PREDNISONE WITHDRAWAL IN HLA IDENTICAL AND ONE HAPLOTYPE MATCHED LIVE RELATED

DONOR AND CADAVER RENAL TRANSPLANT RECIPIENTS Hariharan S, Schroeder TJ, Weiskittel P, Alexander JW, First MR XIIth International Congress of Nephrology, Jerusalem, Israel, June 1993 *168. CLINICAL COURSE OF MALIGNANCIES IN RENAL TRANSPLANT RECIPIENTS Barrett WL, First MR, Aaron BS, Penn I XIIth International Congress of Nephrology, Jerusalem, Israel, June 1993 *169. PHARMACOKINETICS OF 256U87, AN ACYCLOVIR PRODRUG, IN RENAL TRANSPLANT PATIENTS First MR, Blum MR, Brennan P, Connors J, Dummer S, Lee I, Schroeder TJ, Smiley L, Van Buren

D, Warwick J, Weller S XIIth International Congress of Nephrology, Jerusalem, Israel, June 1993 *170. PATIENT OUTCOME AFTER FAILED RENAL TRANSPLANTATION: ANALYSIS OF RISK FIACTORS Hariharan S, Schroeder TJ, First, MR

47

XIIth International Congress of Nephrology. Jerusalem, Israel, June 1993 *171. LACK OF EFFECT OF PREGNANCY ON RENAL ALLOGRAFT SURVIVAL OR FUNCTION Combs A, Weiskittel P, Miodovnik M, Berlepsch S, First MR XIIth International Congress of Nephrology, Jerusalem, Israel, June 1993 *172. DIABETIC NEPHROPATHY AFTER RENAL TRANSPLANTATION: CLINICAL AND PATHOLOGIC

FEATURES Hariharan S, Smith RD, First MR XIIth International Congress of Nephrology, Jerusalem, Israel, June 1993 *173. IS CYTOMEGALOVIRUS A COFACTOR IN CYCLOSPORINE-ASSOCIATED GLOMERULAR AND ARTERIOLAR THROMBOSIS? Smith RD, Hariharan S, Schroeder TJ, First MR XIIth International Congress of Nephrology, Jerusalem, Israel, June 1993 *174. T CELL SUBSET MONITORING DURING OKT3 THERAPY Schroeder TJ, Shah M, Hariharan S, Bhat G, Hanto D, Ryckman F, Balistreri W, First MR Clinical Applications of Cytometry, Eighth Annual Meeting Charleston, South Carolina, September 15-18, 1993 *175. A COMPARISON OF T CELL SUBSET MONITORING OF POLYCLONAL ANTILYMPHOCYTE AGENTS

FOLLOWING CADAVERIC RENAL TRANSPLANTATION Schroeder TJ, Shah M, Hariharan S, Alexander W, First MR Clinical Applications of Cytometry, Eighth Annual Meeting Charleston, South Carolina, September 15-18, 1993 *176. SOLUBLE CLASS I HLA ANTIGENS IN SERUM FOLLOWING RENAL TRANSPLANTATION Schroeder TJ, Pouletty P, Shimizu RM, Benson N, Michael A, Hariharan S, Alexander JW, First MR Histocompatibility and Immunogenetics, 19th Annual Meeting Phoenix, Arizona, October 2-7, 1993 *177. IMPACT OF CYCLOSPORINE A IN ELDERLY RENAL TRANSPLANT RECIPIENTS Hariharan S, Schroeder TJ, First MR The American Society of Nephrology, 26th Annual Meeting Boston, Massachusetts, November 14-17, 1993 *178. SOLUBLE CLASS I HLA ANTIGENS (sHLA) IN SERUM FOLLOWING RENAL TRANSPLANTATION Schroeder TJ, Pouletty P, Shimizu R, Benson N, Michael A, Hariharan S, Alexander JW, First MR The American Society of Nephrology, 26th Annual Meeting Boston, Massachusetts, November 14-17, 1993 *179. LACK OF EFFECT OF PREGNANCY ON RENAL ALLOGRAFT SURVIVAL OR FUNCTION Combs A, Weiskittel P, Miodovnik M, Berlepsch S, First MR The American Society of Nephrology, 26th Annual Meeting Boston, Massachusetts, November 14-17, 1993 *180. PLASMA CYTOKINE DETERMINATIONS ASSOCIATED WITH CHRONIC REJECTION. Schroeder TJ for the Chronic Rejection Multi-Center Study Group The American Society of Nephrology, 26th Annual Meeting Boston, Massachusetts, November 14-17, 1993

48

*181. CAUSE AND OUTCOME OF RENAL DYSFUNCTION FOLLOWING OKT3 THERAPY IN KIDNEY TRANSPLANT RECIPIENTS

Schlueter KT, Hariharan S, Schroeder TJ, First MR The American Society of Nephrology, 26th Annual Meeting Boston, Massachusetts, November 14-17, 1993 *182. INDOMETHACIN AND PENTOXIFYLLINE AS PREMEDICATION FOR OKT3 RELATED FIRST DOSE

REACTIONS Schroeder TJ, First MR, Weiskittel P, Hariharan S, Alexander J The American Society of Nephrology, 26th Annual Meeting Boston, Massachusetts, November 14-17, 1993 *183. SAFETY AND EFFICACY OF rHuEPO IN CORRECTING THE ANEMIA OF PATIENTS WITH CHRONIC RENAL

ALLOGRAFT REJECTION Muirhead N for the Erythropoietin Transplant Study Group, Robarts Research Institute, London, Ontario,

Canada The American Society of Nephrology, 26th Annual Meeting Boston, Massachusetts, November 14-17, 1993 *184. USEFULNESS OF SERUM FRUCTOSAMINE AND GLYCOALBUMIN FOR MONITORING GLYCEMIC

CONTROL IN DIABETIC PATIENTS Magnotti, Jr., RA, Jenkins SH, First MR, Weiskittel PD, Ghosn S Academy of Clinical Laboratory Physicians and Scientists San Francisco, California, May 1994 *185 LACK OF EFFECT OF PREGNANCY ON RENAL ALLOGRAFT SURVIVAL OR FUNCTION First MR, Combs A, Weiskittel P, Miodovnik M, Berlepsch S American Society of Transplant Physicians, 13th annual meeting Chicago, Illinois, May 1994 *186. OUTCOME OF CADAVERIC RENAL TRANSPLANTATION AS PER INDUCTION TREATMENT IN THE

CYCLOSPORINE ERA Hariharan S, Alexander JW, Schroeder TJ, First MR American Society of Transplant Physicians, 13th annual meeting Chicago, Illinois, May 1994 *187. A COMPARISON OF THREE POLYCLONAL ANTILYMPHOCYTE AGENTS AS PART OF A QUADRUPLE

SEQUENTIAL IMMUNOSUPPRESSIVE PROTOCOL FOLLOWING PRIMARY CADAVERIC RENAL TRANSPLANT

Schroeder TJ, Shah M, Hariharan S, Alexander JW, First MR American Society of Transplant Physicians, 13th annual meeting Chicago, Illinois, May 1994 *188. THE RELATIONSHIP BETWEEN CYCLOSPORINE (CyA) BIOAVAILABILITY AND CLINICAL OUTCOME IN

RENAL TRANSPLANT RECIPIENTS Schroeder TJ, Hariharan S, First MR American Society of Transplant Physicians, 13th annual meeting Chicago, Illinois, May 1994 *189. PRELIMINARY REPORT ON THE UNOS AD HOC DONATIONS COMMITTEE RETROSPECTIVE STUDY OF

EXPANDED DONORS Bennett LE, First MR, McGaw L, Breen TJ, Alexander JW American Society of Transplant Physicians, 13th annual meeting Chicago, Illinois, May 1994 *190. THE RELATIONSHIP BETWEEN CYCLOSPORINE (CyA) BIOAVAILABILITY AND CLINICAL OUTCOME IN

RENAL TRANSPLANT RECIPIENTS

49

Schroeder TJ, Hariharan S, First MR 15th International Congress of the Transplantation Society Kyoto, Japan, September 1994 *191. PRELIMINARY REPORT ON THE UNOS AD HOC DONATIONS COMMITTEE RETROSPECTIVE STUDY OF

EXPANDED DONORS Bennett LE, First MR, McGaw L, Breen TJ, Alexander JW 15th International Congress of the Transplantation Society Kyoto, Japan, September 1994 *192. IMPACT OF FIRST ACUTE REJECTION EPISODE AND SEVERITY OF REJECTION ON CADAVERIC RENAL

ALLOGRAFT SURVIVAL. Hariharan S, Peddi VR, Schroeder TJ, First MR American Society of Nephrology, 27th annual meeting Orlando, Florida, October 1994 *193. IMPACT OF GANCICLOVIR PROPHYLAXIS ON CMV INFECTION IN CADAVERIC RENAL ALLOGRAFT

RECIPIENTS Peddi VR, Hariharan S, Schroeder TJ, First MR

American Society of Nephrology, 27th annual meeting Orlando, Florida, October 1994 *194. VARIATIONS IN BIOAVAILABILITY (F) OF SANDIMUNE CYCLOSPORINE, (CyA) AND RELATIONSHIP TO

CLINICAL OUTCOME IN RENAL TRANSPLANT SUBPOPULATIONS Schroeder TJ, Hariharan S, First MR. American College of Clinical Pharmacology, 23rd annual meeting Orlando, Florida, October 1994 *195. HISTOPLASMOSIS IN RENAL ALLOGRAFT RECIPIENTS Peddi VR, Hariharan S, First MR National Kidney Foundation, Spring Clinical Nephrology Meetings Washington DC, March 1995 *196. BLACK RENAL TRANSPLANT RECIPIENTS MAINTAIN LESS FREQUENT THERAPEUTIC CYCLOSPORINE

LEVELS THAN WHITE RECIPIENTS Schroeder TJ, Shah M, Hariharan S, First, MR The American Society of Transplant Physicians, 14th Annual Scientific Meeting Chicago, Illinois, May 1995 *197. POOR EARLY POST-TRANSPLANT CYCLOSPORINE BIOAVAILABILITY IS ASSOCIATED WITH A

SUBSEQUENT INCREASE IN UTILIZATION OF RESOURCES FOLLOWING RENAL TRANSPLANTATION Schroeder TJ, Shah M, Hariharan S, First MR The American Society of Transplant Physicians, 14th Annual Scientific Meeting Chicago, Illinois, May 1995 *198. A RANDOMIZED PROSPECTIVE CONTROLLED TRIAL OF KETOCONAZOLE IN CYCLOSPORINE TREATED

RENAL TRANSPLANT RECIPIENTS First MR, Schroeder TJ, Shah M, Hariharan S, Alexander JW, Weiskittel P The American Society of Transplant Physicians, 14th Annual Scientific Meeting Chicago, Illinois, May 1995 *199. CONVERSION FROM CYCLOSPORIN TO TACROLIMUS IN COMBINED KIDNEY AND PANCREAS

TRANSPLANT RECIPIENTS Hariharan S, Munda R, Demmy AM, Schroeder TJ, Alexander JW, First MR The American Society of Transplant Physicians, 14th Annual Scientific Meeting Chicago, Illinois, May 1995

50

*200. THE IMPORTANCE OF ALLOGRAFT BIOPSY IN RENAL TRANSPLANT RECIPIENTS: CORRELATION BETWEEN CLINICAL AND HISTOLOGICAL DIAGNOSIS

Al-Awwa I, Hariharan S, First MR The American Society of Transplant Physicians, 14th Annual Scientific Meeting Chicago, Illinois, May 1995 *201. ROLE OF GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) IN REVERSING NEUTROPENIA IN

RENAL ALLOGRAFT RECIPIENTS Peddi VR, Hariharan S, Schroeder TJ, First MR The American Society of Transplant Physicians, 14th Annual Scientific Meeting Chicago, Illinois, May 1995 *202. CONVERSION FROM CYCLOSPORIN TO TACROLIMUS IN COMBINED KIDNEY AND PANCREAS

TRANSPLANT RECIPIENTS Hariharan S, Munda R, Demmy AM, Schroeder TJ, Alexander JW, First MR 5th Congress of the International Pancreas and Islet Transplant Association Miami, Florida, June 1995 *203. COMPARISON BETWEEN OKT3 AND METHYLPREDNISOLONE TREATMENT FOR PRIMARY ACUTE

REJECTION AFTER COMBINED KIDNEY AND PANCREAS TRANSPLANTATION El-Ghoroury MA, Hariharan S, Munda R, Demmey A, Schroeder TJ, Alexander JW, First MR

5th Congress of the International Pancreas and Islet Transplant Association Miami, Florida, June 1995 *204. IMPACT OF GANCICLOVIR PROPHYLAXIS ON CMV INFECTION IN CADAVERIC KIDNEY VS COMBINED

KIDNEY AND PANCREAS TRANSPLANTATION Peddi VR, Hariharan S, Munda R, Schroeder TJ, First MR 5th Congress of the International Pancreas and Islet Transplant Association Miami, Florida, June 1995 *205. ROLE OF GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) IN REVERSING NEUTROPENIA IN

RENAL ALLOGRAFT RECIPIENTS Peddi VR, Hariharan S, Schroeder TJ, First MR XIIIth International Congress of Nephrology, Madrid, Spain, July 1995 *206. BLACK RENAL TRANSPLANT RECIPIENTS MAINTAIN LESS FREQUENT THERAPEUTIC CYCLOSPORINE

LEVELS THAN WHITE RECIPIENTS Schroeder TJ, Shah M, Hariharan S, First MR

XIIIth International Congress of Nephrology, Madrid, Spain, July 1995 *207. POOR EARLY POST-TRANSPLANT CYCLOSPORINE BIOAVAILABILITY IS ASSOCIATED WITH A

SUBSEQUENT INCREASE IN UTILIZATION OF RESOURCES FOLLOWING RENAL TRANSPLANTATION Schroeder TJ, Shah M, Hariharan S, First MR XIIIth International Congress of Nephrology, Madrid, Spain, July 1995 *208. LONG-TERM FOLLOW-UP OF RENAL FUNCTION AND CAUSES OF GRAFT LOSS IN THE CYCLOSPORINE

ERA AFTER RENAL TRANSPLANTATION Valente JF, Hariharan S, Alexander JW, Schroeder TJ, Weiskittel PD, First MR

XIIIth International Congress of Nephrology, Madrid, Spain, July 1995 *209. THE IMPORTANCE OF ALLOGRAFT BIOPSY IN RENAL TRANSPLANT RECIPIENTS: CORRELATION

BETWEEN CLINICAL AND HISTOLOGICAL DIAGNOSIS Al-Awwa I, Hariharan S, First MR

XIIIth International Congress of Nephrology, Madrid, Spain, July 1995

51

*210. CONVERSION FROM CYCLOSPORIN TO TACROLIMUS IN COMBINED KIDNEY AND PANCREAS

TRANSPLANT RECIPIENTS Hariharan S, Munda R, Demmy AM, Schroeder TJ, Alexander JW, First MR XIIIth International Congress of Nephrology, Madrid, Spain, July 1995 *211. IMPACT OF GANCICLOVIR PROPHYLAXIS ON CMV INFECTION IN CADAVERIC KIDNEY VS COMBINED

KIDNEY AND PANCREAS TRANSPLANTATION Peddi VR, Hariharan S, Munda R, Schroeder TJ, First MR XIIIth International Congress of Nephrology, Madrid, Spain, July 1995 *212. COMPARISON BETWEEN OKT3 AND METHYLPREDNISOLONE TREATMENT FOR PRIMARY ACUTE

REJECTION AFTER COMBINED KIDNEY AND PANCREAS TRANSPLANTATION El-Ghoroury MA, Hariharan S, Munda R, Demmey AM, Schroeder TJ, Alexander JW, First MR XIIIth International Congress of Nephrology, Madrid, Spain, July 1995 *213. A RANDOMIZED PROSPECTIVE CONTROLLED TRIAL OF KETOCONAZOLE IN CYCLOSPORINE TREATED

RENAL TRANSPLANT RECIPIENTS First MR, Schroeder TJ, Shah M, Hariharan S, Alexander JW, Weiskittel P XIIIth International Congress of Nephrology, Madrid, Spain, July 1995 *214. INCREASED CYCLOSPORINE EXPOSURE IN PATIENTS SWITCHED FROM CYCLOSPORINE SOLUTION TO

CAPSULES Schroeder TJ, Shah M, Hariharan S, First MR XIIIth International Congress of Nephrology, Madrid, Spain, July 1995 *215. HISTOLOGIC PREDICTORS OF GRAFT OUTCOME IN RECIPIENTS OF RENAL ALLOGRAFTS FROM HIGH

RISK DONORS Smith RD, Viero RM, Granholm NA, Cavallo T, Schroeder T, Hariharan S, Alexander JW, First MR XIII International Congress of Nephrology, Madrid, Spain, July 1995 *216. COMPARISON OF TACROLIMUS (FK-506) ASSAYS: ABBOTT MEIA AND INCSTAR ELISA Schlueter K, Schroeder T, Pesce A, Warner A, First MR American Association of Clinical Chemistry Annual Meeting Washington DC, July 1995 *217. MONITORING AND MANAGEMENT OF IMMUNOSUPPRESSION IN PEDIATRIC TRANSPLANT

RECIPIENTS Schroeder TJ, First MR 6th International Pediatric Laboratory Medicine Congress Vancouver, Canada, July 1995 *218. PROTEINURIA FOLLOWING RENAL TRANSPLANTATION: CORRELATION WITH HISTOPATHOLOGY

AND OUTCOME Peddi VR, Dean D, Hariharan S, Cavallo T, Schroeder TJ, First MR. American Society of Nephrology, 28th Annual Meeting San Diego, California, November 1995 *219. CAUSES OF RENAL ALLOGRAFT LOSS IN BLACK VS. WHITE RECIPIENTS Valente JF, Hariharan S, Peddi

VR, Schroeder TJ, Alexander JW, First MR. American Society of Nephrology, 28th Annual Meeting San Diego, California, November 1995 *220. THE IMPORTANCE OF ALLOGRAFT BIOPSY IN RENAL TRANSPLANT RECIPIENTS: CORRELATION

BETWEEN CLINICAL AND HISTOLOGICAL DIAGNOSIS Al-Awwa I, Hariharan S, First MR.

52

American Society of Nephrology, 28th Annual Meeting San Diego, California, November 1995 *221. THE EFFECT OF FLUCONAZOLE ON TACROLIMUS (FK506) BLOOD LEVELS IN RENAL TRANSPLANT

RECIPIENTS Hariharan S, Schlueter K, Peddi VR, Schroeder TJ, First MR. American Society of Nephrology, 28th Annual Meeting San Diego, California, 1995 *222. PREDNISONE WITHDRAWAL IN DIABETIC RENAL ALLOGRAFT RECIPIENTS Bains AS, Hariharan S, Peddi VR, Schroeder TJ, Weiskittel PA, First MR. American Society of Nephrology, 28th Annual Meeting San Diego, California, 1995 *223. DETECTION OF EPSTEIN-BARR VIRUS MESSAGE IN RENAL ALLOGRAFTS Viero RM, First MR, Cavallo T American Society of Nephrology, 28th Annual Meeting San Diego, California, 1995 *224. CONVERSION TO NEORAL IN STABLE RENAL TRANSPLANT RECIPIENTS The Sandoz Study Group American Society of Nephrology, 28th Annual Meeting San Diego, California, 1995 *225. PROTEINURIA FOLLOWING RENAL TRANSPLANTATION: CORRELATION WITH HISTOPATHOLOGY

AND OUTCOME Peddi VR, Dean D, Hariharan S, Cavallo T, Schroeder TJ, First MR The American Society of Transplant Physicians, 15th Annual Scientific Meeting, Dallas, Texas, May 1996 *226. KETOCONAZOLE IS NOT ASSOCIATAED WITH INCREASED INPATIENT OR OUTPATIENT RESOURCES

WHLE DECREASING CYCLOSPORINE ANNUAL COSTS BY APPROXIMATELY $3,300 PER PATIENT First MR, Schroeder TJ, Daoud AJ, Gardner C, Weiskittel P. The American Society of Transplant Physicians, 15th Annual Scientific Meeting, Dallas, Texas, May 1996 *227. LONG-TERM RENAL AND PANCREAS FUNCTION WITH TACROLIMUS RESCUE THERAPY FOLLOWING

PANCREAS TRANSPLANTATION Hariharan S, Peddi VR, Munda R, Demmy AM, Schroeder TJ, Alexander JW, First MR The American Society of Transplant Physicians, 15th Annual Scientific Meeting, Dallas, Texas, May 1996 *228. ANALYSIS OF RISK FACTORS AFFECTING OUTCOME OF PEDIATRIC DONOR KIDNEYS TRANSPLANTED

INTO ADULT RECIPIENTS Rahusen F, Peddi VR, Hariharan S, Munda R, Alexander JW, First MR The American Society of Transplant Physicians, 15th Annual Scientific Meeting Dallas, Texas, May 1996

*229. FK506 IN PANCREAS TRANSPLANTATION: A MULTICENTER ANALYSIS. The FK506 Pancreas Transplant Cooperative Study Group The American Society of Transplant Physicians, 15th Annual Scientific Meeting Dallas, Texas, May 1996 *230. FK506 IN KIDNEY TRANSPLANTATION: RESULTS OF THE U.S. RANDOMIZED, COMPARATIVE, PHASE III

STUDY The FK 506 U.S. Kidney Transplant Multicenter Study Group The American Society of Transplant Physicians, 15th Annual Scientific Meeting

53

Dallas, Texas, May 1996 *231. EFFICACY AND SAFETY OF TACROLIMUS (FK) vs. CYCLOSPORINE (CYA) IN KIDNEY AND PANCREAS

TRANSPLANT RECIPIENTS El-Ghoroury M, Hariharan S, Peddi VR, Munda R, Schroeder TJ, Demmy A, Alexander JW, First MR The American Society of Transplant Physicians, 15th Annual Scientific Meeting Dallas, Texas, May 1996 *232. A COMPARISON OF SAFETY AND EFFICACY OF TWO IMMUNOSUPPRESSIVE REGIMENS:

MYOPHENOLATE MOFETIL, PREDNISONE AND CYCLOSPORINE AND MYCOPHENOLATE MOFETIL PREDNISONE AND TACROLIMUS

First MR, Schroeder TJ, Shah M, Hariharan S, Peddi VR, Weiskittel P The American Society of Transplant Physicians, 15th Annual Scientific Meeting Dallas, Texas, May 1996 *233. ASSOCIATION BETWEEN CLINICAL SIGNS AND ACUTE REJECTION IN RENAL TRANSPLANT

RECIPIENTS The 1995 Efficacy Endpoints Conference Group The American Society of Transplant Physicians, 15th Annual Scientific Meeting Dallas, Texas, May 1996 *234. DEFINING CLINICAL ENDPOINTS IN REJECTION TREATMENT WITH ANTI-LYMPHOCYTE AGENTS The 1995 Efficacy Endpoints Conference Group The American Society of Transplant Physicians, 15th Annual Scientific Meeting Dallas, Texas, May 1996 *235. THE ROLE OF BANFF CLASSIFICATION IN CLINICAL IMMUNOSUPPRESSION TRIALS The 1995 Efficacy Endpoints Conference Group The American Society of Transplant Physicians, 15th Annual Scientific Meeting Dallas Texas, May 1996 *236. CHARACTERIZING THE CILNICAL RESPONSE TO CORTICOSTERID REJECTION THERAPY FOR USE IN

CLINICAL TRIAL DESIGN The 1995 Efficacy Endpoints Conference Group The American Society of Transplant Physicians, 15th Annual Scientific Meeting Dallas, Texas, May 1996 *237. CHANGING HISTOLOGICAL PATTERNS IN RENAL TRANSPLANT RECIPIENTS OVER AN EIGHT YEAR

PERIOD Schroeder TJ, First MR, Daoud J, Peddi VR, Hariharan S, Smith R, Cavallo T The American Society of Transplant Physicians, 15th Annual Scientific Meeting Dallas, Texas, May 1996 *238. THE ROLE OF BANFF CLASSIFICATION IN CLINICAL IMMUNOSUPPRESSION TRIALS The 1995 Efficacy Endpoints Conference Group XVI International Congress of the Transplantation Society Barcelona, Spain, September, 1996 *239. FK506 IN KIDNEY TRANSPLANTATION: RESULTS OF THE U.S. RANDOMIZED, COMPARATIVE, PHASE

III STUDY FK506 U.S. Kidney Transplant Study Group XVI International Congress of the Transplantation Society Barcelona, Spain, September, 1996 *240. PROTEINURIA FOLLOWING RENAL TRANSPLANTATION: CORRELATION WITH HISTOPATHOLOGY

AND OUTCOME Peddi VR, Dean D, Hariharan S, Cavallo T, Schroeder TJ, First MR XVI International Congress of the Transplantation Society Barcelona, Spain, September, 1996 *241. A GENERIC CYCLOSPORINE FORMULATION DEVELOPMENT PROGRAM Schroeder TJ, Levy R, Pouletty P, First MR XVI International Congress of the Transplantation Society

54

Barcelona, Spain, September, 1996 *242. FK506 FOR INDUCTION OR RESCUE THERAPY AFTER PANCREAS TRANSPLANTATION: A

MULTICENTER ANALYSIS FK506 Pancreas Transplant Cooperative Study Group XVI International Congress of the Transplantation Society Barcelona, Spain, September, 1996 *243. ORGAN PRESERVATION AND PROCUREMENT Grinyo JM, Lloveras J, Matesanz R, First MR XVI International Congress of the Transplantation Society Barcelona, Spain, September, 1996 *244. EFFICACY AND SAFETY OF TACROLIMUS (FK) VS. CYCLOSPORINE (CYA) IN KIDNEY AND PANCREAS

TRANSPLANT RECIPIENTS El-Ghoroury M, Hariharan S, Peddi VR, Munda R, Schroeder TJ, Demmy A, Alexander JW, First MR XVI International Congress of the Transplantation Society Barcelona, Spain, September, 1996 *245. LONG-TERM RENAL AND PANCREAS FUNCTION WITH TACROLIMUS RESCUE THERAPY FOLLOWING

PANCREAS TRANSPLANTATION Hariharan S, Peddi VR, Munda R, Demmy AM, Schroeder TJ, Alexander JW, First MR XVI International Congress of the Transplantation Society Barcelona, Spain, September, 1996 *246. SIMULTANEOUS USE OF FK506 AND MYCOPHENOLATE MOFETIL IN PANCREAS AND KIDNEY

TRANSPLANT RECIPIENTS: A MULTICENTER REPORT Stratta RJ, First MR, Egidi F, Corry RJ, Johnson CP, Marsh CL, Burke GW, Gruessner RWG, Sutherland DER, Kaufman D, Bartlett ST, Sollinger HW, Boudreaux JP, Beneditti E XVI International Congress of the Transplantation Society Barcelona, Spain, September, 1996 *247. A COMPARISON OF THE QUANSTAT AND ELISA ASSAYS FOR DETERMINATION OF OKT3 SERUM

CONCENTRATIONS AT THE UNIVERSITY OF CINCINNATI Daoud J, Womble DO, Schroeder T, Bhat G, First MR American Society for Histocompatibility and Immunogenetics 22nd Annual Meeting, San Diego, California,

October, 1996 *248. A GENERIC CYCLOSPORINE FORMULATION DEVELOPMENT PROGRAM Schroeder TJ, Levy R, Pouletty P, First MR American Society of Nephrology, 29th Annual Meeting New Orleans, November, 1996 *249. RECURRENT AND DE NOVO RENAL DISEASES AFTER RENAL TRANSPLANTATION IN THE

CYCLOSPORINE ERA: REPORT FROM THE RENAL ALLOGRAFT RECURRENT DISEASE REGISTRY (RARDR)

Hariharan S, Peddi VR, First MR, Savin VJ, Roza AM, Johnson C, Adams M American Society of Nephrology, 29th Annual Meeting New Orleans, November, 1996 *250. THYMOGLOBULIN IS EFFECTIVE IN REVERSING RESISTANT ACUTE REJECTION IN TRANSPLANT

RECIPIENTS Schroeder TJ, Kano J, Rossiter H, Berger-Moran H, First MR American Society of Nephrology, 29th Annual Meeting New Orleans, November, 1996

55

*251. CHARACTERIZATION OF EPISODES OF PERSISTENT RENAL ALLOGRAFT REJECTION The 1995 Efficacy Endpoint Conference Group American Society of Nephrology, 29th Annual Meeting New Orleans, November, 1996 *252. BIOPSY FOR PERSISTENT DYSFUNCTION FOLLOWING ANTIREJECTION THERAPY The 1995 Efficacy Endpoint Conference Group American Society of Nephrology, 1996 Annual Meeting New Orleans, November, 1996 *253. AN INTERNATIONAL MULTICENTER RENAL ALLOGRAFT REJECTION DATABASE TO DEFINE

ENDPOINTS FOR CLINICAL TRIAL DESIGN The 1995 Efficacy Endpoint Conference Group American Society of Nephrology, 1996 Annual Meeting New Orleans, November, 1996 *254. CHANGING HISTOLOGICAL PATTERNS IN RENAL TRANSPLANT RECIPIENTS OVER AN EIGHT YEAR

PERIOD First MR, Schroeder TJ, Daoud J, Peddi R, Hariharan S, Smith R, Cavallo T The 1995 Efficacy Endpoint Conference Group American Society of Nephrology, 1996 Annual Meeting New Orleans, November, 1996 *255. CYCLOSPORINE NEPHROTOXICITY IN RENAL TRANSPLANT RECIPIENTS: CORRELATION WITH

HISTOPATHOLOGY Peddi VR, Hariharan S, Schroeder TJ, Smith R, Cavallo T, First MR American Society of Nephrology, 29th Annual Meeting New Orleans, November, 1996 *256. CONVERSION TO NEORAL IN STABLE RENAL TRANSPLANT RECIPIENTS Sandoz Study Group American Society of Nephrology, 29th Annual Meeting New Orleans, November, 1996 *257. CYCLOSPORINE PHARMACOKINETICS IN STABLE RENAL TRANSPLANT RECIPIENTS AFTER NEORAL

CONVERSION Sandoz Study Group American Society of Nephrology, 29th Annual Meeting New Orleans, November, 1996 *258. HPV SUBTYPE ANALYSIS IN LOWER GENITAL TRACT (LGT) NEOPLASMS OF FEMALE RENAL

TRANSPLANT PATIENTS Brown MR, Noffsinger A, First MR, Penn I, Husseinzadeh N. Society of Gynecologic Oncologists, 29th Annual Meeting Orlando, Florida, February, 1997 *259. LONG-TERM OUTCOME OF CADAVER KIDNEY TRANSPLANTATION FROM EXPANDED CRITERIA

DONORS - A SINGLE CENTER EXPERIENCE Golconda M, Whiting J, Smith R, Hayes R, Alexander JW, First MR American Society of Transplant Physicians, 15th Annual Scientific Meeting Chicago, Illinois, May, 1997 *260. USE OF TACROLIMUS (FK) BASED IMMUNOSUPPRESSION ELIMINATES ACUTE REJECTION AS A

MAJOR COMPLICATION FOLLOWING SIMULTANEOUS KIDNEY AND PANCREAS TRANSPLANTATION (SKP)

Peddi VR, Kamath S, Demmy A, Munda R, Alexander JW, First MR

56

American Society of Transplant Physicians, 15th Annual Scientific Meeting Chicago, Illinois, May, 1997 *261. A BLINDED RETROSPECTIVE ANALYSIS OF RENAL ALLOGRAFT PATHOLOGY USING THE BANFF

SCHEMA: IMPLICATIONS FOR CLINICAL MANAGEMENT Dean D, Kamath S, Peddi VR, Schroeder TJ, First MR, Cavallo T American Society of Transplant Physicians, 15th Annual Scientific Meeting Chicago, Illinois, May, 1997 *262. EFFICACY OF OKT3 AS PRIMARY THERAPY FOR HISTOLOGICALLY CONFIRMED ACUTE RENAL

ALLOGRAFT REJECTION Kamath S, Dean D, Peddi VR, Schroeder TJ, Alexander JW, Cavallo T, First MR American Society of Transplant Physicians, 15th Annual Scientific Meeting Chicago, Illinois, May, 1997 *263. CHARACTERISTICS OF LONG-TERM RENAL TRANSPLANT SURVIVORS Peddi VR, Whiting J, Weiskittel PD, Alexander JW, First, MR American Society of Transplant Physicians, 15th Annual Scientific Meeting Chicago, Illinois, May, 1997 *264. RECURRENT AND DE-NOVO GLOMERULAR DISEASE AFTER RENAL TRANSPLANTATION: A REPORT

FROM THE RENAL ALLOGRAFT RECURRENT DISEASE REGISTRY (RARDR) Hariharan S, George V, Adams MA, Davis CL, First MR, Johnson CP, Roza AM, Vincenti F, Savin VJ American Society of Transplant Physicians, 15th Annual Scientific Meeting Chicago, Illinois, May, 1997 *265. IMPACT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AFTER RENAL TRANSPLANTATION: A

REPORT FROM THE RENAL ALLOGRAFT RECURRENT DISEASE REGISTRY (RARDR) Hariharan S, George V, Adams MA, Davis CL, Johnson CP, First MR, Peddi VR, Roza AM, Vincenti F American Society of Transplant Physicians, 15th Annual Scientific Meeting Chicago, Illinois, May, 1997 *266. A PHARMACOKINETIC COMPARISON OF SANGSTAT CYCLOSPORINE FORMULATON 35 AND SANDOZ

NEORAL IN HEALTHY VOLUNTEERS IN TWO PILOT STUDIES First MR, Weiskittel P, Burton M, Womble D, Shah M, Daoud J, Schroeder TJ American Society of Transplant Physicians, 15th Annual Scientific Meeting Chicago, Illinois, May, 1997 *267. A PROGRAM TO DEVELOP A CYCLOSPORINE FORMULATION THAT IS BIOEQUIVALENT TO NEORAL Schroeder TJ, First MR, Alloway R, Gaber O, Levy R, Berger-Moran H, Floch R, Pouletty P American Society of Transplant Physicians, 15th Annual Scientific Meeting Chicago, Illinois, May, 1997 *268. CORRELATION OF POST TREATMENT RENAL ALLOGRAFT BIOPSIES TO REJECTION REVERSAL The U.S. Multicenter Thymoglobulin Study Group American Society of Transplant Physicians, 15th Annual Scientific Meeting Chicago, Illinois, May, 1997 *269. THE 1996 DOUBLE BLINDED RANDOMIZED MULTICENTER PHASE III CLINICAL TRIAL OF

THYMOGLOBULIN VERSUS ATGAM IN THE TREATMENT OF ACUTE GRAFT REJECTION FOLLOWING RENAL TRANSPLANTATION

The U.S. Multicenter Thymoglobulin Study Group American Society of Transplant Physicians, 15th Annual Scientific Meeting Chicago, Illinois, May, 1997

57

*270. THYMOGLOBULIN IS MORE EFFECTIVE THAN ATGAM IN MAINTAINING T CELL DEPLETION DURING AND FOLLOWING THERAPY

Woodle ES, Basadonna G, First MR, Gaber AO, Skinberg HR, Horn HR, Kano J, Schroeder TJ American Society of Transplant Physicians, 15th Annual Scientific Meeting Chicago, Illinois, May, 1997 *271. THYMOGLOBULIN SUCCESSFULLY PREVENTS RECURRENT REJECTION First MR for The U.S. Multicenter Thymoblobulin Study Group American Society of Transplant Physicians, 15th Annual Scientific Meeting Chicago, Illinois, May, 1997 *272. RACIAL DIFFERENCES IN KIDNEY TRANSPLANTATION: RESULTS OF A U.S. MULTICENTER,

RANDOMIZED TRIAL The FK506 Kidney Transplant Study Group American Society of Transplant Physicians, 15th Annual Scientific Meeting Chicago, Illinois, May, 1997 *273. ASSESSMENT OF THE FREQUENCY AND COSTS OF POST-TRANSPLANT HOSPITALIZATIONS IN

PATIENTS RECEIVING TACROLIMUS VERSUS CYCLOSPORINE The FK506 Kidney Transplant Study Group American Society of Transplant Physicians, 15th Annual Scientific Meeting Chicago, Illinois, May, 1997 *274. ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN KIDNEY TRANSPLANT PATIENTS RECEIVING

FK506-BASED VERSUS CYCLOSPORINE-BASED IMMUNOSUPPRESSION The FK506 Kidney Transplant Study Group American Society of Transplant Physicians, 15th Annual Scientific Meeting Chicago, Illinois, May, 1997 *275. TACROLIMUS IN KIDNEY TRANSPLANTATION: TWO-YEAR RESULTS OF THE U.S. RANDOMIZED,

COMPARATIVE, PHASE III STUIDY The FK506 Kidney Transplant Study Group American Society of Transplant Surgeons, 23rd Annual Meeting Chicago, Illinois, May, 1997 *276. AN ANALYSIS OF RENAL ALLOGRAFT LOSS DUE TO DEATH WITH A FUNCTIONING GRAFT Peddi VR, First MR International Society of Transplant Surgeons, 23rd Annual Meeting Chicago, Illinois, May, 1997 *277. ECONOMIC COSTS OF EXPANDED CRITERIA DONORS IN RENAL TRANSPLANTATION Whiting J, Golconda M, Hayes R, Smith R, First MR, Alexander JW American Society of Transplant Surgeons, 23rd Annual Meeting Chicagio, Illinois, May, 1997 *278. VARIATIONS IN HISTOLOGICAL PATTERNS IN RENAL TRANSPLANT RECIPIENTS ASSOCIATED WITH

CHANGES IN IMMUNOSUPPRESSION Schroeder TJ, First, MR, Daoud AJ, Peddi R, Hariharan S, Smith RD, Cavallo T International Society of Nephrology, Sydney, Australia, June, 1997 *279. TREATMENT OF RESISTANT ACUTE REJECTION WITH THYMOGLOBULIN First MR, Kano J, Horn HR, Berger-Moran H, Schroeder TJ

58

International Society of Nephrology, Sydney, Australia, June, 1997 *280. THYMOGLOBULIN REVERSES ACUTE RENAL ALLOGRAFT REJECTION BETTER THAN ATGAM: A

DOUBLE-BLINDED RANDOMIZED CLINICAL TRIAL Thymoglobulin Study Group International Society of Nephrology, Sydney, Australia, June, 1997 *281. CYCLOSPORINE NEPHROTOXICITY IN RENAL TRANSPLANT RECIPIENTS: CORRELATION WITH

HISTOPATHOLOGY Peddi VR, Hariharan S, Schroeder TJ, Smith R, Cavallo T, First MR International Society of Nephrology, Sydney, Australia, June, 1997 *282. MYCOPHENOLATE MOFETIL IN COMBINATION WITH EITHER CYCLOSPORINE OR TACROLIMUS IS

EQUALLY SAFE AND EFFICACIOUS First MR, Daoud AJ, Schroeder TJ, Shah M, Hariharan S, Peddi R, Weiskittel P International Society of Nephrology, Sydney, Australia, June, 1997 *283. CYSTO-ENTERIC CONVERSION FOR PANCREATIC ALLOGRAFTS: THE CASE FOR EARLY INTERVENTION Kaplan AJ, Valente JF, Alexander JW, First MR, Demmy AM, Munda R International Surgical Week 1997, Acapulco, Mexico, August, 1997 *284. EFFICACY OF OKT3 AS PRIMARY THERAPY FOR HISTOLOGICALLY CONFIRMED ACUTE RENAL

ALLOGRAFT REJECTION IN SIMULTANEOUS KIDNEY AND PANCREAS TRANSPLANT RECIPIENTS Peddi VR, Kamath S, Schroeder TJ, Munda R, First MR Sixth Congress of the International Pancreas and Islet Transplant Association Milan, Italy, September, 1997 *285. USE OF TACROLIMUS (FK) BASED IMMUNOSUPPRESSION ELIMINATES ACUTE REJECTION AS A

MAJOR COMPLICATION FOLLOWING SIMULTANEOUS KIDNEY AND PANCREAS TRANSPLANTATION Peddi VR, Demmy AM, Munda R, Alexander JW, First MR Sixth Congress of the International Pancreas and Islet Transplant Association Milan, Italy, September, 1997 *286. IMPROVED CYCLOSPORINE PHARMACOKINETICS IN MAINTENANCE RENAL TRANSPLANTATION

RECIPIENTS CONVERTED TO CYCLOSPORINE-MICROEMULSION Pescovitz M. First MR European Society for Organ Transplantation Budapest, Hungary, September, 1997 *287. AN IMMUNOHISTOCHEMICAL ANALYSIS OF VENOUS STENOSIS IN PTFE DIALYSIS GRAFTS Roy-Chaudhury P, Heffelfinger SC, Miller Mary Ann, Denman D, Munda R, First MR, Galla JG, Whiting J American Society of Nephrology, 30th Annual Meeting San Antonio, Texas, November, 1997 *288. RECURRENT AND DE-NOVO GLOMERULAR DISEASE AFTER RENAL TRANSPLANTATION: A REPORT

FROM THE RENAL ALLOGRAFT RECURRENT DISEASE REGISTRY (RARDR) Hariharan S, George V, Adams MB, Davis CL, Johnson CP, First MR, Peddi VR, Roza AM, Vincenti F American Society of Nephrology, 30th Annual Meeting San Antonio, Texas, November, 1997 *289. TACROLIMUS (FK506) IN KIDNEY TRANSPLANTATION: THREE YEAR SURVIVAL RESULTS OF THE U.S.

MULTICENTER, RANDOMIZED, COMPARATIVE STUDY The FK506 Kidney Transplant Study Group The International Congress of Immunosuppression Orlando, Florida, December, 1997

59

*290. EFFECT OF RACE AND IMMUNOSUPPRESSION IN RENAL TRANSPLANTATION: THREE-YEAR SURVIVAL RESULTS FROM A U.S. MULTICENTER RANDOMIZED TRIAL

The FK506 Kidney Transplant Study Group The International Congress of Immunosuppression Orlando, Florida, December, 1997 *291. HYPERTENSION IN RENAL TRANSPLANT RECIPIENTS: 2-YEAR RESULTS FROM THE FK506

MULTICENTER, RANDOMIZED COMPARATIVE TRIAL The FK506 Kidney Transplant Study Group The International Congress of Immunosuppression Orlando, Florida, December, 1997 *292. CMV INFECTIONS IN RENAL TRANSPLANT RECIPIENTS: RESULTS OF THE U.S. MULTICENTER FK506

KIDNEY TRANSPLANT STUDY The FK506 Kidney Transplant Study Group The International Congress of Immunosuppression Orlando, Florida, December, 1997 *293. HISTOPATHOLOGIC FINDINGS FROM TWO-YEAR PROTOCOL BIOPSIES FROM A U.S. MULTICENTER

KIDNEY TRANSPLANT TRIAL The FK506 Kidney Transplant Study Group The International Congress of Immunosuppression Orlando, Florida, December, 1997 *294. AN ECONOMIC ASSESSMENT OF POST-TRANSPLANT HOSPITALIZATIONS AMONG KIDNEY

TRANSPLANT PATIENTS RECEIVING TACROLIMUS VERSUS CYCLOSPORINE IMMUNOSUPPRESSIVE THERAPY

The FK506 Kidney Transplant Study Group The International Congress of Immunosuppression Orlando, Florida, December, 1997 *295. ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN KIDNEY TRANSPLANT PATIENTS RECEIVING

FK506-BASED VERSUS CYCLOSPORINE-BASED IMMUNOSUPPRESSION The FK506 Kidney Transplant Study Group The International Congress of Immunosuppression Orlando, Florida, December, 1997 *296. EFFICACY OF OKT3 AS PRIMARY THERAPY FOR HISTOLOGICALLY CONFIRMED ACUTE RENAL

ALLOGRAFT REJECTION Kamath S, Dean D, Peddi VR, Schroeder TJ, Alexander JW, Cavallo T, First MR The International Congress of Immunosuppression Orlando, Florida, December, 1997 *297. LONG-TERM KIDNEY AND PANCREAS FUNCTION WITH TACROLIMUS (FK506) IMMUNOSUPPRESSION

FOLLOWING SIMULTANEOUS KIDNEY AND PANCREAS TRANSPLANTATION (SKP) Peddi VR, Demmy AM, Munda R, Alexander JW, First MR The International Congress of Immunosuppression Orlando, Florida, December, 1997 *298. WHO SHOULD FUND CHRONIC REJECTION TRIALS? First MR American Society of Transplant Physicians, Winter Symposium San Juan, Puerto Rico, January 1998 *299. CONVERSION OF STABLE RENAL TRANSPLANT RECIPIENTS FROM SANDIMMUNE TO SANG-35, A

NOVEL CYCLOSPORINE FORMULATION, USING A DOSE-NORMALIZED EQUIVALENCE METHOD

60

First MR, Weiskittel P, Burton M, Shah M, Dreyer D, Fleck P, Bey C, Peddi R, Canafax D, Schroeder TJ The Third International Conference on New Trends in Clinical and Experimental Immunosuppression Geneva, Switzerland, February, 1998 *300. A META-ANALYSIS TO ASSESS THE SAFETY AND TOLERABILITY OF TWO FORMULATIONS OF

CYCLOSPORINE: SANDIMMUNE AND NEORAL Shah MB, Martin JE, Schroeder TJ, First MR The Third International Conference on New Trends in Clinical and Experimental Immunosuppression Geneva, Switzerland, February, 1998 *301. PHARMACOECONOMIC ANALYSIS OF MYCOPHENOLATE MOFETIL VERSUS AZATHIOPRINE IN

CADAVERIC RENAL TRANSPLANTATION Baker GM, Martin JE, Jang R, Myre SA, Armistead JA, Schroeder TJ, First MR The Third International Conference on New Trends in Clinical and Experimental Immunosuppression Geneva, Switzerland, February, 1998 *302. TACROLIMUS USE IN KIDNEY-PANCREAS RECIPIENTS IS ASSOCIATED WITH LESS ACUTE RENAL

DYSFUNCTION THAN CYCLOSPORINE Fleck P, Schroeder TJ, Daoud J, Peddi R, First MR The Third International Conference on New Trends in Clinical and Experimental Immunosuppression Geneva, Switzerland, February, 1998 *303. AN ANALYSIS OF THE INCIDENCE, CAUSES, AND TIMING OF ACUTE RENAL DYSFUNCTION AFTER

RENAL TRANSPLANTATION Fleck P, Schroeder TJ, Shah MB, Daoud AJ, Peddi R, First MR The Third International Conference on New Trends in Clinical and Experimental Immunosuppression Geneva, Switzerland, February, 1998 *304. CONVERSION OF STABLE RENAL TRANSPLANT RECIPIENTS FROM SANDIMMUNE TO SANG-35, A

NOVEL GENERIC CYCLOSPORINE FORMULATION, USING A DOSE-NORMALIZED EQUIVALENCE METHOD

First MR, Weiskittel P, Burton M, Shah M, Dreyer D, Fleck P, Bey C, Peddi R, Schroeder TJ New Dimensions in Transplantation, Florence, Italy, February 1998 *305. A META-ANALYSIS TO ASSESS THE SAFETY AND TOLERABILITY OF TWO FORMULATIONS OF

CYCLOSPORINE: SANDIMMUNE AND NEORAL Shah MB, Schroeder TJ, First MR New Dimensions in Transplantation, Florence, Italy, February 1998 *306. CONVERSION TO NEORAL IN STABLE RENAL TRANSPLANT RECIPIENTS The Sandoz Study Group New Dimensions in Transplantation, Florence, Italy, February 1998 *307. MYCOPHENOLATE MOFETIL INDUCED COLONIC ULCERATION IN A RENAL TRANSPLANT RECIPIENT Golconda M, Valente J, Gilinsky N, First R Seventh Annual Spring Clinical Nephrology Meetings of the National Kidney Foundation, Nashville,

Tennessee, March 1998 *308. A META-ANALYSIS TO ASSESS THE SAFETY AND TOLERABILITY OF TWO FORMULATIONS OF

CYCLOSPORINE: SANDIMMUNE AND NEORAL Shah MB, Martin JE, Schroeder TJ, First MR American Society of Transplant Physicians, 17th Annual Meeting Chicago, Illinois, June 1998

61

*309. PHARMACOKINETIC ANALYSIS OF MYCOPHENOLATE MOFETIL VERSUS AZATHIOPRINE IN CADAVERIC RENAL TRANSPLANTATION

Baker GM, Martin JE, Jang R, Myre SA, Armistead JA, Schroeder TJ, First MR American Society of Transplant Physicians, 17th Annual Meeting Chicago, Illinois, June 1998 *310. CLINICAL DETERMINANTS OF HEALTH RELATED QUALITY OF LIFE (HRQL) IN SOLID ORGAN

TRANSPLANT RECIPIENTS Whiting J, Nabel J, Grossman P, Martin J, Hanto D, First MR American Society of Transplant Physicians, 17th Annual Meeting Chicago, Illinois, June 1998 *311. A SERIES OF COMPARATIVE TRIALS BETWEEN SANG-35 AND OTHER CYCLOSPORINE (CsA)

FORMULATIONS IN STABLE RENAL TRANSPLANT PATIENTS (Pts) Schroeder TJ, First MR, Alloway RR, Canafax DM, Gaber AO, Gaston R American Society of Transplant Physicians, 17th Annual Meeting Chicago, Illinois, June 1998 *312. TACROLIMUS USE IN KIDNEY-PANCREAS RECIPIENTS IS ASSOCIATED WITH LESS ACUTE RENAL

DYSFUNCTION THAN CYCLOSPORINE Fleck P, Schroeder T, Daoud J, Peddi R, First MR American Society of Transplant Physicians, 17th Annual Meeting Chicago, Illinois, June 1998 *313. LONG-TERM OUTCOME IN SIMULTANEOUS KIDNEY AND PANCREAS (SKP) TRANSPLANT RECIPIENTS

WITH FUNCTIONING ALLOGRAFTS AT ONE YEAR AFTER TRANSPLANTATION Peddi VR, Munda R, Demmy AM, First MR American Society of Transplant Physicians, 17th Annual Meeting Chicago, Illinois, June 1998 *314. OKT3 AS PRIMARY THERAPY FOR BIOPSY PROVEN ACUTE RENAL ALLOGRAFT REJECTION IN

SIMULTANEOUS KIDNEY AND PANCREAS TRANSPLANT (SKP) RECIPIENTS Peddi VR, Schroeder TJ, Munda R, First MR American Society of Transplant Physicians, 17th Annual Meeting Chicago, Illinois, June 1998 *315. COLONIC ULCERATION - A PREVIOUSLY UNREPORTED ADVERSE EFFECT OF MYCOPHENOLATE

MOFETIL Golconda M, Valente J, Bejarano P, Gilinsky N, First MR American Society of Transplant Physicians, 17th Annual Meeting Chicago, Illinois, June 1998 *316. RECURRENT/DE NOVO MEMBRANOUS NEPHROPATHY AFTER RENAL TRANSPLANTATION: A

REPORT FROM THE RENAL ALLOGRAFT DISEASE REGISTRY (RADR) Piering AW, Brennan D, Ouseph R, Vincenti F, Davis C, First MR, Hariharan S American Society of Transplant Physicians, 17th Annual Meeting Chicago, Illinois, June 1998 *317. RECURRENT AND DE NOVO DISEASES AFTER RENAL TRANSPLANTATION: A REPORT FROM THE

RENAL ALLOGRAFT DISEASE REGISTRY (RADR) Hariharan S, Pelz C, George V, Adams MB, Brennan D, Davis CL, Johnson CP, First MR, Ouseph R, Roza AM,

Vincenti F American Society of Transplant Physicians, 17th Annual Meeting Chicago, Illinois, June 1998

62

*318. THE COST-EFFECTIVENESS OF TRANSPLANTATION WITH EXPANDED DONOR KIDNEY (EDKs)- A MARKOV MODEL

Zavala E, Whiting J, Alexander JW, First MR American Society of Transplant Physicians, 17th Annual Meeting Chicago, Illinois, June 1998 *319. CORRELATION BETWEEN BANFF CRITERIA AND OUTCOME AT 12 MONTHS FOLLOWING ACUTE

REJECTION IN MULTICENTER RANDOMIZED TRIAL The Thymoglobulin Multicenter Study Group American Society of Transplant Physicians, 17th Annual Meeting Chicago, Illinois, June 1998 *320. ATGAM LEVELS IN KIDNEY TRANSPLANT PATIENTS TREATED FOR ACUTE REJECTION The US Thymoglobulin TM Multi-Center Study Group American Society of Transplant Physicians, 17th Annual Meeting Chicago, Illinois, June 1998 *321. 12 MONTH INTENT TO TREAT ANALYSIS OF THE DOUBLE BLIND RANDOMIZED MULTICENTER

THYMOGLOBULIN VS Atgam TRIAL FOR THE TREATMENT OF ACTUE REJECTION FOLLOWING RENAL TRANSPLANTATION

The US Thymoglobulin TM Multi-Center Study Group American Society of Transplant Physicians, 17th Annual Meeting Chicago, Illinois, June 1998 *322. VALACICLOVIR REDUCES THE INCIDENCE OF CYTOMEGALOVIRUS DISEASE AND ACUTE GRAFT

REJECTION IN CMV-SERONEGATIVE RECIPIENTS OF A SEROPOSITIVE RENAL ALLOGRAFT Valaciclovir International Study Group American Society of Transplant Physicians, 17th Annual Meeting Chicago, Illinois, June 1998 *323. VALACICLOVIR REDUCES THE INCIDENCE OF CYTOMEGALOVIRUS (CMV) DISEASE AND OTHER

OPPORTUNISTIC INFECTIONS IN CMV-SERONEGATIVE RECIPIENTS OF A SEROPOSITIVE CADAVERIC RENAL ALLOGRAFT

Keating M, Kovarik J, Salmela K, First MR, Lee IC, Coggon GL, Crisp A International Congress of Infectious Diseases, Boston, Massachusetts, June 1998 *324. IMMUNOLOGICAL HIGH-RISK RECIPIENT STRATEGIES First MR XVII World Congress of the Transplantation Society Montreal, Canada, July 1998 *325. A META-ANALYSIS TO ASSESS THE SAFETY AND TOLERABILITY OF TWO FORMULATIONS OF

CYCLOSPORINE: SANDIMMUNE AND NEORAL Shah MB, Martin JE, Schroeder TJ, First MR XVII World Congress of the Transplantation Society Montreal, Canada, July 1998 *326. GRAFT OUTCOME IN PATIENTS WITH BIOPSY PROVEN CHORNIC RENAL ALLOGRAFT REJECTION Peddi VR, Schroeder TJ, Wesikittel P, First MR XVII World Congress of the Transplantation Society Montreal, Canada, July 1998 *327. LONG-TERM OUTCOME IN SIMULTANEOUS KIDNEY AND PANCREAS (SKP) TRANSPLANT RECIPIENTS

WITH FUNCTIONING ALLOGRAFTS AT ONE YEAR AFTER TRANSPLANTATION Peddi VR, Munda R, Demmy AM, First MR

63

XVII World Congress of the Transplantation Society Montreal, Canada, July 1998 *328. COLONIC ULCERATION - A PREVIOUSLY UNREPORTED ADVERSE EFFECT OF MYCOPHENOLATE

MOFETIL Golconda M, Valente J, Bejarano P, Gilinsky N, First MR XVII World Congress of the Transplantation Society Montreal, Canada, July 1998 *329. SANG-35 VS NEORAL OR SANDIMMUNE IN STABLE RENAL TRANSPLANT PATIENTS Gaston R, First MR, Alloway RR, Canafax DM, Gaber AO, Schroeder TJ XVII World Congress of the Transplantation Society Montreal, Canada, July 1998 *330. PHARMACOKINETIC TRIALS IN NORMALS, KIDNEY, AND LIVER TRANSPLANT PATIENTS: SANG-35

VS. NEORAL, CYCLOSPORINE Schroeder T, First R, Alloway R, Pan S-H, Gaber O, Lopez R, Fisher R, Irish W, Canafax D, Pouletty P XVII World Congress of the Transplantation Society Montreal, Canada, July 1998 *331. CYCLOSPORINE EXPOSURE FOLLOWING SANDIMMUNE TO SANG-35 CONVERSION AND DOSE

ADJUSTMENT IN KIDNEY TRANSPLANT PATIENTS First MR, Weiskittel P, Burton M, Shah M, Dreyer D, Fleck P, Bey C, Peddi VR Canafax D XVII World Congress of the Transplantation Society Montreal, Canada, July 1998 *332. COST-EFFECTIVENESS OF EXPANDED DONOR KIDNEYS Zavala E, Whiting J, Alexander JW, First MR XVII World Congress of the Transplantation Society Montreal, Canada, July 1998 *333. PHARMACOECONOMICS ANALYSIS OF MYCOPHENOLATE MOFETIL VERSUS AZATHIOPRINE IN

CADAVERIC RENAL TRANSPLANTATION Baker GM, Martin GE, Jang R, Myre SA, Armistead JA, Schroeder TJ, First MR XVII World Congress of the Transplantation Society Montreal, Canada, July 1998 *334. CYCLOSPORINE EXPOSURE FOLLOWING SANDIMMUNE TO SANG-35 CONVERSION AND DOSE

ADJUSTMENTS IN KIDNEY TRANSPLANT PATIENTS First MR, Weiskittel P, Burton M, Shah M, Dreyer D, Fleck P, Bey C, Peddi VR, Canafax D, Schroeder TJ American Society of Nephrology, 31st Annual Meeting Philadelphia, Pennsylvania, October 1998 *335. ACUTE RENAL DYSFUNCTION IS A COMMON LATE POST-TRANSPLANT COMPLICATION Fleck PR, Schroeder TJ, Shah MB, Daoud AJ, Peddi VR, First MR American Society of Nephrology, 31st Annual Meeting Philadelphia, Pennsylvania, October 1998 *336. TACROLIMUS (FK506) IS ASSOCIATED WITH LESS ACUTE RENAL DYSFUNCTION (ARD) THAN

CYCLOSPORINE IN KIDNEY-PANCREAS (KP) ALLOGRAFT RECIPIENTS Fleck P, Schroeder TJ, Daoud AJ, Peddi VR, First MR American Society of Nephrology, 31st Annual Meeting Philadelphia, Pennsylvania, October 1998

64

*337. RENAL ALLOGRAFT OUTCOME IN PATIENTS WITH BIOPSY PROVEN CHRONIC REJECTION Peddi VR, Schroeder TJ, Weiskittel P, First MR American Society of Nephrology, 31st Annual Meeting Philadelphia, Pennsylvania, October 1998 *338. A COMPARISON OF THE SAFETY AND TOLERABILITY OF NEORAL AND SANDIMMUNE IN RENAL

TRANSPLANT RECIPIENTS: A META-ANALYSIS Shah MB, Martin JE, Schroeder TJ, First MR American Society of Nephrology, 31st Annual Meeting Philadelphia, Pennsylvania, October 1998 *339. VENOUS NEOINTIMAL HYPERPLASIA IN PTFE DIALYSIS GRAFTS: A ROLE FOR CYTOKINES, M0 AND

ANGIOGENESIS Roy-Chaudhury P, Whiting J, Miller W, Reaves A, Denman D, Munda R, First MR, Heffelfinger SC American Society of Nephrology, 31st Annual Meeting Philadelphia, Pennsylvania, October 1998 *340. VENOUS STENOSIS IN PTFE DIALYSIS GRAFTS: DEVELOPMENT OF A PIG MODEL OF AV GRAFT

STENOSIS Roy-Chaudhury P, Heffelfinger SC, Miller M, Reaves A, Denman D, First MR, Whiting J American Society of Nephrology, 31st Annual Meeting Philadelphia, Pennsylvania, October 1998 *341. RISE FACTORS FOR GRAFT LOSS DUE TO RECURRENT DISEASE AFTER RENAL TRANSPLANTATION: A

REPORT FROM THE RENAL ALLOGRAFT DISEASE REGISTRY Hariharan S, Pelz C, George V, Adams MB, Brennan D, Davis CP, Johnson CP, First MR, Peddi R, Ouseph R,

Roza AM, Vincent F American Society of Nephrology, 31st Annual Meeting Philadelphia, Pennsylvania, October 1998 *342. THYMOGLOBULIN MAY BE MORE EFFICACIOUS THAN ATGAM REDUCING RECURRENT ACUTE RENAL

ALLOGRAFT REJECTION: RESULTS OF THE US MULTICENTER, DOUBLE-BLINDED, COMPARATIVE TRIAL

The US Thymoglobulin Multi-Center Study Group. American Society of Nephrology, 31st Annual Meeting Philadelphia, Pennsylvania, October 1998 *343. CYCLOSPORINE EXPOSURE FOLLOWING SANDIMMUNE AND SANG-35 CONVERSION AND DOSE

ADJUSTMENTS IN KIDNEY TRANSPLANT RECIPIENT Peddi VR, Weiskittel P, Schroeder TJ, First MR Indian Society of Nephrology Annual Congress Bangalore, India, October 1998 *344. SANG CYA: AN EXAMPLE THAT BIOEQUIVALENCE EQUALS THERAPEUTIC INTERCHANGABILITY IN

A NARROW THERAPEUTIC WINDOW DRUG: Renlund D, Gaston RF, Pan SH, First MR. National Kidney Foundation, 8th Annual Clinical Nephrology Meeting Washington, D.C., April 1999 *345. LONG-TERM RENAL ALLOGRAFT SURVIVAL: PROGNOSTIC IMPLICATION OF DONOR SOURCE;

SEVERITY, TIMING, AND NUMBER OF ACUTE REJECTION EPISODES; AND PROTEINURIA Manzoor K, Peddi VR, First MR.

65

American Society of Transplant Physicians, 18th Annual Scientific Meeting Chicago, Illinois, May 1999 *346. EFFICACY OF A MODIFIED DACLIUZUMAB REGIMEN IN PREVENTING ACUTE REJECTION IN KIDNEY

AND KIDNEY-PANCREAS TRANSPLANT RECIPIENTS Golconda MS, Rayhill SC, First MR, Wu YM, Bertolatus JA, Thomas CP, Hunsicker LC American Society of Transplant Physicians, 18th Annual Scientific Meeting Chicago, Illinois, May 1999 *347. A CLINICAL AND ECONOMIC EVALUATION OF DACLIZUMAB AND ATGAM INDUCTION IN HIGH RISK

RENAL TRANSPLANT RECIPIENTS Shah MB, Martin JF, Schroeder TJ, Peddi VR, Whiting J, Alexander JW, First MR American Society of Transplant Physicians, 18th Annual Scientific Meeting Chicago, Illinois, May 1999 *348. RICK FACTORS FOR DEVELOPMENT OF POST TRANSPLANT FOCAL SEGMENTAL

GLOMERULOSCLEROSIS (FSGS) AND GRAFT FAILURE: A REPORT FROM RENAL ALLOGRAFT DISEASE REGISTRY (RADR)

Ahuja M, George V, Brennan D, Davis C, First MR, Johnson CP, Ouseph R, Peddi VR, Vincenti F, Hariharan S American Society of Transplant Physicians, 18th Annual Scientific Meeting Chicago, Illinois, May 1999 *349. ECONOMIC ANALYSIS OF LONG-TERM KETOCONAZOLE/CYCLOSPORINE USE IN KIDNEY TRANSPLANT

RECIPIENTS Martin JE, Shah MB, Schroeder TJ, First MR American Society of Transplant Physicians, 18th Annual Scientific Meeting Chicago, Illinois, May 1999 *350. ECONOMIC COST OF EXPANDED CRITERIA DONORS IN CADAVERIC RENAL TRANSPLANTATION Schnitzler MA, Zavala E, Woodward RS, Whiting J, Cohen DC, Lowell JA, Martin JE, Singer GG, First MR,

Brennan DC American Society of Transplant Physicians, 18th Annual Scientific Meeting Chicago, Illinois, May 1999 *351. DEVELOPMENT AND MULTICENTER VALIDATION OF A QUALITY OF LIFE INSTRUMENT FOR

TRANSPLANT RECIPIENTS Whiting JF, Martin J, Dewan N, Baas L, Nabel J, First MR American Society of Transplant Physicians, 18th Annual Scientific Meeting Chicago, Illinois, May 1999 *352. PERIPHERAL VASCULAR DISEASE AFTER PANCREAS TRANSPLANTS Johnson SR, Kelly B, Valenk JF, Peddi VR, First MR, Demmy A, Munda R American Society of Transplant Physicians, 18th Annual Scientific Meeting Chicago, Illinois, May 1999 *353. MERKEL’S CELL CARCINOMA IN ORGAN RECIPIENTS: REPORT OF 41 CASES Penn I, First MR American Society of Transplant Surgeons, 25th Annual Scientific Meeting Chicago, Illinois, May 1999 *354. METABOLIC INDICATORS OF PANCREAS ALLOGRAFT FUNCTION IN SIMULTANEOUS KIDNEY AND

PANCREAS (SKP) ALLOGRAFT FUNCTION Peddi VR, Demmy R, Munda R, First MR 7th World Congress of the International Pancreas and Islet Transplant Association Sydney, Australia, August 1999

66

*355. TACROLIMUS IS ASSOCIATED WITH LESS ACUTE RENAL DYSFUNCTION THAN CYCLOSPORINE IN

KIDNEY-PANCREAS ALLOGRAFT RECIPIENTS Peddi VR, Fleck P, Schroeder TJ, Daoud AJ, Munda R, First MR 7th World Congress of the International Pancreas and Islet Transplant Association Sydney, Australia, August 1999 *356. LONG-TERM COMPLICATIONS, OUTCOME, AND QUALITY OF LIFE IN SIMULTANEOUS KIDNEY AND

PANCREAS TRANSPLANT RECIPIENTS WITH FUNCTIONING GRAFTS AT ONE-YEAR AFTER TRANSPLANTATION

Peddi VR, Whiting J, Demmy AM, Munda R, First MR 7th World Congress of the International Pancreas and Islet Transplant Association Sydney, Australia, August 1999 *357. ALPHA SMOOTH MUSCLE ACTIN AS A PROGNOSTIC MARKER FOR CHRONIC ALLOGRAFT

DYSFUNCTION Roy-Chaudhury P, Manzoor K, Miller M, Reaves A, Armstrong J, Nanayakkara N, Peddi VR, First MR, Smith R. American Society of Nephrology, 32nd Annual Meeting, Miami Beach, Florida, November 1999 *358. MEDICAL COMPLICATIONS, QUALITY OF LIFE, AND OUTCOME IN SIMULTANEOUS KIDNEY AND

PANCREAS (SKP) TRANSPLANT RECIPIENTS Peddi VR, Whiting J, Demmy AM, Munda R, First MR American Society of Nephrology, 32nd Annual Meeting, Miami Beach, Florida, November 1999 *359. SURVIVAL ADVANTAGE WITH LIVING DONOR TRANSPLANTATION Peddi VR, Manzoor K, Weiskittel P, First MR American Society of Nephrology, 32nd Annual Meeting, Miami Beach, Florida, November 1999 *360. AN ECONOMIC EVALUATION OF GANCICLOVIR VERSUS ACYCLOVIR FOR CMV PROPHYLAXIS IN KIDNEY TRANSPLANT RECIPIENTS. James R. Rademacher, Jill E. Martin, James F. Whiting, Timothy J. Schroeder, First MR American Society of Nephrology, 32nd Annual Meeting, Miami Beach, Florida, November 1999 *361. A LONG-TERM EVALUATION OF THE INCIDENCE AND RESOURCE UTILIZATION OF BONE COMPLICATIONS IN KIDNEY TRANSPLANT RECIPIENTS Uday M. Khosla, Jill E. Martin, James F. Whiting, Malay B. Shah, Tim J. Schroeder, First MR American Society of Nephrology, 32nd Annual Meeting, Miami Beach, Florida, November 1999 *362. SANG CYA USE IN ADULT RENAL, HEART AND LIVER TRANSPLANTATION First MR, Gaston RS, Pan S-H, Renlund D British Transplantation Society Cardiff, Wales, March 2000 *363. HEALTH UTILITY SCORES FOLLOWING RENAL TRANSPLANTATION: A COMPARISON OF METHODS Boyd S, Martin JE, First MR, Whiting JF First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of

Transplantation, May 2000

67

Chicago, Illinois *364. THYMOGLOBULIN INDUCTION THERAPY IN CADAVERIC RENAL ALLOGRAFT RECIPIENTS:

INTERMITTENT DOSING WITH CD3+ LYMPHOCYTE COUNT MONITORING Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES, First MR First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of

Transplantation, May 2000 Chicago, Illinois *365. DIETARY SUPPLEMENTATION WITH L-ARGININE AND CANOLA OIL REDUCES REJECTION EPISODES,

RENAL BIOPSIES, REHOSPITALIZATION AND BLOOD PRESSURE FOLLOWING RENAL TRANSPLANTATION

Alexander JW, Ofstedal T, Stanley L, Erickson A, Greenberg N, James L, First MR, Whiting JF, Woodle ES First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of

Transplantation, May 2000 Chicago, Illinois *366. QUALITY OF L IFE (QOL) AS A PREDICTOR OF MORBIDITY, MORTALITY AND RESOURCE UTILIZATION IN RECIPIENTS OF SOLID ORGAN TRANSPLANTS Phillips AL, Walker EL, Martin JE, First MR, Hanto DW, Whiting JF First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of

Transplantation, May 2000 Chicago, Illinois *367. THE ECONOMIC IMPACT OF OBESITY IN RENAL TRANSPLANTATION Martin JE, Whiting JF, Cohen DC, Schnitzler MA, First MR XVIII International Congress of the Transplantation Society Rome, Italy, September 2000 *368. ORGAN SHORTAGE AND ALLOCATION ISSUES First MR XVIII International Congress of the Transplantation Society Rome, Italy, September 2000 *369. L-ARGININE AND CANOLA OIL, IMPROVE OUTCOME AFTER RENAL TRANSPLANTATION Alexander JW, Ofstedal L, Erickson SA, Greenberg N, First MR, Whiting ES, Woodle ES XVIII International Congress of the Transplantation Society Rome, Italy, September 2000 *370. QUALITY OF LIFE (QOL) AS A PREDICTOR OF MORBIDITY, MORTALITY AND RESOURCE UTILIZATION AFTER SOLID ORGAN TRANSPLANT Phillips AL, Walker EL, Martin JE, First MR, Hanto DW, Whiting JF XVIII International Congress of the Transplantation Society Rome, Italy, September 2000 *371. HEALTH UTILITY SCORES FOLLOWING RENAL TRANSPLANTATION: A COMPARISON OF METHODS Schneider S, Martin JE, First MR, Whiting JF XVIII International Congress of the Transplantation Society Rome, Italy, September 2000 *372. QUALITY OF LIFE (QOL) AMONG MEDICAID TRANSPLANT RECIPIENTS Martin JE, Shireman T, Whiting JF, First MR XVIII International Congress of the Transplantation Society Rome, Italy, September 2000 *373. THE COST OF TRANSPLANT GRAFT MAINTENANCE FOLLOWING SOLID

68

ORGAN TRANSPLANTATION Shireman T, Martin J, First MR, Whiting JF XVIII International Congress of the Transplantation Society Rome, Italy, September 2000 *374. POST-TRANSPLANT CARDIOVASCULAR RISK: IMPACT ON LONG-TERM PATIENTS SURVIVAL First MR XVIII International Congress of the Transplantation Society Rome, Italy, September 2000 *375. LONG-TERM EXPERIENCE WITH DOSAGE FORMS AND FORMULATION INTERCHANGES OF

CYCLOSPORINE First MR, Weiskittel P, Peddi VR 33rd Annual Meeting of the American Society of Nephrology Toronto, Canada, October 2000 *376. THYMOGLOBULIN INDUCTION THERAPY IN HIGH-RISK RENAL ALLOGRAFT RECIPIENTS Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES, First MR 33rd Annual Meeting of the American Society of Nephrology Toronto, Canada, October 2000 *377. CHARACTERISTICS OF HLA -IDENTICAL RENAL TRANSPLANT RECIPIENTS Peddi VR, Weiskittel P, Alexander JW, First MR 33rd Annual Meeting of the American Society of Nephrology Toronto, Canada, October 2000 *378. POST-TRANSPLANT DIABETES MELLITUS (PTDM): INCIDENCE, RISK FACTORS AND MANAGEMENT First MR, Gerber D, Hariharan S, Kaufman DB, Shapiro R 33rd Annual Meeting of the American Society of Nephrology Toronto, Canada, October 2000 *379. KAPOSI’S SARCOMA IN SOLID ORGAN TRANSPLANTATION: ISRAEL PENN INTERNATIONAL

TRANSPLANT TUMOR REGISTRY EXPERIENCE IN THE UNITED STATES Hanaway MJ, Buell JF, Lo A, Trofe J, Beebe T, First MR, Woodle ES American Society of Transplantation, Transplantation 2001 Chicago, Illinois, May 2001 *380 CAN PATAIENTS WITH CNS TUMORS SAFELY BE USED IN EXPANDING THE DONOR POOL? Buell JF, Trofe J, Hanaway MJ, First MR, Beebe T, Peddi VR, Rilo H, Woodle ES. American Society of Transplantation, Transplantation 2001 Chicago, Illinois, May 2001 *381. TRANSMISSION OF DONOR CANCER INTO CARDIO-THORACIC TRANSPLANT RECIPIENTS Buell JF, Trofe J, Rosengard B, Hanaway MJ, Rilo H, Beebe T, First MR, Woodle ES American Society of Transplantation, Transplantation 2001 Chicago, Illinois, May 2001 *382. A DONOR SELECTION ALGORITHM FOR NON-HEART-BEATING DONORS ALLOWS HIGH RETRIEVAL

RATES AND EXCELLENT GRAFT FUNCTION Buell JF, Aull M, Lo A, Hanaway MJ, Munda R, Alexander JW, Fidler J, Rilo H, Hanto DH, Lewis D, First MR,

Woodle ES American Society of Transplantation, Transplantation 2001

69

Chicago, Illinois, May 2001 *383. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN KIDNEY TRANSPLANTATION: A 32-YEAR

EXPERIENCE IN 405 PATIENTS FROM THE ISRAEL PENN TRANSPLANT TUMOR REGISTRY Trofe J, Buell JF, Hanaway M, Beebe T, First MR, Alloway RR, Lo A, Rilo H, Woodle ES American Society of Transplantation, Transplantation 2001 Chicago, Illinois, May 2001 *384. MELANOMA IN SOLID ORGAN TRANSPLANTATION: A 25 YEAR EXPERIENCE IN 143 PATIENTS FROM THE

ISRAEL PENN INTERNATIONAL TRANSPLANT TUMOR REGISTRY Trofe J, Buell JF, Hanaway M, First MR, Beebe T, Woodle ES American Society of Transplantation, Transplantation 2001 Chicago, Illinois, May 2001 *385. LONG-TERM GRAFT FUNCTION IN RENAL TRANSPLANTATION USING NON-HEART BEATING DONORS Aull M, First MR, Cardi M, Peddi VR, Weiskittel P, Berilla E, Meredith L, Trofe J, Zavala E, Alloway RR, Woodle ES,

Buell JF American Society of Transplantation, Transplantation 2001 Chicago, Illinois, May 2001 *386. EXPERIENCE WITH 274 CARDIAC TRANSPLANT RECIPIENTS POST-TRANSPLANT LYMPHOPROLIFERATIVE

DISORDER: A REPORT FROM THE ISRAEL PENN TRANSPLANT TUMOR REGISTRY Aull M, Trofe J, Alloway RR, Hanaway M, First MR, Wagoner L, Bebee T, Woodle ES, Buell JF American Society of Transplantation, Transplantation 2001 Chicago, Illinois, May 2001 *387. TRANSMISSION OF A DONOR CANCER INTO CARDIOTHORACIC TRANSPLANT RECIPIENTS: A REPORT

FROM THE ISRAEL PENN INTERNATIONAL TRANSPLANT TUMOR REGISTRY Aull M, Alloway RR, Trofe J, First MR, Peddi VR, Woodle ES, Buell JF American Society of Transplantation, Transplantation 2001 Chicago, Illinois, May 2001 *388. SIROLIMUS SUBSTITUTION FOR CALCINEURIN-INHIBITORS IN RENAL ALLOGRAFT RECIPIENTS WITH

CALCINEURIN-INHIBITOR NEPHROTOXICITY Govil A, Peddi VR, Goel S, Woodle ES, First MR Aull M, Alloway RR, Trofe J, First MR, Peddi VR, Woodle ES, Buell JF American Society of Transplantation, Transplantation 2001 Chicago, Illinois, May 2001 *389. SAFETY AND EFFICACY OF THYMOGLOBULIN INDUCTION WITH INTERMITTENT DOSING BASED ON CD3+

LYMPHOCYTE COUNTS IN HIGH RISH CADAVER RENAL TRANSPLANT RECIPIENTS Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES, First MR Aull M, Alloway RR, Trofe J, First MR, Peddi VR, Woodle ES, Buell JF American Society of Transplantation, Transplantation 2001 Chicago, Illinois, May 2001 *390. COST ANALYSIS OF THYMOGLOBULIN INDUCTION WITH INTERMITTENT DOSING BASED ON CD3+

LYMPHOCYTE COUNTS IN HIGH-RISK CADAVER RENAL TRANSPLANT RECIPIENTS Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES, First MR American Society of Transplantation, Transplantation 2001 Chicago, Illinois, May 2001 *391. REPEAT RENAL TRANSPLANTATION AFTER PREVIOUS SIMULTANEOUS KIDNEY AND PANCREAS

TRANSPLANTATION AND RENAL ALLOGRAFT LOSS Peddi VR, Munda R, Hanaway M, First MR

70

8th World Congress of the International Pancreas and Islet Transplant Association Innsbruck, Austria, June 2001 *392. IMPACT OF ANTIVIRAL PROPHYLAXIS ON CYTOMEGALOVIRUS INFECTION IN PANCREAS TRANSPLANT

RECIPIENTS IN THE CURRENT IMMUNOSUPPRESSION ERA Peddi VR, Roy-Chaudhury P, Munda R, Woodle ES, First MR 8th World Congress of the International Pancreas and Islet Transplant Association Innsbruck, Austria, June 2001 *393. COST-ANALYSIS OF THYMOGLOBULIN INDUCTION WITH INTERMITTENT DOSING BASED ON CD3+

LYMPHOCYTE COUNTS IN PANCREAS TRANSPLANT RECIPIENTS Peddi VR, Roy-Chaudhury P, Buell J, Woodle ES, First MR 8th World Congress of the International Pancreas and Islet Transplant Association Innsbruck, Austria, June 2001 *394. EFFICACY OF THYMOGLOBULIN INDUCTION WITH INTERMITTENT DOSING BASED ON CD3+ LYMPHOCYTE

COUNTS IN PANCREAS TRANSPLANT RECIPIENTS Peddi VR, Roy-Chaudhury P, Woodle ES, First MR 8th World Congress of the International Pancreas and Islet Transplant Association Innsbruck, Austria, June 2001 *395. COMPARISON OF GRAFT AND PATIENT SURVIVAL IN THE PAST AND PRESENT ERA IN SIMULTANEOUS

KIDNEY AND PANCREAS TRANSPLANT RECIPIENTS Peddi VR, Munda R, First MR 8th World Congress of the International Pancreas and Islet Transplant Association Innsbruck, Austria, June 2001 *396. HLA-IDENTICAL RENAL TRANSPLANT RECIPIENTS: IMMUNOSUPPRESSION, LONG-TERM COMPLICATIONS AND SURVIVAL Peddi VR, Weiskittel Pl, Alexander JW, Woodle ES, First MR 2001 A Transplant Odyssey Istanbul, Turkey, August 2001 *397. CONTROL OF RISK FACTORS FOR CARDIOVASCULAR DISEASE IN LONG-TERM RENAL TRANSPLANT

RECIPIENTS First MR, Peddi VR, Weiskittel P, Woodle ES 2001 A Transplant Odyssey Istanbul, Turkey, August 2001 *398. ARE CARCINOID TUMORS INDOLENT IN TRANSPLANT RECIPIENTS? Buell J, Spight D, Trofe J, Hanaway M, Peddi VR, Woodle ES, First MR 2001 A Transplant Odyssey Istanbul, Turkey, August 2001